ࡱ> '` <bjbjLULU -.?.?iF$$$@4%0%%%T&PjPjPjjp &R Lz ::TTą^4QQQQQQQ$UhXxQE%Qd%d%TTh R2d%8T%TMQt%%T@z p#u#Pj2^%'RR<RxXΰxX4xX%` Jt|QQdR&&& I&&& &&&d%d%d%d%d%d% Protocol Review of MBS Items for specific ophthalmology services under the MBS Quality Framework  December 2010 This protocol was commissioned by the Medicare Benefits Division, Department of Health and Ageing, the Australian Government. Researchers: Tracy Merlin Jacqueline Street Christine Holton Vineet Juneja David Tamblyn Benjamin Ellery Sophia Scrimgeour Sophie HennessyManager / Senior Lecturer NHMRC Postdoctoral Researcher Research Fellow Research Officer Research Officer Research Officer Research Assistant Research Assistant Adelaide Health Technology Assessment Discipline of Public Health School of Population Health and Clinical Practice University of Adelaide    Table of contents  TOC \o "1-1" \h \z \t "Heading 3,3,Heading2,2"  HYPERLINK \l "_Toc273725668" 1. INTRODUCTION TO QUALITY FRAMEWORK REVIEWS  PAGEREF _Toc273725668 \h 1  HYPERLINK \l "_Toc273725669" 1.1 Principles to guide MBS reviews  PAGEREF _Toc273725669 \h 2  HYPERLINK \l "_Toc273725670" 1.2 Purpose of this document  PAGEREF _Toc273725670 \h 2  HYPERLINK \l "_Toc273725671" 1.3 Objectives of the review  PAGEREF _Toc273725671 \h 2  HYPERLINK \l "_Toc273725672" 2. BACKGROUND ON Ophthalmology Services under Review  PAGEREF _Toc273725672 \h 3  HYPERLINK \l "_Toc273725673" 2.1 Description of current services  PAGEREF _Toc273725673 \h 3  HYPERLINK \l "_Toc273725674" 2.2 Context  PAGEREF _Toc273725674 \h 9  HYPERLINK \l "_Toc273725675" 2.3 Justification for review  PAGEREF _Toc273725675 \h 11  HYPERLINK \l "_Toc273725676" 3. KEY STAKEHOLDERS  PAGEREF _Toc273725676 \h 11  HYPERLINK \l "_Toc273725677" 3.1 MBS Quality Framework Expert Advisory Committee  PAGEREF _Toc273725677 \h 11  HYPERLINK \l "_Toc273725678" 3.2 Clinical Working Group  PAGEREF _Toc273725678 \h 11  HYPERLINK \l "_Toc273725679" 3.3 Clinical craft groups  PAGEREF _Toc273725679 \h 12  HYPERLINK \l "_Toc273725680" 3.4 Consumers and the general public  PAGEREF _Toc273725680 \h 13  HYPERLINK \l "_Toc273725681" 3.5 Consultants  PAGEREF _Toc273725681 \h 13  HYPERLINK \l "_Toc273725682" 3.6 The Department of Health and Ageing  PAGEREF _Toc273725682 \h 13  HYPERLINK \l "_Toc273725683" 4. REVIEW METHODOLOGY  PAGEREF _Toc273725683 \h 14  HYPERLINK \l "_Toc273725684" 4.1 MBS data  PAGEREF _Toc273725684 \h 17  HYPERLINK \l "_Toc273725685" Clinical/research questions  PAGEREF _Toc273725685 \h 17  HYPERLINK \l "_Toc273725686" 4.2 Guideline concordance  PAGEREF _Toc273725686 \h 17  HYPERLINK \l "_Toc273725687" Clinical/research question  PAGEREF _Toc273725687 \h 17  HYPERLINK \l "_Toc273725688" 4.3 Literature review mini-health technology assessments (mini-HTAs)  PAGEREF _Toc273725688 \h 19  HYPERLINK \l "_Toc273725689" Review questions and literature selection criteria  PAGEREF _Toc273725689 \h 20  HYPERLINK \l "_Toc273725690" Literature search  PAGEREF _Toc273725690 \h 36  HYPERLINK \l "_Toc273725691" Critical appraisal of selected evidence  PAGEREF _Toc273725691 \h 38  HYPERLINK \l "_Toc273725692" Explanatory notes  PAGEREF _Toc273725692 \h 39  HYPERLINK \l "_Toc273725693" 4.4 Stakeholder consultation community engagement  PAGEREF _Toc273725693 \h 41  HYPERLINK \l "_Toc273725694" 4.5 Stakeholder negotiation  PAGEREF _Toc273725694 \h 42  HYPERLINK \l "_Toc273725695" 4.6 Economic evaluation  PAGEREF _Toc273725695 \h 42  HYPERLINK \l "_Toc273725696" 4.7 Review outcomes  PAGEREF _Toc273725696 \h 43  HYPERLINK \l "_Toc273725697" 5. REVIEW TIMEFRAME  PAGEREF _Toc273725697 \h 44  HYPERLINK \l "_Toc273725698" 6. REFERENCES  PAGEREF _Toc273725698 \h 45  HYPERLINK \l "_Toc273725699" Attachment 1  HYPERLINK \l "_Toc273725700" Clinical Practice Guidelines  PAGEREF _Toc273725700 \h 46  1. INTRODUCTION TO QUALITY FRAMEWORK REVIEWS In the 2009-10 Budget, the Australian Government agreed to put in place a new evidence-based framework for managing the Medicare Benefits Schedule into the future through the measure Medicare Benefits Schedule A quality framework for reviewing services (MBS Quality Framework). A key component of the MBS Quality Framework is implementing a systematic approach to reviewing existing MBS items to ensure they reflect contemporary evidence, offer improved health outcomes for patients and represent value for money. The primary focus of the reviews framework is quality-related issues with the key objective of identifying and evaluating current MBS services that present potential safety and quality issues or the opportunity to encourage more appropriate clinical use. Adelaide Health Technology Assessment (AHTA), School of Population Health and Clinical Practice, at the University of Adelaide, as part of its contract with the Department of Health and Ageing will undertake a review of the evidence relating to MBS items for specific Ophthalmology Services (see  REF _Ref270625779 \h  \* MERGEFORMAT Table 1). Table  SEQ Table \* ARABIC 1 Ophthalmological Services listed on the Medicare Benefits Schedule and under review SERVICE NAMEMBS ITEM NOSGlaucoma 11200, 11203, 42746, 42749, 42752, 42770, 42771Electroretinography11204, 11205, 11210, 11211Examination of optic fundi11212Retinal photography 11215, 11218Perimetry 11221, 11222, 11224, 11225, 10940, 10941Orbital echography11237, 11240, 11241, 11242, 11243Removal of foreign body42551, 42554, 42557, 42560, 42563, 42566, 42569, 42644Extirpation of tarsal cyst42575Lacrimal passages42610, 42611, 42614, 42615 Cataract surgery42698, 42701, 42702, 42703, 42704, 42707, 42710, 42713, 42716 Capsulectomy and lensectomy42719, 42722, 42731 Vitrectomy42725Cryotherapy of retina 42728Retinal services 42773, 42776, 42779, 42812, 42818 Eye injection (macular degeneration) 42740 Laser trabeculoplasty 42782, 42783Retinal photocoagulation 42809Removal of silicone oil42815Surgical assist51315 1.1 Principles to guide MBS reviews MBS Quality Framework reviews are underpinned by the following key principles: reviews have a primary focus on improving health outcomes and the financial sustainability of the MBS, through consideration of areas potentially representing: o patient safety risk; o limited health benefit; and/or o inappropriate use (under or over use). reviews are evidence-based, fit-for-purpose and consider all relevant data sources; reviews are conducted in consultation with key stakeholders including, but not limited to, the medical profession and consumers; review topics are made public, with identified opportunities for public submission and outcomes of reviews published; reviews are independent of Government financing decisions and may result in recommendations representing costs or savings to the MBS, as appropriate, based on the evidence; secondary investment strategies to facilitate evidence-based changes in clinical practice are considered; and review activity represents efficient use of Government resources. 1.2 Purpose of this document This document is intended to outline the methodology in providing evidence based analysis to support the review of MBS items for specific Ophthalmology Services. The objectives of the protocol are to: define the relevant clinical questions that the review will focus on; clarify the role of the identified Ophthalmology Services in current clinical practice; clarify the mechanisms for identifying evidence and provide an opportunity for discussion of clinical and methodological issues; clarify timelines associated with this project; and clarify roles and responsibilities of key stakeholders. Once finalised, the protocol should not be altered as it provides the structure for the entire review process. 1.3 Objectives of the review To provide robust, evidence-based analysis to inform recommendations aimed at strengthening the evidence-base for specific Medicare-funded ophthalmology items and their use. 2. BACKGROUND ON Ophthalmology Services under Review 2.1 Description of current services The MBS services being reviewed are presented in  REF _Ref270625884 \h  \* MERGEFORMAT Table 2, along with a description of each service, and the conditions/diseases for which the service is most relevant or commonly used. Initial listing, amendments to listings, setting of use of these services and the health professionals providing these services are given below  REF _Ref270625884 \h  \* MERGEFORMAT Table 2. Table  SEQ Table \* ARABIC 2 Description of MBS Ophthalmological items under review Conditions/diseases relevant to the serviceMBS Item NumberItem Descriptor for the ServiceType of serviceGlaucoma11200 PROVOCATIVE TEST OR TESTS FOR GLAUCOMA, including water drinkingDiagnostic11203TONOGRAPHYin the investigation or management of glaucoma, 1 or both eyesusing an electrical tonography machine producing a directly recorded tracing 42746GLAUCOMA, filtering operation forTherapeutic 42749GLAUCOMA, filtering operation for, where previous filtering operation has been performed42752GLAUCOMA, insertion of Molteno valve for, 1 or more stages42770CYCLODESTRUCTIVE procedures for the treatment of intractable glaucoma, treatment to 1 eye, to a maximum of 2 treatments to that eye in a 2 year period42771CYCLODESTRUCTIVE PROCEDURES for the treatment of intractable glaucoma, treatment to one eye - where it can be demonstrated that a 3rd or subsequent treatment to that eye (including any treatments to which 42770 applies) is indicated in a 2 year period (Anaes.)42782LASER TRABECULOPLASTY - each treatment to 1 eye, to a maximum of 4 treatments to that eye in a 2 year period42783LASER TRABECULOPLASTY - each treatment to 1 eye - where it can be demonstrated that a 5th or subsequent treatment to that eye (including any treatments to which item 42782 applies) is indicated in a 2 year periodVarious retinal diseases11204ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standardsDiagnostic 11205ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards11210PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards 11211DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptationsEye investigations/diseases11212 OPTIC FUNDI, examination of, following intravenous dye injectionDiagnostic11215RETINAL PHOTOGRAPHY, multiple exposures of 1 eye with intravenous dye injection11218RETINAL PHOTOGRAPHY, multiple exposures of both eyes with intravenous dye injectionVarious eye, retinal, optic nerve and brain disorders11221FULL QUANTITATIVE COMPUTERISED PERIMETRY - (automated absolute static threshold) not being a service involving multifocal multichannel objective perimetry, performed by or on behalf of a specialist in the practice of his or her specialty, where indicated by the presence of relevant ocular disease or suspected pathology of the visual pathways or brain with assessment and report, bilateral - to a maximum of 2 examinations (including examinations to which item 11224 applies) in any 12 month period Diagnostic11222FULL QUANTITATIVE COMPUTERISED PERIMETRY (automated absolute static threshold) not being a service involving multifocal multichannel objective perimetry, performed by or on behalf of a specialist in the practice of his or her specialty, with assessment and report, bilateral, where it can be demonstrated that a further examination is indicated in the same 12 month period to which Item 11221 applies due to presence of one of the following conditions:- established glaucoma (where surgery may be required within a six month period) where there has been definite progression of damage over a 12 month period; established neurological disease which may be progressive and where a visual field is necessary for the management of the patient; or monitoring for ocular disease or disease of the visual pathways which may be caused by systemic drug toxicity, where there may also be other disease such as glaucoma or neurological disease -each additional examination Diagnostic11224FULL QUANTITATIVE COMPUTERISED PERIMETRY - (automated absolute static threshold) not being a service involving multifocal multichannel objective perimetry, performed by or on behalf of a specialist in the practice of his or her specialty, where indicated by the presence of relevant ocular disease or suspected pathology of the visual pathways or brain with assessment and report, unilateral - to a maximum of 2 examinations (including examinations to which item 11221 applies) in any 12 month period Diagnostic11225FULL QUANTITATIVE COMPUTERISED PERIMETRY - (automated absolute static threshold) not being a service involving multifocal multichannel objective perimetry, performed by or on behalf of a specialist in the practice of his or her specialty, with assessment and report, unilateral, where it can be demonstrated that a further examination is indicated in the same 12 month period to which item 11224 applies due to presence of one of the following conditions:- established glaucoma (where surgery may be required within a 6 month period) where there has been definite progression of damage over a 12 month period; established neurological disease which may be progressive and where a visual field is necessary for the management of the patient; or monitoring for ocular disease or disease of the visual pathways which may be caused by systemic drug toxicity, where there mayalso be other disease such as glaucoma or neurological disease -each additional examination DiagnosticDiagnosis, monitoring or measurement of orbital masses or orbital measurement to inform lens surgery and cataract surgery11237OCULAR CONTENTS, simultaneous ultrasonic echography by both unidimensional and bidimensional techniques, for the diagnosis, monitoring or measurement of choroidal and ciliary body melanomas, retinoblastoma or suspicious naevi or simulating lesions, one eye, not being a service associated with a service to which items in Group I1 applyDiagnostic 11240ORBITAL CONTENTS, unidimensional ultrasonic echography or partial coherence interferometry of, for the measurement of one eye prior to lens surgery on that eye, not being a service associated with a service to which items in Group I1 apply11241ORBITAL CONTENTS, unidimensional ultrasonic echography or partial coherence interferometry of, for bilateral eye measurement prior to lens surgery on both eyes, not being a service associated with a service to which items in Group I1 apply11242ORBITAL CONTENTS, unidimensional ultrasonic echography or partial coherence interferometry of, for the measurement of an eye previously measured and on which lens surgery has been performed, and where further lens surgery is contemplated in that eye, not being a service associated with a service to which items in Group I1 apply 11243ORBITAL CONTENTS, unidimensional ultrasonic echography or partial coherence interferometry of, for the measurement of a second eye where surgery for the first eye has resulted in more than 1 dioptre of error or where more than 3 years have elapsed since the surgery for the first eye, not being a service associated with a service to which items in Group I1 applyEye trauma42551EYEBALL, PERFORATING WOUND OF, not involving intraocular structuresrepair involving suture of cornea or sclera, or both, not being a service to which item 42632 appliesTherapeutic 42554EYEBALL, PERFORATING WOUND OF, with incarceration or prolapse of uveal tissuerepair 42557EYEBALL, PERFORATING WOUND OF, with incarceration of lens or vitreousrepair42560INTRAOCULAR FOREIGN BODY, magnetic removal from anterior segment42563INTRAOCULAR FOREIGN BODY, nonmagnetic removal from anterior segment42566INTRAOCULAR FOREIGN BODY, magnetic removal from posterior segment42569INTRAOCULAR FOREIGN BODY, nonmagnetic removal from posterior segment42644CORNEA OR SCLERA, removal of imbedded foreign body fromTarsal cysts/ chalazia42575 TARSAL CYST, extirpation ofTherapeuticEpiphora / dacryocystocele (Timo cyst)42610NASOLACRIMAL TUBE (unilateral), removal or replacement of, or LACRIMAL PASSAGES, probing for obstruction, unilateral, with or without lavage - under general anaesthesiaTherapeutic 42611NASOLACRIMAL TUBE (bilateral), removal or replacement of, or LACRIMAL PASSAGES, probing for obstruction, bilateral, with or without lavage - under general anaesthesia42614NASOLACRIMAL TUBE (unilateral), removal or replacement of, or LACRIMAL PASSAGES, probing to establish patency of the lacrimal passage and/or site of obstruction, unilateral, including lavage, not being a service associated with a service to which item 42610 applies (excluding aftercare)42615NASOLACRIMAL TUBE (bilateral), removal or replacement of, or LACRIMAL PASSAGES, probing to establish patency of the lacrimal passage and/or site of obstruction, bilateral, including lavage, not being a service associated with a service to which item 42611 applies (excluding aftercare)Cataract42698LENS EXTRACTION, excluding surgery performed for the correction of refractive error except for anisometropia greater than 3 dioptres following the removal of cataract in the first eyeTherapeutic 42701ARTIFICIAL LENS, insertion of, excluding surgery performed for the correction of refractive errorexcept for anisometropia greater than 3 dioptres following the removal of cataract in the first eye42702LENS EXTRACTION AND INSERTION OF ARTIFICIAL LENS, excluding surgery performed for the correction of refractive errorexcept for anisometropia greater than 3 dioptres following the removal of cataract in the first eye42703ARTIFICIAL LENS, insertion of, into the posterior chamber and suture to the iris and sclera 42704ARTIFICIAL LENS, REMOVAL or REPOSITIONING of by open operation, not being a service associated with a service to which item 42701 applies42707ARTIFICIAL LENS, REMOVAL of and REPLACEMENT with a different lens, excluding surgery performed for the correction of refractive error except for anisometropia greater than 3 dioptres following the removal of cataract in the first eye42710ARTIFICIAL LENS, removal of, and replacement with a lens inserted into the posterior chamber and sutured to the iris or sclera42713INTRAOCULAR LENSES, repositioning of, by the use of a McCannell suture or similar42716CATARACT, JUVENILE, removal of, including subsequent needlings Removal of vitreous lens42719CAPSULECTOMY OR REMOVAL OF VITREOUS, or both, via the anterior chamber by any method, not being a service associated with a service to which item 42698, 42702 or 42716 appliesTherapeutic 42722CAPSULECTOMY by posterior chamber sclerotomy OR REMOVAL OF VITREOUS or VITREOUS BANDS, or both, from the anterior chamber by posterior chamber sclerotomy, by cutting and suction and infusion, not being a service associated with a service to which item 42698, 42702 or 42716 applies - 1 or both procedures42731CAPSULECTOMY or LENSECTOMY, or both, by posterior chamber sclerotomy in conjunction with the removal of vitreous or division of vitreous bands or removal of preretinal membrane from the posterior chamber by cutting and suction and infusion, not being a service associated with any other intraocular operationRetinal detachment, macular pucker, diabetic retinopathy, macular holes, vitreous haemorrhage or opacity42725 VITRECTOMY by posterior chamber sclerotomyincluding the removal of vitreous, division of bands or removal of preretinal membranes where performed, by cutting and suction and infusionTherapeuticEye disease42728 CRYOTHERAPY OF RETINA or other intraocular structures with an internal probe, being a service associated with a service to which item 42725 appliesTherapeutic42818RETINA, CRYOTHERAPY TO, as an independent procedure, with external probe42809RETINA, photocoagulation of, not being a service associated with photodynamic therapy with verteporfin Retinal detachment42773DETACHED RETINA, diathermy or cryotherapy for, not being a service associated with a service to which item 42776 appliesTherapeutic 42776DETACHED RETINA, buckling or resection operation for42779DETACHED RETINA, revision operation for42812DETACHED RETINA, removal of encircling silicone band fromRetinal and subretinal vascular conditionsa, bacterial, fungal and viral infections, intraocular lymphoma, proliferative vitreoretinopathy prophylaxis, submacular haemorrhage42740 PARACENTESIS OF ANTERIOR OR POSTERIOR SEGMENT (including the vitreous) OR BOTH, for the injection of therapeutic substances, or the removal of aqueous or vitreous for diagnostic purposes, 1 or more ofDiagnostic and TherapeuticComplex retinal detachments42815 POSTERIOR CHAMBER, removal of silicone oil from TherapeuticCataract51315 Assistance at cataract and intraocular lens surgery covered by item 42698,42701, 42702, 42704 or 42707, when performed in association with services covered by item 42551 to 42569, 42653, 42656, 42746, 42749, 42752, 42776 or 42779Therapeutica eg choroidal neovascularisation, age-related macular degeneration, diabetic macular oedema, diabetic retinopathy, retinal vein occlusion, and neovascular glaucoma. The MBS funded services listed above are primarily performed in the hospital setting (both day surgery and inpatient), and/or in the rooms of the consultant. For all of the services being investigated, the consultant or health professional performing the service is an ophthalmologist (specialist) only. MBS items for optometry are in a different section of the MBS Category 1, Professional Attendances, Group A10, Optometric services (item numbers 10900 10943). With respect to the Assistance item (51315), the relevant medical practitioner is a Surgical Assistant. The MBS provides information on the year of introduction of each these ophthalmological items, and the year in which the current description was formulated. Of the 61 items being analysed, 29 commenced in 1991 and have not been amended relating primarily to glaucoma, examination of optic fundi, retinal photography, removal of foreign body, extirpation of tarsal cyst, cataract surgery, cryotherapy of retina, retinal services, laser trabeculoplasty and removal of silicone oil; 12 items commenced in 1991 and have since been amended 1 glaucoma item in 1996, 2 perimetry items in 2003, 1 lacrimal passages item in 1998 and 1 in 2001 , 2 cataract surgery items in 2001 and 1 in 2005, 1 (the sole) retinal photocoagulation item in 2002, 1 pars plana vitrectomy item and 3 capsulectomy and lensectomy items in 2005; 2 commenced in 1994 and have since been amended 1 lacrimal passages item in 1998 and 1 in 2001; 2 commenced in 1996 1 cataract surgery item which was amended in 2001 and another 1 which has not been amended; 4 commenced in 1997 2 of these have not been amended (1 relating to laser trabeculoplasty, and 1 for surgical assist with cataracts); 2 perimetry items were amended in 2003; 1 commenced in 1999 and has since been amended 1 orbital echography item in 2004. 5 commenced in 2001 and have not been amended one relating to glaucoma, and the other 4 to electroretinography; 3 commenced in 2001 and have since been amended 3 orbital echography items in 2004; and 1 item commenced in 2003 and has not been amended relating to orbital echography. 2.2 Context Incidence and prevalence of diseases relevant to the services under review Following the 2007-08 National Health Survey conducted by the Australian Bureau of Statistics, it was determined that 52% of the Australian population reported eyesight problems as a long-term medical condition. An estimated 9.4% of Australians aged 55 years or older are visually impaired and 1.2% are blind. Approximately 30% of vision impaired Australians are believed to have untreated cataracts, with 27% having presbyopia  ADDIN EN.CITE Australian Institute of Health and Welfare20091116Australian Institute of Health and Welfare,A guide to Australian eye health dataCat. no. PHE 1192nd edition2009CanberraAIHW(Australian Institute of Health and Welfare 2009). The most prevalent causes of blindness relate to ageing macular degeneration, cataracts, glaucoma, diabetic retinopathy, uncorrected refractive error, eye trauma and trachoma. Of the 1.2% prevalence of blindness in those aged 55 or older, 50% have age-related macular degeneration as the primary cause, 16% glaucoma and 12% cataracts. Using AIHW data, Access Economics estimated that cataract affected more than 1.8 million Australians in 2009, with a prevalence ranging from 2.3% in those aged 40-49 years to 76% in those 80+ years. The estimated incidence of overall five-year cataract surgery was 5.7%, ranging from 0.3% in people aged 49-54 years to 17.4% in those aged 75 years or more  ADDIN EN.CITE Access EconomicsSeptember 20094446Access Economics,Cataract treatment in AustraliaSeptember 2009Access Economics Pty Ltd for Alcon Laboratories Australia Pty Ltd.(Access Economics September 2009). Cataracts are the primary cause of 40% of cases of visual impairment, with macular degeneration the primary cause in 28%  ADDIN EN.CITE Australian Institute of Health and Welfare20053336Australian Institute of Health and Welfare,Vision problems among older AustraliansBulletin no. 27. AIHW cat. No. AUS 60.2005CanberraAIHW(Australian Institute of Health and Welfare 2005). The increasing diabetes problem in Australia has consequences for vision impairment as 15% of people with known diabetes and newly diagnosed diabetes have retinopathy  ADDIN EN.CITE Australian Institute of Health and Welfare20091116Australian Institute of Health and Welfare,A guide to Australian eye health dataCat. no. PHE 1192nd edition2009CanberraAIHW(Australian Institute of Health and Welfare 2009). Similarly, around 3% of the population aged over 50 years has glaucoma  ADDIN EN.CITE Mitchell199688817Mitchell, P Smith, W Attebo, KHealey, PRPrevalence of open-angle glaucoma in AustraliaOphthalmologyOphthalmology1661-9103101996(Mitchell, Smith et al. 1996). Although the ageing Australian population is driving the increasing prevalence of vision impairment, eye disorders (short- or long-sightedness) are still among the top 5 long-term health problems experienced by children  ADDIN EN.CITE Australian Institute of Health and Welfare20091116Australian Institute of Health and Welfare,A guide to Australian eye health dataCat. no. PHE 1192nd edition2009CanberraAIHW(Australian Institute of Health and Welfare 2009). Data available from the AIHW National Hospital Morbidity Database, indicates that in 2008-09, the number of hospital separations by principal diagnosis, for diseases of the eye and adnexa, was 70,660 in public hospitals and 172,995 in private hospitals; and for separations by procedure was 83,308 and 188,343 respectively. The total number of separations by AR-DRG increased steadily from 175,883 in 1998-99 to 280,824 in 2007-08. These data are similar to principal diagnosis data determined by ICD-10-AM, with the number of separations for diseases of the eye and adnexa increasing from 160,340 in 1998-99 to 230,805 in 2007-08. Disorders of the lens accounted for approximately 70% of these eye diseases, with disorders of eyelid, lacrimal system and orbit the next highest at around 10%. The increasing prevalence of eye disease in Australia reflects the ageing nature of the population. Surgical procedures accounted for approximately 95% of AR-DRG hospital separations, with sameday lens procedures making up about 65% of these, and with retinal procedures being the next most common. Same-day lens procedures (C16B) had the 7th highest number of public hospital separations for individual DRGs in 2008-09 at 54,873; and 4th highest of private hospital separations at 127,970. Medical procedures increased slightly from 12,045 in 1998-99 to 14,149 in 2007-08, with the largest individual separation rates being for hyphema and medically managed trauma to the eye. The cost of hospital separations for MDC 02 (diseases and disorders of the eye) for 2008-09 was $556,536,000 ($250m in public hospitals, $305m private). As such, eye disease is a significant health problem for the Australian population and has a significant impact on the national health system. MBS item number usage and expenditure for ophthalmological items Medicare Australia website statistics (item reports) indicate that the highest frequency of individual ophthalmology services across the period 1994-2009 were: Item 11221 Perimetry 3,024,057 Item 42702 Cataract surgery 1,262,741 Item 11240 Orbital echography 997,874 Item 42809 Retinal photocoagulation 648,476 Item 42644 Removal foreign body (cornea) 644,441 The highest cost individual items for 2009 were: Item 42702 Cataract surgery $88,350,739 Item 42740 Eye injection $24,915,656 Item 42809 Retinal photocoagulation $15,973,258 Item 11221 Perimetry $13,896,053 Item 42782 Laser trabeculoplasty $8,813,409 For the 61 items being investigated, the total cost to Medicare for 2009 was $181,916,009. This includes safety net expenditure. Alternate MBS funded services/comparator services Within the optometry MBS items, there are two items which are currently comparable with the ones being investigated for ophthalmology. In the area of computerised perimetry, item 10940 is comparable to item 11221, and item 10941 is comparable to item 11224 (see below). 10940 COMPUTERISED PERIMETRY - Full quantitative computerised perimetry (automated absolute static threshold) not being a service involving multifocal multichannel objective perimetry, performed by an optometrist, where indicated by the presence of relevant ocular disease or suspected pathology of the visual pathways or brain with assessment and report, bilateral - to a maximum of 2 examinations (including examinations to which item 10941 applies) in any 12 month period, not being a service associated with a service to which item 10916, 10918, 10931, 10932 or 10933 applies. 10941 - Full quantitative computerised perimetry (automated absolute static threshold) not being a service involving multifocal multichannel objective perimetry, performed by an optometrist, where indicated by the presence of relevant ocular disease or suspected pathology of the visual pathways or brain with assessment and report, unilateral - to a maximum of 2 examinations (including examinations to which item 10940 applies) in any 12 month period, not being a service associated with a service to which item 10916, 10918, 10931, 10932 or 10933 applies. The comparable ophthalmology items will be included in a concordance exercise with relevant clinical practice guidelines (see Section 4.2). Given the linkages to the optometry items, the Department will use this opportunity to apply the findings of the guideline concordance to the optometry items in consultation with the relevant optometry craft group/s. 2.3 Justification for review Following amendments to the Schedule fee for several cataract items, it was agreed that a review of existing ophthalmology items listed on the MBS would be undertaken as part of the MBS Quality Framework. The review of ophthalmology items will inform recommendations aimed at strengthening the evidence-base of Medicare-funded ophthalmology services and their use. The relevant medical craft groups, the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) and the Australian Society of Ophthalmologists have been involved in the development of the review approach, assisting in identifying existing items that may not appropriately reflect current clinical practice. In addition, RANZCO has nominated several experts to provide clinical input to the review. 3. KEY STAKEHOLDERS 3.1 MBS Quality Framework Expert Advisory Committee The Department is considering establishing an MBS Quality Framework Expert Advisory Committee (MQFEAC) to provide advice to the Department regarding new MBS listing and reviews of existing MBS items. In relation to this review of ophthalmology services, it is envisaged that the MQFEAC will: provide comment on the draft review report, including recommendations, prior to the report going out for public comment; approve the final report should any significant changes be made following the public consultation period; and While some of this work will be undertaken during face to face meetings, some work may also be completed out of session in order to ensure the review progresses in a timely manner. 3.2 Clinical Working Group A Clinical Working Group has been established for the duration of the review of MBS items for specific ophthalmology services to ensure the review reflects an understanding of current Australian clinical practice and draws valid conclusions from the available evidence. While this working group will be given the opportunity to comment on the review protocol and on the final report in their individual capacity, it is not able to make recommendations on future financing arrangements. Members will be experts in the field being reviewed and identified by, although not representing, clinical craft groups. The Clinical Working Group is chaired by the Department of Health and Ageing, and also includes a Medical Adviser from the Department. 3.3 Clinical craft groups The main clinical craft groups that are likely to be affected by this review of MBS items are the: Royal Australian and New Zealand College of Ophthalmologists (RANZCO) The RANZCO is a professional body representing ophthalmologists and eye care specialists practicing in Australia. The mission statement of RANZCO indicates that the Colleges role is to improve the already high standard of eye care in Australia and New Zealand. In pursuit of this mission, the College provides a variety of services centered on its core roles as a higher educational institution and learned society. Australian Society of Ophthalmologists (ASO) The aim of the ASO is to represent the medico-political interests of ophthalmologists within Australia. It has attracted 50% of membership across all Australian states and territories. Optometrists Association Australia, National (OAA) The OAA represents 95% of all practising optometrists and is a not-for-profit organisation comprised of six state divisions, a national office and a National Board which acts as the governing body of the Association. The Association aims to soundly and effectively lead the profession and ensure that optometry evolves as a respected and satisfying profession. The services and resources provided by the Association include: representation of optometrists and their interests to government and other bodies, development and sharing of information regarding vision standards, Medicare guidelines, practice management, financial, marketing and legal services. It also provides information and other services to the Australian public. Australian Association of Medical Surgical Assistants (AAMSA) The AAMSA is an organisation that seeks to protect and promote the professional role of medical surgical assistants in the Australian Healthcare System. The members of AAMSA come from a variety of backgrounds, but all are qualified medical practitioners, who share a common interest in surgery. They are committed to their role in assisting Australian surgeons to provide the highest possible standards of safety and efficiency in their work. Royal Australasian College of Surgeons (RACS) The RACS is a non-profit organisation with the responsibility of training surgeons and maintaining surgical standards in Australia and New Zealand. The College's purpose is to be the unifying force for surgery in Australia and New Zealand, with FRACS standing for excellence in surgical care. Interest in the MBS Quality Framework Review of Ophthalmology items will mainly come from the oculoplastic subspecialties represented within the College. 3.4 Consumers and the general public Consumers and the general public (which may include individual services providers) will be given multiple opportunities to comment on elements of the review, and are also involved in components of the review activity (see Section 4.4). The Consumer Health Forum will be approached directly to comment on the draft protocol and the draft review report. The protocol will be posted on the Department of Health and Ageing website for public comment for a period of three weeks. Written submissions will be invited and addressed individually by the consultants in a document that summarises the feedback received and how it was addressed. Where relevant, the protocol will be revised on the basis of this feedback. Following review of the draft report by the MQFEAC, the report will be released for public consultation for a period of four weeks. Again written submissions will be invited through the medium of the website and will be analysed and addressed individually by the consultants, with incorporation of relevant information into the report, where appropriate. 3.5 Consultants Adelaide Health Technology Assessment (AHTA), School of Population Health and Clinical Practice, at the University of Adelaide is responsible for drafting the review protocol and identifying, analysing and synthesising the evidence related to the identified MBS items for specific Ophthalmology Services through the methodology identified in Section 4. AHTA will provide a review report at the completion of the project that will help inform the Governments consideration of MBS subsidy of these services into the future. As an academic applied research organisation, AHTA maintains an independent view of the ophthalmology items being reviewed as part of the MBS Quality Framework budgetary measure. AHTA has been conducting health technology assessments for a decade and has a wide experience of all types of health/medical interventions for diagnostic, monitoring and therapeutic purposes having conducted health technology assessments on behalf of the Medical Services Advisory Committee (MSAC) and the Pharmaceutical Benefits Advisory Committee. AHTA staff apply best-practice methodologies in their evaluation of all health services, in order to provide the most accurate information to policy makers. AHTA is a non-profit organisation, without ties to industry, and is a member of the International Agencies for Health Technology Assessment (INAHTA). 3.6 The Department of Health and Ageing The Department of Health and Ageing (the Department) has contracted Adelaide Health Technology Assessment (AHTA), School of Population Health and Clinical Practice, at the University of Adelaide to undertake the review of MBS items for specific Ophthalmology Services and is responsible for the ongoing management of this contract. The Department is also responsible for ensuring that the draft protocol and draft review report are made available online for public comment. The Department will be responsible for negotiating with the relevant clinical craft groups with respect to potential minor wording changes of specific ophthalmology items as outlined in Section 4.5. Following the finalisation of the review report, the Department will be responsible for providing advice to the Minister for Health and Ageing on future subsidy arrangement for the MBS items identified for this review of Ophthalmology Services. This advice will be informed by the review report but will also draw on other information such as budgetary considerations. 4. REVIEW METHODOLOGY  REF _Ref272505518 \h  \* MERGEFORMAT Table 3 provides an overview of the methodology that will be used for each of the ophthalmological items under review. The evaluation methodology that is proposed is a mixed method approach consisting of MBS data analysis, mini-health technology assessments (HTAs) that are fit-for-purpose and a guideline concordance analysis. The proposed evaluation method will be tested on each of the 11 services suggested for evidence-based analysis, as well as the 10 services suggested for guideline concordance analysis (with 4 services receiving both evidence-based analysis and guideline concordance analysis). Six services (13 items) will be addressed through negotiation between the Department and the relevant stakeholders. In addition to the methodologies outlined in  REF _Ref272505518 \h  \* MERGEFORMAT Table 3, a consumer engagement process will be undertaken on six services. The resulting outputs from each of these methods will be meta-synthesised into an overall narrative that addresses each of the ophthalmological services under review. The draft protocol, including the defined review methodology for each service, was discussed with the Clinical Working Group and amended as appropriate. Table  SEQ Table \* ARABIC 3 MBS item reviews and amendments MBS ITEMSERVICEIDENTIFICATION SOURCEMETHODRANZCO submissionGuidelinesHighest utilisationOther (Professional Services Review)Mini HTA reviewStakeholder negotiation**Guideline concordance11200, 11203, 42746, 42749, 42752, 42770, 42771 Glaucomaxx11204, 11205, 11210, 11211 Electroretinographyxx11212Examination of optic fundixx11215, 11218 Retinal photographyxxx11221, 11222, 11224, 11225, 10940*, 10941*Perimetry (*)xxxx11237, 11240, 11241, 11242, 11243Orbital echographyxx42551*, 42554*, 42557*, 42560, 42563, 42566, 42569, 42644 *Removal of foreign body (*)xx (Item 42644)xx42575 Expiration of tarsal cystxx42610, 42611, 42614, 42615 Lacrimal passagesxx42698, 42701, 42702, 42703*, 42704*, 42707*, 42710*, 42713*, 42716 Cataract surgery (*)xxxxx42719, 42722, 42731* Capsulectomy and lensectomy (*)xxx42725 * Vitrectomy (*)xx42728Cryotherapy of retinaxxxx42773, 42776, 42779, 42812, 42818* Retinal services (*)xxxxx42740 Eye injectionxxxxx42782, 42783Laser trabeculoplastyxx42809 Retinal photocoagulationxxxx42815Removal of silicone oilxx51315* Surgical assist (*)xx* These items are flagged for minor amendments and will be progressed by the Department having regard to the broader review activity undertaken by the consultant ** The Department will undertake stakeholder negotiation 4.1 MBS data Clinical/research questions How frequent are claims for the MBS item numbers under review? Are there any temporal or geographic trends associated with usage of these item numbers? Are the Medicare claims data consistent with trends in the indicence/prevalence of the conditions/diseases being addressed by the services? The project will commence with an analysis of Medicare claims data for 61 MBS ophthalmology item numbers being reviewed. Medicare Australia website statistics (item reports) will be canvassed as these provide details of the number of services provided (as counts) for each item since 1994, which will enable time-trends to be established. The data will be analysed in terms of age group, gender, and geographical spread (by states). The time trends will be represented in graphical form, and the demographic data in tabular form. Data will also be requested from the Department of Health and Ageing regarding claims on items associated with each of the items under review, along with urban versus rural distribution of claims on each item number and a breakdown of claims by provider. AIHW National Hospital Morbidity database data will be investigated, as appropriate, to provide data on hospital separations related to eye conditions, by diagnosis-related group AR-DRG (Major Diagnostic Category 02), principal diagnosis in ICD-10-AM (group VII, H00-H59), count of procedures ACHI (group III, chapters 160-256) and cost. The data for each service will be presented graphically and in tables with associated interpretive text. The cost of the benefits paid by the government for each service will be obtained and reported for the most recent calendar year, 2009, as well as separately for the first six months of 2010. The analysis of data retrieved from all of these sources will provide insight into equity of access to each of the services under review, age groups likely to be affected if changes are made or items deleted, areas of under- or over-utilisation, and demographic implications for future demand for the services. The demographics of patients claiming services will also be determined ie age, gender breakdown, in order to target consumer recruitment (see Section 4.4) to those that are appropriately representative of consumers currently receiving the service under review. 4.2 Guideline concordance Clinical/research question Is the descriptor for each MBS item number/service under review consistent with evidence-based (or in the absence of evidence, consensus-based) recommendations provided in relevant clinical practice guidelines? Concurrent with the MBS data analysis, an analysis of 10 ophthalmological services (36 items) identified as requiring a guideline concordance analysis will be assessed relative to best practice as recommended in relevant Clinical Practice Guidelines and relevant to practice in Australia. Table  SEQ Table \* ARABIC 4 Ophthalmology items receiving guideline concordance analysis ServiceMBS Item NumbersGlaucoma 11200, 11203, 42746, 42749, 42752, 42770, 42771Electroretinography 11204, 11205, 11210, 11211Retinal photography 11215, 11218Perimetry 11221, 11222, 11224, 11225Cataract surgery 42698, 42701, 42702, 42703, 42704, 42707, 42710, 42713, 42716Cryotherapy of retina42728Retinal services 42773, 42776, 42779, 42812, 42818Laser trabeculoplasty 42782, 42783Eye injection 42740Retinal photocoagulation42809 Guidelines used in this concordance exercise are listed in Attachment 1, and will also be sourced from the NHMRC Guidelines Portal (HYPERLINK "http://www.clinicalguidelines.gov.au/"http://www.clinicalguidelines.gov.au/) and the National Guidelines Clearinghouse (HYPERLINK "http://www.guideline.gov/"http://www.guideline.gov/). Guideline quality will be rated according to the Appraisal of Guidelines for Research and Evaluation (AGREE) appraisal instrument (HYPERLINK "http://www.agreecollaboration.org/instrument/"http://www.agreecollaboration.org/instrument/), and the recommendations regarding the services under review in those evidence-based Guidelines with a high AGREE score will be given more credence than lower rated Guidelines. Should the only available Guidelines be of poor quality, then this will be noted when rating the services concordance with the Guideline. The determination of Guideline concordance will be largely descriptive firstly indicating the quality of the Guideline which is being used as the benchmark for the concordance assessment, describing the Guideline recommendations and relevant information presented in the Guideline text, and then indicating how well the MBS item descriptors reflect the pertinent recommendations and information in the Guideline, and finally suggesting revision or deletion of the MBS item descriptor. As part of the Guideline concordance exercise, MBS item 42740 will be assessed with regard to whether, as suggested by the RANZCO, this item number should be changed to 2 item numbers, on the basis that the existing item number is used for a variety of procedures of varying complexity and for different clinical situations. The most common use of this item is intravitreal injection of therapeutic substances, in particular ranibizumab (Lucentis) for wet age-related macular degeneration. Its usage is expected to continue to increase. It is suggested that it would be more appropriate to have a separate item number for these injections as independent procedures (given they are primarily performed as such), and another item number for intravitreal injections performed during other ocular surgery, and also anterior chamber paracentesis +/- intracameral injection of therapeutic substances. This might allow more accurate tracking of the use of intravitreal therapies, which include Lucentis but also injection of other therapeutic agents. Current definition of 42740: "PARACENTESIS OF ANTERIOR OR POSTERIOR SEGMENT (including the vitreous) OR BOTH, for the injection of therapeutic substances, or the removal of aqueous or vitreous for diagnostic purposes, 1 or more of (Anaes.) (Assist.) Suggested amendments: 1. Deletion of item number 42740 2. Creation of 2 new separate item numbers: A. Descriptor: "PARACENTESIS OF VITREOUS CAVITY, for the intravitreal injection of therapeutic substances, or the removal of vitreous for diagnostic purposes, 1 or more of, as a procedure associated with other intraocular surgery (Anaes)." B. Descriptor: "PARACENTESIS OF ANTERIOR CHAMBER and/or VITREOUS CAVITY, for the injection of therapeutic substances, or the removal of aqueous or vitreous for diagnostic purposes, 1 or more of, as an independent procedure (Anaes.) " It is suggested that a surgical assistant is not required for this procedure, which is usually done on an outpatient basis, and a formal operating theatre is not mandatory as long as appropriate aseptic technique is used (per the RANZCO Guidelines on Intravitreal Therapy). RANZCO suggest that provision for an anaesthetic fee is appropriate for the very small number of circumstances in which the procedure requires an operating theatre environment with sedation or even general anaesthesia (eg in paediatric cases or adults requiring sedation etc). All other MBS items undergoing the Guideline concordance exercise will be reviewed more generally, in terms of best practice in undertaking the relevant service. Following the MBS data and guideline concordance analysis, specific services will be reviewed using two complementary analytic processes: (1) Literature review (see Section 4.3), and (2) Stakeholder consultation community engagement (see Section 4.4). 4.3 Literature review mini-health technology assessments (mini-HTAs) Eleven services (28 items) have been identified by the Department as requiring an evidence-based analysis (see  REF _Ref270692263 \h  \* MERGEFORMAT Table 5). Those MBS items of high utilisation being considered for this review but not prompted by amendments sought by RANZCO will be appraised generally in terms of their safety and effectiveness. For other MBS items identified as requiring revision by RANZCO, the review question has been adapted to address the issue identified by RANZCO. This analysis will be undertaken through literature review in the form of mini-health technology assessment, with processes for literature searching and selection of relevant information using criteria specified a priori in order to ensure transparency and reduce bias in the selection of evidence to inform the respective review questions. Table  SEQ Table \* ARABIC 5 Ophthalmology items receiving evidence-based analysis ServiceMBS Item NumbersOptic fundi 11212Retinal photography11215, 11218Orbital echography 11237, 11240, 11241, 11242, 11243Removal of foreign body42560, 42563, 42566, 42569Extirpation of tarsal cyst 42575Lacrimal passages 42610, 42611, 42614, 42615Capsulectomy and lensectomy 42719, 42722, 42731Cryotherapy of retina 42728Retinal services42773, 42776, 42779, 42812, 42818Retinal photocoagulation 42809Removal of silicone oil 42815 The PICO (Population, Intervention, Comparator, Outcomes) criteria are used to develop well-defined questions for each review. This involves focusing the question on the following four elements: the target population for the intervention; the intervention being considered; the comparator for the existing MBS service (where relevant); and the clinical outcomes that are most relevant to assess safety and effectiveness. The PICO criteria have been determined on the basis of information provided in the literature, as well as clinical advice. These criteria will be applied when selecting literature for these mini-HTAs. Additional criteria for selecting literature have also been outlined ie relevant study designs for assessing the safety and effectiveness of the service, time period within which the literature will be sourced, and language restrictions. Review questions and literature selection criteria Three MBS items relate to examination of the retina and optic fundi, as such the relevant clinical question relates to all three. Is there evidence supporting the poor diagnostic performance or safety of fluoroscein angioscopy (item number 11212) relative to fluoroscein angiography (items 11218, 11215) that would suggest removal of the item for fluoroscein angioscopy from the MBS is warranted? Rationale for deletion: The relevant clinical craft group suggest that this item is outdated and infrequently used. The technology has evolved and fluorescein angioscopy is considered to be inaccurate compared with fluorescein angiography (items 11218 and 11215).  HYPERLINK "http://en.wikipedia.org/wiki/Diabetic_retinopathy" \o "Diabetic retinopathy" Diabetic retinopathy, vein occlusions,  HYPERLINK "http://en.wikipedia.org/wiki/Retinal_artery_occlusion" \o "Retinal artery occlusion" retinal artery occlusions, oedema of the optic disc, and tumours11212 OPTIC FUNDI, examination of, following intravenous dye injection11215RETINAL PHOTOGRAPHY, multiple exposures of 1 eye with intravenous dye injection11218RETINAL PHOTOGRAPHY, multiple exposures of both eyes with intravenous dye injection Pre-specified criteria for the selection of literature to address this question are provided in Table 6.. Table  SEQ Table \* ARABIC 6 Criteria for selecting studies to assess the safety and diagnostic accuracy of fluorescein angioscopy (item number 11212) CharacteristicInclusion CriteriaStudy designNarrative and/or systematic reviews, diagnostic accuracy studies of any design, consensus or evidence-based clinical practice guidelines. Only the most recent, good quality literature will be selected and reported as determined by the NHMRC levels of evidence hierarchy ( REF _Ref270797089 \h  \* MERGEFORMAT Table 17).PopulationPeople undergoing eye investigations or evaluations for eye diseaseInterventionFluorescein angioscopy with intravenous dye injection for examination of the optic fundus (as described by MBS item number 11212)Comparator Fluorescein angiography (as described by MBS item numbers 11215 and 11218)OutcomesLatest occurrence (date) of published research on fluorescein angioscopy, preferred usage of fluorescein angioscopy relative to fluorescein angiography, any safety and/or effectiveness concerns reported in the literatureSearch period2005 10/2010. Continue searching backwards (<2005) if literature is not available.LanguageEnglish language only The mini-HTA on this topic is likely to find limited information as the clinical craft group suggest that it is a service that is infrequently used. As such, the ongoing use of this item number will be largely informed by the MBS data analysis component indicating where (rural vs urban) and how often this item number (11212) is used. Public consultation with retinal specialists will also inform the review as to the current utilisation of this service. Five MBS items concerned with orbital echography will be reviewed, namely: Diagnosis, monitoring or measurement of orbital masses or orbital measurement to inform lens surgery and cataract surgery11237OCULAR CONTENTS, simultaneous ultrasonic echography by both unidimensional and bidimensional techniques, for the diagnosis, monitoring or measurement of choroidal and ciliary body melanomas, retinoblastoma or suspicious naevi or simulating lesions, one eye, not being a service associated with a service to which items in Group I1 apply11240ORBITAL CONTENTS, unidimensional ultrasonic echography or partial coherence interferometry of, for the measurement of one eye prior to lens surgery on that eye, not being a service associated with a service to which items in Group I1 apply11241ORBITAL CONTENTS, unidimensional ultrasonic echography or partial coherence interferometry of, for bilateral eye measurement prior to lens surgery on both eyes, not being a service associated with a service to which items in Group I1 apply11242ORBITAL CONTENTS, unidimensional ultrasonic echography or partial coherence interferometry of, for the measurement of an eye previously measured and on which lens surgery has been performed, and where further lens surgery is contemplated in that eye, not being a service associated with a service to which items in Group I1 apply 11243ORBITAL CONTENTS, unidimensional ultrasonic echography or partial coherence interferometry of, for the measurement of a second eye where surgery for the first eye has resulted in more than 1 dioptre of error or where more than 3 years have elapsed since the surgery for the first eye, not being a service associated with a service to which items in Group I1 apply Are orbital echography and partial coherence interferometry safe, accurate and clinically effective measurement techniques? Pre-specified criteria for the selection of literature to address this question are provided in  REF _Ref272411353 \h  \* MERGEFORMAT Table 7. Table  SEQ Table \* ARABIC 7 Criteria for selecting studies to assess the safety, measurement accuracy, and clinical effectiveness of orbital echography and partial coherence interferometry (item numbers 11237, 11240, 11241, 11242, 11243) CharacteristicInclusion CriteriaStudy designAccuracy Systematic reviews or narrative reviews of diagnostic accuracy/measurement concordance studies or diagnostic accuracy/measurement concordance studies alone are eligible. Systematic reviews or narrative reviews will initially be sought, and in their absence individual studies will be sought. Effectiveness Systematic reviews of randomised controlled trials, randomised controlled trials, systematic reviews or individual studies of a cohort and/or non-randomised design are eligible. A hierarchical step-wise method will be used to select studies according to study design. If there are no systematic reviews of randomised controlled trials available, then randomised controlled trials alone will be selected. Should trial data be unavailable then systematic reviews of non-randomised and/or cohort studies will be selected. In the event that these are not available non-randomised or cohort study designs alone will become eligible. In the event that there are no comparative studies, then recent narrative reviews of clinical practice guidelines will be sourced. Only the most recent, good quality literature will be selected and reported as determined by the NHMRC levels of evidence hierarchy ( REF _Ref270797089 \h  \* MERGEFORMAT Table 17).PopulationPeople requiring (1) diagnosis, monitoring or measurement of orbital masses, or (2) orbital measurement to inform lens or cataract surgeryIntervention/testsUni-dimensional ultrasonic echography Bi-dimensional ultrasonic echographyComparator Laser interferometry (ie partial coherence interferometry)OutcomeSafety Adverse physical health outcomes as a consequence of the procedure. Accuracy Primary measures of agreement or concordance (eg kappa), diagnostic accuracy measures (eg sensitivity, specificity, area under the receiver operator characteristic curve, and others) Effectiveness Primary improvement or restoration of vision, refractive outcomesSearch period2005 10/2010 Should there be limited data available during this period, the search will be extended back in five year increments until sufficient data are sourced.LanguageEnglish language only Two items regarding patient services to remove intraocular foreign bodies will be investigated for deletion from the MBS. Is there evidence supporting the lack of clinical effectiveness or safety of the service described by item number 42560 - INTRAOCULAR FOREIGN BODY, magnetic removal from anterior segment - that would suggest its removal from the MBS is warranted? Rationale for deletion: This item number is considered to reflect outdated technology (giant external magnet) which is no longer used. The item was used on only one occasion in Australia in 2008-2009. It is suggested that intraocular foreign bodies are removed using microsurgical techniques regardless of their magnetic properties, and that the distinction is no longer relevant. Is there evidence supporting the lack of clinical effectiveness or safety of the service described by item number 42566 - INTRAOCULAR FOREIGN BODY, magnetic removal from posterior segment - that would suggest its removal from the MBS is warranted? Rational for deletion: As per rationale for item 42560 above, this item reflects outdated technology / surgical technique. This item was used on only one occasion in Australian in 2008-2009. Pre-specified criteria for the selection of literature to address these questions are provided in  REF _Ref272411457 \h  \* MERGEFORMAT  Table 8. Table  SEQ Table \* ARABIC 8 Criteria for selecting studies to assess the safety and effectiveness of magnetic removal of intraocular foreign bodies (item numbers 42560, 42563, 42566, 42569) CharacteristicInclusion CriteriaStudy designEffectiveness Systematic reviews of randomised controlled trials, randomised controlled trials, systematic reviews or individual studies of a cohort and/or non-randomised design are eligible. A hierarchical step-wise method will be used to select studies according to study design. If there are no systematic reviews of randomised controlled trials available, then randomised controlled trials alone will be selected. Should trial data be unavailable then systematic reviews of non-randomised and/or cohort studies will be selected. In the event that these are not available non-randomised or cohort study designs alone will become eligible. In the event that there are no comparative studies, then recent narrative reviews of clinical practice guidelines will be sourced. Only the most recent, good quality literature will be selected and reported as determined by the NHMRC levels of evidence hierarchy ( REF _Ref270797089 \h  \* MERGEFORMAT Table 17).PopulationPeople with trauma caused by foreign bodies which have penetrated the eyeballInterventionsMagnetic removal of intraocular foreign bodies from either the anterior or posterior segment of the eyeball (items 42560, 42566)Comparator Microsurgery to remove intraocular foreign bodies ie non-magnetic removal via forceps, sclerotomy, scleral tunnel (items 42563, 42569)OutcomeSafety Adverse physical health outcomes as a consequence of procedure to remove the intraocular foreign body, including infection, vitreous loss, or other morbidity associated with the procedure. Effectiveness Primary improvement or restoration of vision, reduction in pain or discomfort, healing rate Secondary length of hospital staySearch period2005 10/2010 Should there be limited data available during this period, the search will be extended back in five year increments until sufficient data are sourced. If the service is only used infrequently, then a targeted search will be undertaken to determine the current state-of-play of the procedure. The most recent narrative reviews and/or systematic reviews (if any) and Clinical Practice Guidelines will be identified and analysed to determine what international opinion is with respect to the service and whether there are any subgroups of patients where the procedures might still have a use.LanguageEnglish language only One high usage MBS item regarding extirpation of tarsal cyst will be reviewed, namely: Tarsal cysts/ chalazia42575 TARSAL CYST, extirpation of Is tarsal cyst extirpation (item number 42575) a safe and effective procedure? Pre-specified criteria for the selection of literature to address this question are provided in  REF _Ref270781641 \h  \* MERGEFORMAT Table 9. Table  SEQ Table \* ARABIC 9 Criteria for selecting studies to assess the safety and effectiveness of tarsal cyst extirpation (item number 42575) CharacteristicInclusion CriteriaStudy designEffectiveness Systematic reviews of randomised controlled trials, randomised controlled trials, or systematic reviews or individual observational (cohort or large single arm studies) or non-randomised designs are eligible. A hierarchical step-wise method will be used to select studies according to study design. If there are no systematic reviews of randomised controlled trials available, then randomised controlled trials alone will be selected. Should trial data be unavailable then systematic reviews of non-randomised and/or observational studies will be selected. In the event that there are no good quality clinical studies available, then recent narrative reviews of clinical practice guidelines will be sourced. Only the most recent, good quality literature will be selected and reported as determined by the NHMRC levels of evidence hierarchy ( REF _Ref270797089 \h  \* MERGEFORMAT Table 17).PopulationPeople with tarsal (meibomian) cysts/chalazia that are unresponsive to supportive care (warm compresses and antibiotics) and/or corticosteroid injectionInterventionSurgical extirpation/removal. Note: Intervention is last line therapyComparator If comparative studies are available then likely comparator would be extended versions of previous line of therapy ie supportive care (warm compresses and antibiotics) and/or corticosteroid injectionOutcomeSafety Adverse physical health outcomes as a consequence of the procedure. Effectiveness Primary improvement or restoration of vision, reduction in pain or discomfort, resolution of the cystSearch period2005 10/2010 Should there be limited data available during this period, the search will be extended back in five year increments until sufficient data are sourced. If the service is only used infrequently, then a targeted search will be undertaken to determine the current state-of-play of the procedure. The most recent narrative reviews and/or systematic reviews (if any) and Clinical Practice Guidelines will be identified and analysed to determine what international opinion is with respect to the service.LanguageEnglish language only Four MBS items concerned with removal of obstruction in lacrimal passages and/or removal/replacement of nasolacrimal tubes will be reviewed, namely: Epiphora / dacryocystocele (Timo cyst)42610NASOLACRIMAL TUBE (unilateral), removal or replacement of, or LACRIMAL PASSAGES, probing for obstruction, unilateral, with or without lavage - under general anaesthesia42611NASOLACRIMAL TUBE (bilateral), removal or replacement of, or LACRIMAL PASSAGES, probing for obstruction, bilateral, with or without lavage - under general anaesthesia42614NASOLACRIMAL TUBE (unilateral), removal or replacement of, or LACRIMAL PASSAGES, probing to establish patency of the lacrimal passage and/or site of obstruction, unilateral, including lavage, not being a service associated with a service to which item 42610 applies (excluding aftercare)42615NASOLACRIMAL TUBE (bilateral), removal or replacement of, or LACRIMAL PASSAGES, probing to establish patency of the lacrimal passage and/or site of obstruction, bilateral, including lavage, not being a service associated with a service to which item 42611 applies (excluding aftercare) Are probing techniques to assess lacrimal passage patency or removal of obstructions and/or removal or replacement of the nasolacrimal tube(s) (item numbers 42610, 42611, 42614 or 42615) safe and effective procedures? Pre-specified criteria for the selection of literature to address this question are provided in  REF _Ref270784153 \h  \* MERGEFORMAT  Table 10. Table  SEQ Table \* ARABIC 10 Criteria for selecting studies to assess the safety and effectiveness of lacrimal passage procedures (item numbers 42610, 42611, 42614, 42615) CharacteristicInclusion CriteriaStudy designEffectiveness Systematic reviews of randomised controlled trials, randomised controlled trials, systematic reviews or individual studies of a cohort and/or non-randomised design are eligible. A hierarchical step-wise method will be used to select studies according to study design. If there are no systematic reviews of randomised controlled trials available, then randomised controlled trials alone will be selected. Should trial data be unavailable then systematic reviews of non-randomised and/or cohort studies will be selected. In the event that these are not available non-randomised or cohort study designs alone will become eligible. Only the most recent, good quality literature will be selected and reported as determined by the NHMRC levels of evidence hierarchy ( REF _Ref270797089 \h  \* MERGEFORMAT Table 17).PopulationAdults with epiphora Children with dacryocystocele (Timo cyst)InterventionProbing techniques to establish patency of lacrimal passages or remove obstruction Remove or replace nasoclacrimal tube(s)Comparator N/AOutcomeSafety Adverse physical health outcomes as a consequence of the procedures. Effectiveness Primary reduction in tear production, quality of life Secondary - reoperationSearch period2005 10/2010 Should there be limited data available during this period, the search will be extended back in five year increments until sufficient data are sourced. If the service is only used infrequently, then a targeted search will be undertaken to determine the current state-of-play of the procedure. The most recent narrative reviews and/or systematic reviews (if any) and Clinical Practice Guidelines will be identified and analysed to determine what international opinion is with respect to the service and whether there are certain subgroups of patients where the procedure has a use.LanguageEnglish language only Two items addressing the repair of retinal tears will be reviewed: Eye disease42728 CRYOTHERAPY OF RETINA or other intraocular structures with an internal probe, being a service associated with a service to which item 42725 applies42818RETINA, CRYOTHERAPY TO, as an independent procedure, with external probe Are item numbers 42728 - CRYOTHERAPY OF RETINA or other intraocular structures with an internal probe and 42818 - RETINA, CRYOTHERAPY TO, as an independent procedure, with external probe safe and effective procedures? Is it reasonable that item numbers 42728 and 42818 could be utilised under the same revised MBS item number? Rationale for deletion of 42728: This item is infrequently used (total 124 services Australia-wide in 08-09). Endocryotherapy is rarely used in contemporary vitreoretinal surgery. It is likely that this item number is being used for other services, and is best deleted. The small number of actual uses of endocryotherapy could be billed using 42818 (see review question below). Suggested amendment to 42818 and rationale: RETINA, CRYOTHERAPY TO, as an independent procedure, with external probe not being a service to which item 42773 applies The current restriction as an independent procedure may have had the unintended consequence of driving increased use of item 42773 (see below), which has a significantly higher fee and is for retinal detachment, rather than retinal tear. 42773DETACHED RETINA, diathermy or cryotherapy for, not being a service associated with a service to which item 42776 appliesPre-specified criteria for the selection of literature to address these related questions are provided in  REF _Ref270785290 \h  \* MERGEFORMAT Table 11. Table  SEQ Table \* ARABIC 11 Criteria for selecting studies to assess the safety and effectiveness of retinal cryotherapy (item numbers 42728, 42818) CharacteristicInclusion CriteriaStudy designNarrative and/or systematic reviews, intervention studies of any design, consensus or evidence-based clinical practice guidelines. Only the most recent, good quality literature will be selected and reported as determined by the NHMRC levels of evidence hierarchy ( REF _Ref270797089 \h  \* MERGEFORMAT Table 17).PopulationEye diseaseInterventionsRetinal cryotherapy using an external probe, Retinal cryotherapy using an internal probe (endocryotherapy)Comparator NAOutcomeLatest occurrence (date) of published research on both procedures, circumstances where these procedures might be used, any safety and/or effectiveness concerns reported in the literature regarding both proceduresSearch period2005 10/2010LanguageEnglish language onlyNA = not applicable Eye disease42809RETINA, photocoagulation of, not being a service associated with photodynamic therapy with verteporfin Is laser photocoagulation (item number 42809) a safe and effective procedure? Pre-specified criteria for the selection of literature to address this question are provided in  REF _Ref272515063 \h  \* MERGEFORMAT Table 12. Table  SEQ Table \* ARABIC 12 Criteria for selecting studies to assess the safety and effectiveness of laser photocoagulation (item number 42809) CharacteristicInclusion CriteriaStudy designNarrative and/or systematic reviews, intervention studies of any design, consensus or evidence-based clinical practice guidelines. Only the most recent, good quality literature will be selected and reported as determined by the NHMRC levels of evidence hierarchy ( REF _Ref270797089 \h  \* MERGEFORMAT Table 17).PopulationPatients requiring laser photocoagulation of the retina (eg for panretinal photocoagulation for diabetes or other vaso-occlusive disease, treatment of retinal tears, local treatment for macroaneurysm or macular oedema)InterventionLaser photocoagulation of the retinaComparator NAOutcomeLatest occurrence (date) of published research on laser photocoagulation, circumstances where this procedure might be used, any safety and/or effectiveness concerns reported in the literature regarding this interventionSearch period2005 10/2010LanguageEnglish language onlyNA = not applicable Three related items regarding capsulectomy, when performed separately or in combination with vitrectomy, will be reviewed, namely: 42719CAPSULECTOMY OR REMOVAL OF VITREOUS, or both, via the anterior chamber by any method, not being a service associated with a service to which item 42698, 42702 or 42716 applies42722CAPSULECTOMY by posterior chamber sclerotomy OR REMOVAL OF VITREOUS or VITREOUS BANDS, or both, from the anterior chamber by posterior chamber sclerotomy, by cutting and suction and infusion, not being a service associated with a service to which item 42698, 42702 or 42716 applies - 1 or both procedures42731CAPSULECTOMY or LENSECTOMY, or both, by posterior chamber sclerotomy in conjunction with the removal of vitreous or division of vitreous bands or removal of preretinal membrane from the posterior chamber by cutting and suction and infusion, not being a service associated with any other intraocular operation There appears to be overlap between these items and a suggestion that the wording of the items could be modified to reflect modern terminology. These items also need to be kept distinct from the cataract (lens removal) and vitrectomy items outlined at 42698, 42702, 42716, 42725. This could result in the removal of one or more of these capsulectomy items and/or a rewording of the items. What types of procedure or combination of procedures are currently used to remove part of the lens capsule? Pre-specified criteria for the selection of literature to address this question are provided in  REF _Ref270716439 \h  \* MERGEFORMAT Table 13. Table  SEQ Table \* ARABIC 13 Criteria for selecting studies to assess the use of capsulectomy or related procedures to remove part of the lens capsule (item numbers 42722, 42719, 42731) CharacteristicInclusion CriteriaStudy designNarrative and/or systematic reviews, intervention studies of any design, consensus or evidence-based clinical practice guidelines. Only the most recent, good quality literature will be selected and reported as determined by the NHMRC levels of evidence hierarchy ( REF _Ref270797089 \h  \* MERGEFORMAT Table 17).PopulationPatients requiring removal of vitreous or lens (usually subsequent to cataract surgery) InterventionLimbal (anterior) vitrectomy, pars plana lensectomy/vitrectomy Comparator NAOutcomeLatest occurrence (date) of published research on limbal or pars plana lensectomy/vitrectomy, circumstances where these vitrectomy/lensectomy procedures might be used, any safety and/or effectiveness concerns reported in the literature regarding these proceduresSearch period2005 10/2010. Continue searching backwards (<2005) if literature is not available.LanguageEnglish language onlyNA = not applicable Four MBS items related to retinal detachment will be reviewed. Retinal detachment42773DETACHED RETINA, diathermy or cryotherapy for, not being a service associated with a service to which item 42776 applies42776DETACHED RETINA, buckling or resection operation for42779DETACHED RETINA, revision operation for42812DETACHED RETINA, removal of encircling silicone band from There is a suggestion that the original intention of item 42779 was to relate to revision of scleral buckling surgery, a retinal reattachment operation, rather than revision of other retinal reattachment operations (eg vitrectomy). It is suggested that revision of scleral buckling is now infrequently performed, but may be significantly more complex than primary retina reattachment procedures such as primary scleral buckling (item 42776) or vitrectomy surgery (42725). This is reflected in higher reimbursement for this item compared with 42776 or 42725. The majority of revisions for retinal detachment procedures are not considered to be revisions of scleral buckles. Re-wording of the descriptor for item 42812 is suggested to: "Removal of scleral buckling material, from an eye having undergone previous scleral buckling surgery (Anaes) (Assist)" Rationale: under these circumstances the retina is usually reattached, so the descriptor "DETACHED RETINA" is incorrect. The material is not necessarily a silicone band, therefore "scleral buckling material" is more accurate. An Assistant's fee may be justified as the procedure, especially in the case of certain types of scleral buckling material, is considered to involve significant dissection, and risk of haemorrhage. It is suggested that the procedure may take over 60 minutes in complex cases, and may involve significant risk of ocular perforation and other potentially sight-threatening complications. What is the revision rate for primary scleral buckling retina reattachment surgery (item 42776), relative to other retinal re-attachment procedures ie diathermy, cryotherapy (item 42773) or vitrectomy (42725)? For scleral buckling (item 42812), for what reason does reoperation occur, other than for failure of retina reattachment? Are some of these revision operations more complex than others? Pre-specified criteria for the selection of literature to address these questions are provided in  REF _Ref270785464 \h  \* MERGEFORMAT Table 14. Table  SEQ Table \* ARABIC 14 Criteria for selecting studies to assess revision following retinal re-attachment surgery CharacteristicInclusion CriteriaStudy designEffectiveness Systematic reviews of randomised controlled trials, randomised controlled trials, systematic reviews or individual studies of a cohort and/or non-randomised design are eligible. A hierarchical step-wise method will be used to select studies according to study design. If there are no systematic reviews of randomised controlled trials available, then randomised controlled trials alone will be selected. Should trial data be unavailable then systematic reviews of non-randomised and/or cohort studies will be selected. In the event that these are not available, non-randomised or cohort study designs alone will become eligible. Only the most recent, good quality literature will be selected and reported as determined by the NHMRC levels of evidence hierarchy ( REF _Ref270797089 \h  \* MERGEFORMAT Table 17).PopulationPeople with retinal detachment People having undergone a previous retinal attachment procedureInterventionsaPrimary retinal attachment procedures Revision of retinal attachment proceduresComparatorsaPrimary retinal attachment procedures will be compared with each other Revision procedures will be compared with each otherOutcomeaSafety Complications associated with the revision procedure Effectiveness Revision rate (failure of primary retinal reattachment), reoperation rate for reasons other than revision (eg removal of scleral buckling material, silicone band) Procedure duration, procedure complexity/need for assistanceSearch period2005 10/2010 Should there be limited data available during this period, the search will be extended back in five year increments until sufficient data are sourced. If the service is only used infrequently, then a targeted search will be undertaken to determine the current state-of-play of the procedure. The most recent narrative reviews and/or systematic reviews (if any) and Clinical Practice Guidelines will be identified and analysed to determine what international opinion is with respect to the service.LanguageEnglish language onlya Numbering relates to the population of interest ie population (1) or population (2) One MBS item concerned with removal of silicone oil following treatment for complex retinal detachments will be reviewed, namely: Complex retinal detachments42815 POSTERIOR CHAMBER, removal of silicone oil from There is a suggestion that this items descriptor should be amended to : "VITREOUS CAVITY, removal of silicone oil or other liquid vitreous substitute from (Anaes.) (Assist.)" Rationale: "posterior chamber" is anatomically inaccurate; also there are other liquid vitreous substitutes such as perfluorocarbons or perfluoro-octanes which may be used instead of silicone oil as a vitreous substitute on a temporary basis, and require removal in a similar fashion. What liquid vitreous substitutes are used in the treatment of complex retinal detachments? Pre-specified criteria for the selection of literature to address this question are provided in  REF _Ref270786189 \h  \* MERGEFORMAT Table 15. Table  SEQ Table \* ARABIC 15 Criteria for selecting studies to assess the the types of liquid vitreous substitutes used in the treatment of macular holes (item number 42815) CharacteristicInclusion CriteriaStudy designNarrative or systematic reviews or any study design, consensus or evidence-based clinical practice guidelines Only the most recent, good quality literature will be selected and reported as determined by the NHMRC levels of evidence hierarchy ( REF _Ref270797089 \h  \* MERGEFORMAT Table 17).PopulationPeople with complex retinal detachmentsInterventionUse of liquid vitreous substitutesComparator NAOutcomeNASearch period2005 10/2010LanguageEnglish language onlyNA = not applicable Literature search As outlined in the selection criteria for each clinical question, the approach to searching for literature will be tailored according to the type of factors influencing usage of procedure described in each item number if the service is still being used considerably then a search for high level literature will be conducted using the Cochrane library including the Cochrane database of systematic reviews, Database of abstracts of reviews of effects (DARE) and the HTA database. The economics database, EconLit, and Embase.com (consisting of both Embase and Medline) will be canvassed using a systematic reviews filter. Literature searches will be restricted to the English language only. B. if the service is only used infrequently, then a targeted search will be undertaken to determine the current state-of-play of the procedure. The most recent narrative reviews and/or systematic reviews (if any) and Clinical Practice Guidelines will be identified and analysed to determine what international opinion is with respect to the service and whether there are any subgroups of patients where the technology might have a use. The literature will be sourced from Embase.com (Medline and Embase) without a filter check but will be searched chronologically. Search strategies generally include a combination of indexing terms (eg MeSH or Emtree headings) and text word terms. Limits will be employed in a hierarchical manner according to the type of literature being sourced ie Limit 1, and if no relevant literature then Limit 2 and if no relevant literature, then Limit 3. This is outlined in  REF _Ref153264328 \h  \* MERGEFORMAT Table 16. Table  SEQ Table \* ARABIC 16 Suggested search terms for review of ophthalmological items Clinical questionSearch termsfluoroscein angioscopy Population ('eye'/exp OR 'eye disease'/exp) AND Intervention ('angioscopy'/exp OR angioscop* OR 'fluorescein'/exp) AND Limits [English language]/lim AND [humans]/lim AND [2005-2011]/py AND [systematic review]/lim [humans]/lim AND [2005-2011]/py AND ([systematic review]/lim OR [controlled clinical trial]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) [article]/lim AND [humans]/lim AND [2005-2011]/pyorbital echography / partial coherence interferometry Population ('eye'/exp OR 'eye disease'/exp) AND Intervention ('echography'/exp OR echograph* OR 'interferometry'/exp OR interferomet*) AND Limits [English language]/lim AND [humans]/lim AND [2005-2011]/py AND [systematic review]/lim [humans]/lim AND [2005-2011]/py AND ([systematic review]/lim OR [controlled clinical trial]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) [article]/lim AND [humans]/lim AND [2005-2011]/pyremoval of intraocular foreign body Population ('eye'/exp OR 'eye disease'/exp) AND Intervention ('magnetism'/exp OR 'magnetic separation'/exp OR 'magnetic and electromagnetic equipment'/exp OR ('eye surgery'/exp AND 'foreign body'/exp)) AND Limits [English language]/lim AND [humans]/lim AND [2005-2011]/py AND [systematic review]/lim [humans]/lim AND [2005-2011]/py AND ([systematic review]/lim OR [controlled clinical trial]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) [article]/lim AND [humans]/lim AND [2005-2011]/pytarsal cyst extirpation Population 'chalazion'/exp OR 'chalazi*' OR 'tarsal' NEAR/2 'cyst' OR 'meibomian' NEAR/2 'cyst' AND Intervention Not required Limits [English language]/lim AND [humans]/lim AND [2005-2011]/py AND [systematic review]/lim [humans]/lim AND [2005-2011]/py AND ([systematic review]/lim OR [controlled clinical trial]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) [article]/lim AND [humans]/lim AND [2005-2011]/pylacrimal passage obstruction and remova/replacement of nasolacrimal tubePopulation 'lacrimal apparatus'/exp OR 'nasolacrimal tube' OR 'lacrimal passages' OR 'lacrimal gland disease'/exp OR dacryocyst* OR 'epiphora' AND Intervention 'eye surgery'/exp OR 'eye surgery' Limits [English language]/lim AND [humans]/lim AND [2005-2011]/py AND [systematic review]/lim [humans]/lim AND [2005-2011]/py AND ([systematic review]/lim OR [controlled clinical trial]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) [article]/lim AND [humans]/lim AND [2005-2011]/pyretinal cryotherapy Population ('eye'/exp OR 'eye disease'/exp) AND Intervention ('cryotherapy'/exp OR retin* near/2 cryo*) AND Limits [English language]/lim AND [humans]/lim AND [2005-2011]/py AND [systematic review]/lim [humans]/lim AND [2005-2011]/py AND ([systematic review]/lim OR [controlled clinical trial]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) [article]/lim AND [humans]/lim AND [2005-2011]/pylaser photocoagulationPopulation ('eye'/exp OR 'eye disease'/exp) AND Intervention ('laser coagulation'/exp OR photocoagulat*) Limits [English language]/lim AND [humans]/lim AND [2005-2011]/py AND [systematic review]/lim [humans]/lim AND [2005-2011]/py AND ([systematic review]/lim OR [controlled clinical trial]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) [article]/lim AND [humans]/lim AND [2005-2011]/pycapsulectomy/lensectomy/ removal of vitreousPopulation ('eye'/exp OR 'eye disease'/exp) AND Intervention ('capsulotomy'/exp OR 'lensectomy'/exp OR 'vitrectomy'/exp) Limits [English language]/lim AND [humans]/lim AND [2005-2011]/py AND [systematic review]/lim [humans]/lim AND [2005-2011]/py AND ([systematic review]/lim OR [controlled clinical trial]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) [article]/lim AND [humans]/lim AND [2005-2011]/pyrevision of retinal attachment procedurePopulation 'retina detachment'/exp OR detach* OR 'vitreous body detachment' AND Intervention ('retina surgery'/exp OR vitrectomy/exp) AND Limits [English language]/lim AND [humans]/lim AND [2005-2011]/py AND [systematic review]/lim [humans]/lim AND [2005-2011]/py AND ([systematic review]/lim OR [controlled clinical trial]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) [article]/lim AND [humans]/lim AND [2005-2011]/pyliquid vitreous substitutesPopulation 'vitreous'/exp OR 'retina detachment'/exp OR detach* OR 'vitreous body detachment'/exp OR 'vitrectomy'/exp AND Intervention (intraocular NEAR/2 tamponade OR 'vitreous' NEAR/10 substitut* OR 'silicone gel'/exp OR 'organofluorine derivative'/exp OR 'glycosaminoglycan'/exp) AND Limits [English language]/lim AND [humans]/lim AND [2005-2011]/py AND [systematic review]/lim [humans]/lim AND [2005-2011]/py AND ([systematic review]/lim OR [controlled clinical trial]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) [article]/lim AND [humans]/lim AND [2005-2011]/py Critical appraisal of selected evidence The literature will be categorised according to NHMRC levels of evidence (see  REF _Ref270797089 \h  \* MERGEFORMAT Table 17), critically appraised using checklists relevant for each type of literature, and then synthesised according to the evidence matrix for NHMRC Grades of recommendation (see  REF _Ref153261406 \h  \* MERGEFORMAT Table 18). Relevant checklists include PRISMA for systematic reviews and health technology assessments  ADDIN EN.CITE Liberati200999917Liberati, AAltman, DGTetzlaff, JMulrow, CGtzsche, PC, et alThe PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration.PLoS MedPLoS Mede1000100672009doi:10.1371/journal.pmed.1000100(Liberati, Altman et al. 2009); SIGN checklists for appraising randomised and non-randomised controlled trials and observational studies  ADDIN EN.CITE SIGN200810101044SIGN, A guideline developer's handbook2008EdinburghScottish Intercollegiate Guidelines Network(SIGN 2008); and the QUADAS checklist for appraising diagnostic accuracy studies  ADDIN EN.CITE Whiting200311111117Whiting, P., Rutjes, A.W. et alThe development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews BMC Medical Research Methodology25312003(Whiting 2003). Table  SEQ Table \* ARABIC 17 Designations of levels of evidence  ADDIN EN.CITE Merlin T200966617Merlin T,Weston A,Tooher R,Extending an evidence hierarchy to include topics other than treatment: revising the Australian levels of evidenceBMC Medical Research MethodologyBMC Medical Research Methodology934 2009Internethttp://www.biomedcentral.com/1471-2288/9/34doi:10.1186/1471-2288-9-34NHMRC200977744NHMRC,NHMRC levels of evidence and grades for recommendations for developers of guidelines.20101/10/102009Canberra, ACTNational Health and Medical Research CouncilInternethttp://www.nhmrc.gov.au/_files_nhmrc/file/guidelines/evidence_statement_form.pdf(Merlin T, Weston A et al. 2009; NHMRC 2009) LevelIntervention 1Diagnostic accuracy 2I 4A systematic review of level II studiesA systematic review of level II studiesIIA randomised controlled trialA study of test accuracy with: an independent, blinded comparison with a valid reference standard,5 among consecutive persons with a defined clinical presentation6III-1A pseudorandomised controlled trial (i.e. alternate allocation or some other method)A study of test accuracy with: an independent, blinded comparison with a valid reference standard,5 among non-consecutive persons with a defined clinical presentation6III-2A comparative study with concurrent controls: % Non-randomised, experimental trial9 % Cohort study % Case-control study % Interrupted time series with a control groupA comparison with reference standard that does not meet the criteria required for Level II and III-1 evidenceIII-3A comparative study without concurrent controls: % Historical control study % Two or more single arm study10 % Interrupted time series without a parallel control groupDiagnostic case-control study6IVCase series with either post-test or pre-test/post-test outcomesStudy of diagnostic yield (no reference standard)11 Explanatory notes 1 Definitions of these study designs are provided on pages 7-8 How to use the evidence: assessment and application of scientific evidence (NHMRC 2000b) and in the accompanying Glossary. 2 These levels of evidence apply only to studies of assessing the accuracy of diagnostic or screening tests. To assess the overall effectiveness of a diagnostic test there also needs to be a consideration of the impact of the test on patient management and health outcomes (Medical Services Advisory Committee 2005, Sackett and Haynes 2002). The evidence hierarchy given in the Intervention column should be used when assessing the impact of a diagnostic test on health outcomes relative to an existing method of diagnosis/comparator test(s). The evidence hierarchy given in the Screening column should be used when assessing the impact of a screening test on health outcomes relative to no screening or opportunistic screening. 4 A systematic review will only be assigned a level of evidence as high as the studies it contains, excepting where those studies are of level II evidence. Systematic reviews of level II evidence provide more data than the individual studies and any meta-analyses will increase the precision of the overall results, reducing the likelihood that the results are affected by chance. Systematic reviews of lower level evidence present results of likely poor internal validity and thus are rated on the likelihood that the results have been affected by bias, rather than whether the systematic review itself is of good quality. Systematic review quality should be assessed separately. A systematic review should consist of at least two studies. In systematic reviews that include different study designs, the overall level of evidence should relate to each individual outcome/result, as different studies (and study designs) might contribute to each different outcome. 5 The validity of the reference standard should be determined in the context of the disease under review. Criteria for determining the validity of the reference standard should be pre-specified. This can include the choice of the reference standard(s) and its timing in relation to the index test. The validity of the reference standard can be determined through quality appraisal of the study (Whiting et al 2003). 6 Well-designed population based case-control studies (eg. population based screening studies where test accuracy is assessed on all cases, with a random sample of controls) do capture a population with a representative spectrum of disease and thus fulfil the requirements for a valid assembly of patients. However, in some cases the population assembled is not representative of the use of the test in practice. In diagnostic case-control studies a selected sample of patients already known to have the disease are compared with a separate group of normal/healthy people known to be free of the disease. In this situation patients with borderline or mild expressions of the disease, and conditions mimicking the disease are excluded, which can lead to exaggeration of both sensitivity and specificity. This is called spectrum bias or spectrum effect because the spectrum of study participants will not be representative of patients seen in practice (Mulherin and Miller 2002). 9 This also includes controlled before-and-after (pre-test/post-test) studies, as well as adjusted indirect comparisons (ie. utilise A vs B and B vs C, to determine A vs C with statistical adjustment for B). 10 Comparing single arm studies ie. case series from two studies. This would also include unadjusted indirect comparisons (ie. utilise A vs B and B vs C, to determine A vs C but where there is no statistical adjustment for B). 11 Studies of diagnostic yield provide the yield of diagnosed patients, as determined by an index test, without confirmation of the accuracy of this diagnosis by a reference standard. These may be the only alternative when there is no reliable reference standard. Note A: Assessment of comparative harms/safety should occur according to the hierarchy presented for each of the research questions, with the proviso that this assessment occurs within the context of the topic being assessed. Some harms (and other outcomes) are rare and cannot feasibly be captured within randomised controlled trials, in which case lower levels of evidence may be the only type of evidence that is practically achievable; physical harms and psychological harms may need to be addressed by different study designs; harms from diagnostic testing include the likelihood of false positive and false negative results; harms from screening include the likelihood of false alarm and false reassurance results. Note B: When a level of evidence is attributed in the text of a document, it should also be framed according to its corresponding research question eg. level II intervention evidence; level IV diagnostic evidence; level III-2 prognostic evidence. Note C: Each individual study that is attributed a level of evidence should be rigorously appraised using validated or commonly used checklists or appraisal tools to ensure that factors other than study design have not affected the validity of the results. Source: Hierarchies adapted and modified from: NHMRC 1999; Bandolier 1999; Lijmer et al. 1999; Phillips et al. 2001. The overall body of research evidence will be assessed and synthesised to address each clinical question according to  REF _Ref153261406 \h  \* MERGEFORMAT Table 18. An evidence rating from A (excellent) to D (poor) will be assigned to the evidence, considering each of the components outlined in the body of evidence matrix. In the absence of such literature, expert opinion and narratives will be synthesised according to the credibility of the source of such material. Table  SEQ Table \* ARABIC 18 Body of evidence assessment matrix (adapted from  ADDIN EN.CITE NHMRC200977744NHMRC,NHMRC levels of evidence and grades for recommendations for developers of guidelines.20101/10/102009Canberra, ACTNational Health and Medical Research CouncilInternethttp://www.nhmrc.gov.au/_files_nhmrc/file/guidelines/evidence_statement_form.pdf(NHMRC 2009)) ComponentABCDExcellentGoodSatisfactoryPoorEvidence base1one or more level I studies with a low risk of bias or several level II studies with a low risk of biasone or two level II studies with a low risk of bias or a SR/several level III studies with a low risk of biasone or two level III studies with a low risk of bias, or level I or II studies with a moderate risk of biaslevel IV studies, or level I to III studies/SRs with a high risk of biasConsistency2all studies consistentmost studies consistent and inconsistency may be explainedsome inconsistency reflecting genuine uncertainty around clinical questionevidence is inconsistentClinical impactvery largesubstantialmoderateslight or restrictedGeneralisabilitypopulation/s studied in body of evidence are the same as the target population population/s studied in the body of evidence are similar to the target population population/s studied in body of evidence differ to target population but it is clinically sensible to apply this evidence to target population3population/s studied in body of evidence differ to target population and hard to judge whether it is sensible to generalise to target populationApplicabilitydirectly applicable to Australian healthcare contextapplicable to Australian healthcare context with few caveatsprobably applicable to Australian healthcare context with some caveatsnot applicable to Australian healthcare contextSR = systematic review; several = more than two studies 1 Level of evidence determined from the NHMRC evidence hierarchy  REF _Ref270797089 \h  \* MERGEFORMAT Table 17. 2 If there is only one study, rank this component as not applicable. 3 For example, results in adults that are clinically sensible to apply to children OR psychosocial outcomes for one cancer that may be applicable to patients with another cancer 4.4 Stakeholder consultation community engagement Community engagement will be conducted to determine consumers revealed preferences and experiences concerning the services under review. Six services will be selected from those receiving Guideline concordance analysis and/or a mini-HTA four of these will be the most common services while the remaining two will be reserved for potentially problematic services (ie painful procedures, long hospital stay etc). Consumer engagement concerning the four most common services will occur mainly through the canvassing of internet blogs and qualitative literature, although telephone and internet interviewing of consumers will be undertaken, if possible. The aim will be to determine consumer experiences with the ophthalmological service under review, their preferences for modifying the service and/or to identify any consumer concerns or hardship should the service be removed. Should interviewing be conducted, consumers will be recruited via the Consumer Health Forum, local ophthalmologists or patient advocacy groups sending out letters, or via contact with authors of internet blogs. Eligibility for recruitment will be matched, as far as practicable, to the demographic characteristics that MBS data analysis indicates the primary consumers. Ethics approval has been received through the University approval process. The two additional services will receive a limited revealed preference assessment via canvassing internet consumer blogs and the qualitative literature on the topic only. The qualitative literature search will be undertaken using the Embase.com and Scopus databases. Blogs (also known as weblogs) are on-line journals documenting views and experiences of a single author, or in some cases a small group of authors. English language blogs from developed countries concerning the services under review will be identified through a Google advanced domain search and, where relevant, bloggers will be contacted and asked for an interview. Commercial blogs will be excluded. All literature will be imported into NVivo for thematic coding and analysis. Research questions will be drafted to address each of the six services once they are identified during the MBS data analysis phase. 4.5 Stakeholder negotiation Several item descriptors for the ophthalmological items under review will be discussed and potentially amended through negotiation between the Department and relevant stakeholders. Most of these amendments will relate to corrections of terminology. Items to be addressed are in  REF _Ref270800379 \h Table 19. Table  SEQ Table \* ARABIC 19 Ophthalmology items potentially being revised through negotiation ServiceMBS Item NumbersRemoval of foreign body42551, 42554, 42557, 42644Cataract surgery 42703, 42704, 42707, 42710, 42713Capsulectomy and lensectomy42731Retinal services 42818Vitrectomy42725Surgical assist 51315 As outlined previously, the Department will also be reviewing optometry perimetry items 10940 and 10941 separately, and will undertake stakeholder negotiation with the relevant optometry craft groups. With respect to the surgical assist item (51315) given below, there is a suggestion that there is an anomaly in the wording as it does not allow for surgical assistants to participate in surgery where both phacoemulsification to remove the lens (42698, 42702) and vitrectomy (42725) are required. Cataract51315 Assistance at cataract and intraocular lens surgery covered by item 42698,42701, 42702, 42704 or 42707, when performed in association with services covered by item 42551 to 42569, 42653, 42656, 42746, 42749, 42752, 42776 or 42779 A suggested amendment to item 51315 is suggested as a consequence: Suggested amendment and rationale: "Assistance at cataract and intraocular lens surgery covered by item 42698, 42701, 42702, 42704 or 42707, when performed in association with services covered by item 42551 to 42569, 42653, 42656, 42725, 42746, 42749, 42752, 42776 or 42779" Pars plana vitrectomy (item 42725) is an intraocular procedure during which lens removal / IOL implantation may be required in selected cases, as with the other item codes already listed as associated services. This combination of surgery may be required to allow improved visualisation for the vitrectomy procedure (hence improved safety) and avoids the need for a second surgery (ie subsequent cataract surgery). 4.6 Economic evaluation Only a preliminary economic evaluation of the services will be conducted, relying on literature identified through the searches outlined in Section 4.3 and MBS item costs only. In the literature searches, acceptable evidence would include trial-based costing studies, cost analyses and economic modelling studies. Acceptable outcomes would include: cost, incremental cost-effectiveness ratio eg cost per event avoided, cost per life year gained, cost per quality adjusted life year or disability adjusted life year. The applicability of any identified economic analyses to the Australian health system would be assessed. A formal modelled economic evaluation of the different ophthalmology items will not be conducted during this review. 4.7 Review outcomes The conclusions regarding the ophthalmological services that are assessed will be provided in a draft report. This report will be presented in chapters according to each service being reviewed. The results of the MBS item data analysis, guideline concordance activity, mini-HTA and consumer engagement will be synthesised for each service under review. A summary statement and conclusion will be developed for each service chapter. Following public consultation and feedback, the report will be finalised. The evaluation method that is tested for this review will also be assessed and critiqued as part of the project, with suggestions for its modification/revision provided, along with the final report. Reviews are expected to result in primary and supplementary review outcomes as shown below: Primary review outcomes Where an evaluation suggests that an item under review is supported by the evidence, the likely recommendation will be that the MBS listing will be retained in its current form. However, should an evaluation suggest that listed MBS items or services are inconsistent with contemporary evidence in relation to its clinical use or effectiveness, direct amendments to the MBS may be recommended. These may include one or more of the following changes: addition or removal of MBS items; changes to the Schedule fee; refinement of MBS item descriptors to better target patient groups, clinical indicators and/or promote the use of optimal clinical pathways; and/or potential for interim-listing pending the collection of item-specific data. Potential amendments to the MBS arising from reviews will be undertaken through consultation with the relevant stakeholder groups. Supplementary review outcomes - initiatives to facilitate evidence-based changes in clinical practice In addition to primary review outcomes relating to MBS reimbursement, reviews may indicate the need for secondary investment strategies aimed at bridging the divide between current evidence, including clinical guidelines and current clinical practice. To achieve this, a number of strategies may be implemented following the evaluation of individual items or services. These may include, but are not limited to, the following: development or revision of clinical practice guidelines for evaluated services where there is an identified need; strengthening or targeting of auditing/compliance activities; education and training initiatives for practitioners and/or consumers; exploring incentive-based initiatives to promote improved clinical practices or linking education and training programs to access incentives; and the development of research opportunities where gaps in effective service provision are evident. The identification of mechanisms to support evidence-based best practice will complement and reinforce any primary outcome MBS amendments to help improve health outcomes for patients, whilst ensuring the most efficient use of limited resources. 5. REVIEW TIMEFRAME The following key milestones are associated with this review of ophthalmological services: MilestoneTimeDraft review protocol submitted to the Department for considerationOctober, 2010Draft review protocol available for public comment October, 2010Completion of each evidence based review activity MBS data analysis Guideline concordance Community engagement Evidence-based analysis / mini-HTAs November, 2010 November, 2010 November, 2010 December, 2010Submission of draft review report to MQFEAC for consideration January February, 2011Draft review report available for public comment (minimum of four weeks)  January February, 2011Submission of final reportMarch April, 2011 6. REFERENCES Access Economics (September 2009). Cataract treatment in Australia, Access Economics Pty Ltd for Alcon Laboratories Australia Pty Ltd. Australian Institute of Health and Welfare (2005). Vision problems among older Australians. Canberra, AIHW. Australian Institute of Health and Welfare (2009). A guide to Australian eye health data. Canberra, AIHW. Liberati, A., D. Altman, et al. (2009). "The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration." PLoS Med 6(7): e1000100. Merlin T, Weston A, et al. (2009). "Extending an evidence hierarchy to include topics other than treatment: revising the Australian levels of evidence." BMC Medical Research Methodology 9(34 ). Mitchell, P., W. Smith, et al. (1996). "Prevalence of open-angle glaucoma in Australia." Ophthalmology 103(10): 1661-1669. NHMRC (2009). NHMRC levels of evidence and grades for recommendations for developers of guidelines. Canberra, ACT, National Health and Medical Research Council. 2010. SIGN (2008). A guideline developer's handbook. Edinburgh, Scottish Intercollegiate Guidelines Network. Whiting, P., Rutjes, A.W. et al (2003). "The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews." BMC Medical Research Methodology 3(1): 25. Attachment 1 Clinical Practice Guidelines Glaucoma Guidelines for Screening, Prognosis, Diagnosis, Management and Prevention of Glaucoma (Draft). Please note, it is expected these guidelines will be endorsed in August 2010. Access from http://www.nhmrc.gov.au/guidelines/consult/consultations/glaucoma_screening_guidelines.htm NICE Guidance: Glaucoma diagnosis and management of chronic open angle glaucoma and ocular hypertension (April 2009). Access from: http://guidance.nice.org.uk/CG85/Guidance/pdf/English RANZCO: Guidelines for Collaborative Care of Glaucoma Patients (undated). Access from http://www.ranzco.edu/aboutus/ranzco-policies-and-procedures/policy/GUIDELINES_FOR_COLLABORATIVE_CARE_OF_GLAUCOMA_PATIENTS.pdf American Academy of Ophthalmology Practice Patterns Open Angle Glaucoma European Glaucoma Society guidelines. www.eugs.org/ World Glaucoma Association publications. www.worldglaucoma.org/ SEAGIG (Southeast Asian Glaucoma Interest Group) guidelines. www.seagig.org/ Retinal services American Academy of Ophthalmology: Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern (September 2008). Access from http://one.aao.org/CE/PracticeGuidelines/PPP.aspx?p=1 Macular degeneration American Academy of Ophthalmology: Age-Related Macular Degeneration Preferred Practice Pattern (September 2008). Access from http://one.aao.org/CE/PracticeGuidelines/PPP.aspx?p=1 RANZCO: Medications for Age-Related Macular Degeneration (AMD) (undated). Access from http://www.ranzco.edu/aboutus/ranzco-policies-and-procedures/policy/Additional%20information%20on%20PBS%20access%20to%20AMD%20therapies%20-%20August%202007.pdf Cataracts American Academy of Ophthalmology: Cataract in the Adult Eye Preferred Practice Pattern (September 2006). Access from http://one.aao.org/CE/PracticeGuidelines/PPP.aspx?p=1 Canadian Ophthalmological Society evidence-based clinical practice guidelines for cataract surgery in the adult eye (October 2008). Access from http://eyesite.ca/english/program-and-services/policy-statements-guidelines/index.htm RANZCO: Cataract and Intraocular Lens Surgery (March 2006). Access from http://www.ranzco.edu/aboutus/ranzco-policies-and-procedures/policy/Cataract_Surgery.pdf Electroretinography Standard for clinical electroretinography (2008 update). Access from  HYPERLINK "http://www.iscev.org/standards/index.html" http://www.iscev.org/standards/index.html Standard for clinical electrooculography (2006). Access from  HYPERLINK "http://www.iscev.org/standards/index.html" http://www.iscev.org/standards/index.html Standard for clinical pattern electroretinography (2007 update). Access from  HYPERLINK "http://www.iscev.org/standards/index.html" http://www.iscev.org/standards/index.html Guidelines for clinical multifocal electroretinography (2007). Access from  HYPERLINK "http://www.iscev.org/standards/index.html" http://www.iscev.org/standards/index.html   HYPERLINK "http://www.aihw.gov.au/hospitals/datacubes/index.cfm" http://www.aihw.gov.au/hospitals/datacubes/index.cfm   HYPERLINK "http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1" http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1  http://www.ranzco.edu/  http://aso.asn.au/index.php?option=com_content&view=article&id=2&Itemid=20  http://www.optometrists.asn.au/AboutUs/tabid/74/language/en-US/Default.aspx  http://www.aamsa.org.au/about.php  http://www.surgeons.org/Content/NavigationMenu/WhoWeAre/Overview/default.htm  http://www.health.gov.au/internet/main/publishing.nsf/Content/MBRT-Public_consultation-reviews_of_existing_MBS_items  Richardson WS, Scott MD, Wilson MC et al. (1995) The well built clinical question: a key to evidence based decisions. ACP Journal Club, 123, ppA-12.  Note -    .;CcdfgijklmpswxofofZI=f4h35OJQJhxhko5OJQJ jhJ?+h,$5OJQJUhxh,$5OJQJh,$5OJQJhko5OJQJh,$5CJ8OJQJaJ8(h,$hko5B* CJHOJQJaJHph"h#75B* CJHOJQJaJHph(h,$ho5B* CJHOJQJaJHphh,$5CJHOJQJaJHho5CJHOJQJaJHhxhko5CJ(OJQJaJ((h,$hko5B* CJ0OJQJaJ0phI}    defghijklnopqrstuvwxyz$a$gdko$a$gd3gdko$a$gdkoR9;wxyz  & 7 8 e ̷ޗypyeYeNeNCNhBqhJOJQJhBqhTsOJQJheLshko5OJQJhBqhkoOJQJhJ5OJQJhTs5OJQJhko5OJQJhMzhko5OJQJhxhkoOJQJ(h,$hko5B* CJ(OJQJaJ(phI}(h,$ho5B* CJ(OJQJaJ(phI}"h[5B* CJ(OJQJaJ(phI}hxhko5OJQJhxh,$5OJQJh,$5OJQJz  & 8 I W e u   x$j& #$/Ifgdko$x$j& #$/Ifgdko gdkogdko$a$gdko  & ' : ; < Ź筣vh_Nv j]hxh,$5OJQJUh,$5OJQJj^bh,$5OJQJUhxh,$5OJQJ"hxh,$56CJOJQJaJh,$56CJOJQJaJh,$mHnHsH hxhko5OJQJheLshko5OJQJheLsheLs5OJQJhBqhJOJQJhBqhTsOJQJhBqhkoOJQJhBqhkoh0OJQJ ' : ; < b ~ qqqqqUdhx$j& #$/Ifgdkoorfdhx$j& #$/Ifgdkockdka$$Ifl0 !D  6 j,"64 lapx$j& #$/Ifgdko  gdkogdkoDkda$$IflF !," 6 j,"64 la  p "  % gd- #  % gd-gdkogd,$$a$gd,$ gdko ; < = > Z [ \ ] snZJj$hPUh-0JU&h-CJOJQJaJmHnHsH tH hOjh-Ujh-U h-j*hPUh-0JUh-hPUh-0JjhPUh-0JUhfOJQJjhfOJQJUh;0rhkoOJQJ:hk\hko5;B* CJOJQJ\aJmHnHphsH hkomHnHsH        / 0 1 2 N O P j k l m n o p q r ɵɵwɵjh-UjhPUh-0JUjh-UjhPUh-0JUh-&h-CJOJQJaJmHnHsH tH jhPUh-0JU hOjh-Ujh-U h-hPUh-0J.p F Z(K bnV!Xi $  % gd- #  % gd- "  % gd- $ % & @ A B C D E F G H d e f g Ӽɷ⚖yɷ⚖ijhPUh-0JUjh-Uj hPUh-0JUh-hPUh-0J&h-CJOJQJaJmHnHsH tH hOjh-Ujh-U h-hPUh-0J;jhPUh-0JUjhPUh-0JU& 789STUWXYZ[\xyz{׺׺顔׺׺w׺jwh-UjhPUh-0JUj}h-U h-jhPUh-0JUh-hPUh-0J&h-CJOJQJaJmHnHsH tH jhPUh-0JU hOjh-Ujh-U*!"#%&'()*FGHIcdeԽʸ٠ِԃʸ٠sfjeh-UjhPUh-0JUjkh-UjhPUh-0JUh-&h-CJOJQJaJmHnHsH tH hOjqh-Ujh-U h-hPUh-0JjhPUh-0JUjhPUh-0JU(()*DEFHIJKLMijkl{|}ƲƭƐƭsƭj֔hPUh-0JUjYh-UjܓhPUh-0JUj_h-U h-jhPUh-0JUh-hPUh-0J&h-CJOJQJaJmHnHsH tH jhPUh-0JUjh-U hO-   '()*?@A[\]_`abcdѽѴѴѽѴѴvѽѴjGh-UjʖhPUh-0JUjMh-UjЕhPUh-0JUh-hPUh-0J&h-CJOJQJaJmHnHsH tH jhPUh-0JU hOjh-UjSh-U h-+   /012KLMghiklmnopԽʸ٠ِԃʸ٠sfj5h-UjhPUh-0JUj;h-UjhPUh-0JUh-&h-CJOJQJaJmHnHsH tH hOjAh-Ujh-U h-hPUh-0JjhPUh-0JUjėhPUh-0JU(345OPQSTUVWXtuvwƲƭƐƭsƭjhPUh-0JUj)h-UjhPUh-0JUj/h-U h-jhPUh-0JUh-hPUh-0J&h-CJOJQJaJmHnHsH tH jhPUh-0JUjh-U hO- !"#?@ABijkѽѴѴѽѴѴvѽѴjh-UjhPUh-0JUjh-UjhPUh-0JUh-hPUh-0J&h-CJOJQJaJmHnHsH tH jhPUh-0JU hOjh-Uj#h-U h-+567QRSUVWXYZvwxy   Խʸ٠ِԃʸ٠sfjh-UjhPUh-0JUj h-UjhPUh-0JUh-&h-CJOJQJaJmHnHsH tH hOjh-Ujh-U h-hPUh-0JjhPUh-0JUjhPUh-0JU( 0123FGHbcdfghijkƲƭƐƭsƭjvhPUh-0JUjh-Uj|hPUh-0JUjh-U h-jhPUh-0JUh-hPUh-0J&h-CJOJQJaJmHnHsH tH jhPUh-0JUjh-U hO-i2 $Ifgd~mgd{ Sgd{xgd9+gd9+$a$gdko #  % gd-    /012>?AB^_`a}~ѽѴѴѴцyѽ_WhOJQJ3jhfB*OJQJUmHnHphsH tH ujjh-UhPUh-0J;jhPUh-0JUjphPUh-0JUh-hPUh-0J&h-CJOJQJaJmHnHsH tH jhPUh-0JU hOjh-Ujh-U h-!JRS[\cxT&'./01黰˨ˠrj_Whv|OJQJhOhOOJQJh{OJQJ#jhvQhzOJQJUjhvQOJQJUhvQOJQJh#7OJQJhwOJQJh6)OJQJh>h>OJQJh,OJQJh$OJQJh>OJQJh;0rh,6OJQJ]h>OJQJh;0rh,OJQJhh,B* ph"1289NOPQR+,-HNOdpqr}+,-HîtthhOJQJh~mh~mCJOJQJaJ)hh~mB*OJQJmHnHphtH hh;1OJQJ)h~mh~mB*OJQJmHnHphtH h~mh~m5CJOJQJaJ h{h{h>h{hOjh{h40U h{h40h>OJQJ(v $Ifgd~m $IfgdqKvkdd$$Ifl.0HU"a0 "4 laytv|, $IfgdqKvkd$$Ifl.0HU"a0 "4 laytv|,-HNv $Ifgd;1 $IfgdqKvkdΨ$$Ifl.0HU"a0 "4 laytv|NOdq $IfgdqKvkd$$Ifl.0HU"a0 "4 laytv|qr}v $Ifgd;1 $IfgdqKvkd8$$Ifl.0HU"a0 "4 laytv| $IfgdqKvkd$$Ifl.0HU"a0 "4 laytv|,v $Ifgdf $IfgdqKvkd$$Ifl.0HU"a0 "4 laytv|,-HN $IfgdqKvkdW$$Ifl.0HU"a0 "4 laytv|HMNOa}~ +12Dgh ƱƂƱpƂՂ^#hfB*OJQJmHnHphtH #hB*OJQJmHnHphtH )h~mh~mB*OJQJmHnHphtH h~mhCJOJQJaJhhOJQJ)h~mhB*OJQJmHnHphtH h~mh~mCJOJQJaJ)hh~mB*OJQJmHnHphtH )hhB*OJQJmHnHphtH $NOa}v $Ifgd $IfgdqKvkd $$Ifl.0HU"a0 "4 laytv|}~v $Ifgd $IfgdqKvkd$$Ifl.0HU"a0 "4 laytv $Ifgd $IfgdqKvkdv$$Ifl.0HU"a0 "4 layt v $Ifgd $IfgdqKvkd+$$Ifl.0HU"a0 "4 layt+1v $Ifgd $IfgdqKvkd$$Ifl.0HU"a0 "4 laytv|12Dgv $Ifgd $IfgdqKvkd$$Ifl.0HU"a0 "4 laytv|ghv $Ifgd $IfgdqKvkdJ$$Ifl.0HU"a0 "4 laytv $Ifgd $IfgdqKvkd$$Ifl.0HU"a0 "4 laytv $Ifgd $IfgdqKvkd$$Ifl.0HU"a0 "4 laytv $Ifgd $IfgdqKvkdi$$Ifl.0HU"a0 "4 laytv|  v $Ifgd $IfgdqKvkd$$Ifl.0HU"a0 "4 laytv|      : -!/!E!G!g!i!J$K$L$j$$$$$ %%%%&¾}umem}ZO}hwh,OJQJhwhwOJQJh#7OJQJhwOJQJh6)OJQJhBqh,OJQJ hBqh,hOJQJh,OJQJhh,OJQJ^Jhh,OJQJ hh,hv|h;0rh;0rOJQJh;0rOJQJ)hhfB*OJQJmHnHphtH )h~mhfB*OJQJmHnHphtH     : -!E!g!!!~whYYYhx^`gdW(x^`gdW(xgdW(6gd{gd,vkdӴ$$Ifl.0HU"a0 "4 laytv| !l""#$K$L$j$ %5%~%%]&&&?'@'^' (C(h(*xgdDgdW(gd,xgdW(6gd{ ^`gd,x^`gdW(&>'?'@'^' ( ( ((A(C(h(((((((((J))))Ⱦ}i`TK=KjhUOJQJU]hUOJQJ]hOhOOJQJ]h{OJQJ]&jh7hzOJQJU]h7OJQJ]jh7OJQJU]hDOJQJ] h{h,h#7h#7;B* phh#7h,;B* phhvQ;B* phh9+CJaJh?OJQJ h9+h,h,CJaJhBqh;0rOJQJhBqh;0r6OJQJ]))** * * ******+*,*-*e*f***********ü|||o_PhB4hiCJOJQJaJhDhi5CJOJQJaJhi5CJOJQJaJhB4hD5CJOJQJaJhD5CJOJQJaJhv5CJOJQJaJ h{h{hOjh{h7U h{h7hDOJQJ]hOhOOJQJ]jhUOJQJU]hUOJQJ] jhUOJQJU]*e*f******?kd$$Ifl4\Vj  (}i 0&64 layt; $IfgdWQ $IfgdDgd{ Sgd{***$+/+0+1+7+>kdc$$Ifl4\Vj  (}i 0&64 layt; $$Ifa$gdv $IfgdD $$Ifa$gdD*#+$+.+0+6+7+++++++, , ,,,i,j,k,l,r,s,,,,,,,M-N-O-P-V-W---$.).R.[.\.].^.d.e..񘈘yh%hiCJOJQJaJh]hiCJOJQJ\aJh]hiCJOJQJaJ1hahiB*CJOJQJaJmHnHphtH +hiB*CJOJQJaJmHnHphtH hiCJOJQJaJhB4hiCJOJQJaJhahiCJOJQJaJ/7+++++++MDDD $IfgdDkd$$Ifl4\Vj  ( }i  0&64 layt; $Ifgdv $Ifgda+, , , ,,j,k,SJJJA $IfgdqK $IfgdDkd$$Ifl4\Vj  ( }i 0&64 layt; $$Ifa$gdvk,l,m,s,,,_VVVM $IfgdqK $IfgdDkdº$$Ifl4\Vj  ( }i  0&64 layt;,,,,N-O-_VVVM $IfgdqK $IfgdDkd׻$$Ifl4\Vj  ( }i  0&64 layt;O-P-Q-W-\.]._VVVP$If $IfgdDkd$$Ifl4\Vj  ( }i  0&64 layt;].^._.e..._VMMG$If $Ifgd"* $IfgdDkd$$Ifl4\Vj  ( }i  0&64 layt;....... //////////000000111 11111 2 2W2X2Y2Z2ɽɮɂɽɽɽɽrchB4hRCJOJQJaJh]hiCJH*OJQJaJhi5CJOJQJaJh7hiCJOJQJ\aJh7hiCJOJQJaJh%hiCJOJQJaJhiCJOJQJaJhB4hiCJOJQJaJ1hahiB*CJOJQJaJmHnHphtH hahiCJOJQJaJ$....//_VMMG$If $Ifgd"* $IfgdDkd$$Ifl4\Vj  ( }i  0&64 layt;///_V $IfgdDkd+$$Ifl4\Vj  ( }i  0&64 layt;////000~uuii $$Ifa$gdqK $IfgdD $$Ifa$gdYtkdN$$IflV(  ļ0&64 lap ļyt;000011_VVMM $Ifgda $IfgdDkd $$Ifl4\Vj  (}i 0&64 layt;111 111_VVMM $Ifgda $IfgdDkd8$$Ifl4\Vj  ( }i  0&64 layt;1111V2W2_VVMM $Ifgda $IfgdDkdM$$Ifl4\Vj  ( }i  0&64 layt;W2X2Y2_V $Ifgd6Ikdb$$Ifl4\Vj  ( }i  0&64 layt;Y2Z2v2}222~uui $$Ifa$gdj%b $IfgdD $$Ifa$gdZQtkd$$IflV(  ļ0&64 lap ļyt;Z2u2v2{2}2222222 3#3)3*3333333;5G5e5555555566I7N7778W8o9999999!;.;L;;;ȹȹȹȬȹ}}ȹ}}}ȹ}}h]hiCJOJQJ\aJh]hiCJOJQJaJh,hi5CJOJQJaJhi5CJOJQJaJhahiCJOJQJaJhB4hiCJOJQJaJh/:hiCJOJQJaJhiCJOJQJaJhZQ5CJOJQJaJ12222!3"3_SJJ> $$Ifa$gdY $IfgdD $$Ifa$gd6Ikd@$$Ifl4\Vj  (}i 0&64 layt;"3#3$3*3~33_VVMM $Ifgda $IfgdDkdo$$Ifl4\Vj  (}i 0&64 layt;333_V $Ifgd6Ikd$$Ifl4\Vj  ( }i  0&64 layt;333355~ul` $$Ifa$gdj%b $Ifgda $IfgdD $$Ifa$gd;>tkd$$IflV(  ļ0&64 lap ļyt;55557)88o9_VVM@@@  & F$Ifgd: $Ifgda $IfgdDkdn$$Ifl4\Vj  (}i 0&64 layt;o999999;;JAA $IfgdDkd$$Ifl4\Vj  ( }i 0&64 layt; $$Ifa$gdj%b $Ifgda;;;;;'<<u=X?x?????@@@@@XAYAcAfAgAmA^B_B`BfBWCXCYC_CDDDD F#FǷǷ⧚~l~~~~"hahi5CJOJQJ\aJhshiCJOJQJaJhpN5CJOJQJaJhi5CJOJQJaJhDl7hi5CJOJQJaJh]hiCJOJQJ\aJh]hiCJOJQJaJhiCJOJQJaJhB4hiCJOJQJaJhahiCJOJQJaJ&;;;;w=>>X?_VVM@@@  & F$Ifgd: $Ifgda $IfgdDkd$$Ifl4\Vj  ( }i 0&64 layt;X?z????JA $Ifgd6Ikd$$Ifl4\Vj  ( }i 0&64 layt; $$Ifa$gdj%b $Ifgda??@@YAdAeA~uuii $$Ifa$gdDl7 $IfgdD $$Ifa$gd}tkd$$IflV(  ļ0&64 lap ļyt;eAfAgAmA]B^B_VVMM $Ifgda $IfgdDkdk$$Ifl4\Vj  (}i 0&64 layt;^B_B`BfBVCWC_VVMM $Ifgda $IfgdDkd$$Ifl4\Vj  ( }i  0&64 layt;WCXCYC_CDD_VVMM $Ifgda $IfgdDkd$$Ifl4\Vj  ( }i  0&64 layt;DDDDF F_VVMM $Ifgda $IfgdDkd$$Ifl4\Vj  ( }i  0&64 layt; F!F"F_V $Ifgd6Ikd$$Ifl4\Vj  ( }i  0&64 layt;"F#F.F4FFFF~uuii $$Ifa$gd} $IfgdD $$Ifa$gd6Itkd$$IflV(  ļ0&64 lap ļyt;#F-F.F4FFFFFFFIGMGNGTGGGGGGGGGG8H;HV_VVMM $Ifgda $IfgdDkd$$Ifl4\Vj  ( }i  0&64 layt;>V?V@V_V $Ifgd6Ikd$$Ifl4\Vj  ( }i  0&64 layt;@VAVVVjWvW~uui $$Ifa$gdz $IfgdD $$Ifa$gd6Itkd%$$IflV(  ļ0&64 lap ļyt;vWwWxWaX $Ifgd6Ikd$$Ifl\Vj  (}i 0&64 layt;xWyWWW X,X~uui $$Ifa$gdxv $IfgdD $$Ifa$gd$Wtkd$$IflV(  ļ0&64 lap ļyt;,X-X.X4X}X~X_SJJJ $Ifgdp $$Ifa$gd6Ikd$$Ifl4\Vj  (}i 0&64 layt;~XXXXXXX_SJJJA $Ifgdp $Ifgd] $$Ifa$gd6Ikd$$Ifl4\Vj  (}i  0&64 layt;XXXYY YYYYYYYYYYYYZZZAZDZFZGZpZqZZZZZ[Ŷ񶪶񶪶񶪶❍{k\Mh%h?CJOJQJaJh/:h?CJOJQJaJhG_h?5CJOJQJaJ"h^jh?5CJH*OJQJaJh^jh?5CJOJQJaJh?5CJOJQJaJh;CJOJQJaJhB4h;CJOJQJaJhG_h;5CJOJQJaJh;5CJOJQJaJhB4h?CJOJQJaJh%h;CJOJQJaJXXX_V $Ifgd6Ikd$$Ifl4\Vj  (}i  0&64 layt;XXY YYYY~ul`` $$Ifa$gdxv $Ifgd6I $IfgdD $$Ifa$gdG_tkd$$IflV(  ļ0&64 lap ļyt;YYYYYY_VVMV $Ifgd6I $IfgdDkd$$Ifl4\Vj  (}i 0&64 layt;YYYYYZ_VVMV $Ifgd6I $IfgdDkd$$Ifl4\Vj  ( }i  0&64 layt;ZZZZBZCZ_VVMV $Ifgd6I $IfgdDkd$$Ifl4\Vj  ( }i  0&64 layt;CZDZEZ_V $Ifgd6Ikd $$Ifl4C\Vj  ( }i  0&64 layt))EZFZZZ[[~uui $$Ifa$gdxv $IfgdD $$Ifa$gd^jtkd!$$IflV(  ļ0&64 lap ļyt;[[[[[\\\6\7\8\9\D\H\P\Q\X\=]>]I]K]L]]]]]ȹ垏ȹpdUMhuQCJaJh%=h,CJOJQJaJh%=CJOJQJaJh%=h^jCJOJQJaJh%=h^jCJH*OJQJaJhB4h;CJOJQJaJh;CJOJQJaJh%h?CJOJQJaJhsh?CJOJQJaJhG_h?5CJOJQJaJh?5CJOJQJaJh?CJOJQJaJhB4h?CJOJQJaJ[[[aX $Ifgd6Ikd$$Ifl\Vj  (}i 0&64 layt;[[\\7\8\9\E\~uuuui $$Ifa$gd\R $IfgdD $$Ifa$gd9<tkd$$IflV(  ļ0&64 lap ļyt;E\F\G\aX $Ifgd6Ikd$$Ifl\Vj  (}i 0&64 layt;G\H\Q\X\>]J]~uui $$Ifa$gd\R $IfgdD $$Ifa$gd;tkdk$$IflV(  ļ0&64 lap ļyt;J]K]]]^^/`0``a\\WRRRM:gdd:gdAgdV5gd,kd&$$Ifl\Vj  (}i 0&64 layt;]^%^1^f^w^|^^^^^^^_V_a__.`/`0`4`7`8`O`q`````````cc격yppg^^hUOJQJ]h;1OJQJ]h~COJQJ]hROJQJ]h +6hOMOJQJ]h>OJQJ]hAOJQJ]hOMOJQJ]hzVOJQJ]h'dOJQJ]0h7hOMB*OJPJQJ]aJnH phtH *hzVB*OJPJQJ]aJnH phtH *h7B*OJPJQJ]aJnH phtH "`bfcc:dd?ee f_f`fnffCkI~Ɂ 45wxH$gdX2xH$gdMxH$gd.nxH$gdhx^h`gd8 6gd{gd,  & FxH$gd:c#c4c=e>ef f_f`fafnff/g6g:g=gDgggggggggh/hJhOhShdhehfhkk@kAkBkkklȼ䳧䳞xohgbOJQJ]hQOJQJ]mHnHuhiOJQJ]jhQOJQJU]h.nOJQJ]h+hOMOJQJ]hOJQJ]h~Ch~C5OJQJ hW(h,hv|huQCJaJhLOJQJ]hOMOJQJ]hUOJQJ]h3OJQJ](lllZm\m]mmmEpFpgphpjpppppppssssstBtatbtct w w=w>w@wLwwwwnzozzzz{{{{{){j{k{l{~߾ߵ֕hOJQJ]mHnHujhOJQJU]hOJQJ]hOMOJQJ]h.nOJQJ]hgbOJQJ]hQOJQJ]mHnHuhiOJQJ]jhQOJQJU]hb.OJQJ]h-"xOJQJ]4~~F~G~I~~~%56:vw}߅-ѵѧѧўўѕwgw^wUhGOJQJ]hZOJQJ]jhX20J-OJQJU]hX2OJQJ]hM5OJQJh+hM5OJQJh-5OJQJh8OJQJ]hQ{hMH*OJQJ]h;hMOJQJ]jhM0J-OJQJU]hMOJQJ]hOMOJQJ]hQOJQJ]mHnHujhQOJQJU]!8^Afef7^gdv]xgdv]hx^h`gd8 xH$gd; & F  9!xH$gdsSxH$gdX2 & F  9!xH$gdG-ST^{~5YZ[l؇ه$24=>dfgyUhGdhv]OJQJ]h8hOM5OJQJh85OJQJhv]OJQJ]hX2OJQJ]hUOJQJ]hV(OJQJ]hc+OJQJ]hROJQJ]hsSOJQJ]h8OJQJ]hGOJQJ]hOMOJQJ]-UÉʼn(+pyÒĒ&˽˯ˡ˓ynjcUhMjOJQJmHnHtH h+h,h5thvh,B* phh5tB* phhQ:hQ:OJQJ hW(h,hv]B*OJQJ]phhH4B*OJQJ]phhsB*OJQJ]phh'dB*OJQJ]ph hQ:hv]B*OJQJ]phhzhv]OJQJhv]OJQJ hv]hv]B*OJQJ]phÒ ݕė>Ƙǘxgdxgd+x^`gdw#xgdw# x7$8$H$gdw#gdvgdQ:6gd{hx^h`gdv]xgd'd&•ݕ)-DZ Y[ŘƘǘȘɘ =@D¾|qiaiaiaYhJOJQJhsOJQJha"OJQJhhy/OJQJhOJQJh?OJQJh(OJQJhwOJQJh_OJQJhZOJQJhh,OJQJ hh,h5thhOJQJh,OJQJhhw#OJQJhw#hw#B*OJQJph hw#hw#OJQJmHnHtH "ǘȘF1^K,j(VA  & FxgdBP  & Fxgdw  & Fxgdh5  & FxgdJ & Fx^`gdM  & FxgdJ  & Fxgd+  & Fxgdsxgd+6gd{xgdDFl™ÙO./01^#JKS\]a<=(𼰼蚏vk`k`k`kTh6hJ6OJQJh6hJOJQJh6h+BOJQJhJhsOJQJjhM0J-OJQJUhMhMOJQJhMOJQJjh+B0J-OJQJUha"ha"6OJQJha"ha"OJQJh6h6OJQJh6h/OJQJh6ha"OJQJhJOJQJha"OJQJhsOJQJ()*+,ijtu%&'(_{|}AʾʑzldYUQJ hh,h5thy/hha"OJQJhb+OJQJjhBP0J-OJQJUhBPhBP6OJQJhBPhBPOJQJhBPOJQJjhw0J-OJQJUhwhw6OJQJhwhwOJQJhwhh5OJQJhwOJQJhJOJQJ!jh6h+B0J-OJQJUh6h+BOJQJh66OJQJAߣ+09\o lmnopsӨߨ궭󢞗zogogo\zoh2Bh2BOJQJh2BOJQJhh,OJQJ#hh,6B*OJQJ]phh>h2BOJQJ hh,h5thhOJQJhvbOJQJ]h2OJQJ]h*OJQJ]jh?0J-OJQJU]h0|OJQJ]hZOJQJ]hUOJQJ]hUh,OJQJ]$A noҬӬIخ)pq MN$a$gd@1  3^gd gd}HxgdLT 3^gd}HgdTxgd+6gd{xgd+ߪ߫:FѬҬӬԬ@ڭޭ߭׮خTYŷ|t|iaVtahh_OJQJh_OJQJhhfkOJQJh6)OJQJhfkOJQJ#hh,6B*OJQJ]phh>hfkOJQJhh,OJQJ hh,h5thah,6OJQJ]hh2BOJQJheOJQJhzNOJQJh=c&OJQJh/OJQJh2BOJQJh,OJQJ!)*@AQRYZʱ=mnw۲ܲ[\̺̺̌wewP>PP>"hh)LCJOJQJaJmHnHsH (hJh|0CJOJQJaJmHnHsH "hZCJOJQJaJmHnHsH (hJh}HCJOJQJaJmHnHsH (hOhOCJOJQJaJmHnHsH 1jh@1CJOJQJUaJmHnHsH "h@1CJOJQJaJmHnHsH +jh@1CJOJQJUaJmHnHsH hTh,B* phh 3B* phhhOJQJ³ʳSTjk{|Ǵȴpʴʛʴq_qJ8J"hZCJOJQJaJmHnHsH (hJh}HCJOJQJaJmHnHsH "hCJOJQJaJmHnHsH (hJh@1CJOJQJaJmHnHsH (hOhOCJOJQJaJmHnHsH 1jh@1CJOJQJUaJmHnHsH +jh@1CJOJQJUaJmHnHsH "h@1CJOJQJaJmHnHsH "hh)LCJOJQJaJmHnHsH "h(CJOJQJaJmHnHsH pqĵ )*+,-LMNVW^_tu|ظبؕ}vl\M\M\M\Mh@YhOCJOJQJaJh@YhO5CJOJQJaJh23\hO5CJ h@YhOh hOjh@YUh@Yha%hJhB*OJQJmH phsH hB*OJQJmH phsH hwB*OJQJmH phsH htCB*OJQJmH phsH %hJh}HB*OJQJmH phsH (hJhryCJOJQJaJmHnHsH NW_u|$xx$Ifa$gd@1|}~* xx$Ifgd@1kd $$Ifl\ ->  '  t(0;44 la1p(yt ĶŶͶζӶԶնYZ 0146opuv}~ CD^_ĝhaCJOJQJaJh(h(CJOJQJaJh(hOCJOJQJaJhi1\CJOJQJaJh(CJOJQJaJh@Yh CJOJQJaJh?5CJOJQJaJh@YhOCJOJQJaJh@YhO5CJOJQJaJ3նGPQSTUVWYZvFf  $$Ifa$gd@1 $Ifgd@1Ff $xx$Ifa$gd@1ͷFfFf $Ifgd@1Ff $$Ifa$gd@1%&')+,.01Sfghjkmnopȸʸ˸͸ڸFf $Ifgdi1\Ff $$Ifa$gd@1 $Ifgd@1ڸ۸ݸ߸ (:;<>?ABCDFf%Ff " $Ifgd@1Ff $$Ifa$gd@1_fgnovw~ 56WX{|ʺ˺$%6:ABDE#()*+6PQRָh8htB*phh8h 3B*phh0 hTh,h 3hah hOCJOJQJaJh@Yhh)LCJOJQJaJh@Yh CJOJQJaJhaCJOJQJaJh@YhOCJOJQJaJ1D Ff"+Ff( $$Ifa$gd@1 $Ifgd@1 *,./02356Zoqstuwy{|Ff74Ff01 $Ifgd@1Ff). $$Ifa$gd@1ºúźƺǺȺʺ˺ҺFfE:Ff>7 $$Ifa$gd@1 $Ifgd@1';=>?@ACDE^gdOFfZCFfS@ $Ifgd@1FfL= $$Ifa$gd@1#$%&'(6RvwGH @AH$gd- 3d^gdLT 3 & FdgdLTgd86gd{6^gdO^gdORWw{|ܼݼwxŽӽ뾣mR:R.haB*OJQJ_H mHnHphsH tH u4hJh2yB*OJQJ_H mHnHphsH tH u4h(hsB*OJQJ_H mHnHphsH tH u4h(h2yB*OJQJ_H mHnHphsH tH u4hJh0B*OJQJ_H mHnHphsH tH u4hJhB*OJQJ_H mHnHphsH tH u"h6)CJOJQJaJmHnHsH (hJhtCJOJQJaJmHnHsH $:FGH ʯy^F.^..h-B*OJQJ_H mHnHphsH tH u.h\wIB*OJQJ_H mHnHphsH tH u4hJh-B*OJQJ_H mHnHphsH tH uh-OJQJmH sH hJOJQJmH sH hJhJOJQJmH sH hJhLTOJQJmH sH 4hJhJB*OJQJ_H mHnHphsH tH u4hJh2yB*OJQJ_H mHnHphsH tH u4hJhbT;B*OJQJ_H mHnHphsH tH uBp|@AFuz7͵͚mXCX.X(hJhACJOJQJaJmHnHsH (hJhJCJOJQJaJmHnHsH (hJh0CJOJQJaJmHnHsH "h-CJOJQJaJmHnHsH 4hJhLTB*OJQJ_H mHnHphsH tH u4hJhbT;B*OJQJ_H mHnHphsH tH u.hZB*OJQJ_H mHnHphsH tH u4hJh2yB*OJQJ_H mHnHphsH tH u.h-B*OJQJ_H mHnHphsH tH u7DFHIJKLb}PQ'0kYD/YkY(h9hp|CJOJQJaJmHnHsH (h9h\wICJOJQJaJmHnHsH "h\wICJOJQJaJmHnHsH (h\wIh|0CJOJQJaJmHnHsH )h\wIhBB*OJQJmHnHphtH #hBB*OJQJmHnHphtH h8h 3B*phhd hTh0h 3(hJhACJOJQJaJmHnHsH (hJh0CJOJQJaJmHnHsH (hJhJCJOJQJaJmHnHsH AGHb}PQt3$If^gdlfgdY SgdY 3^gd|0 x7$8$H$gd 3 & Fx7$8$H$gd:gd86gd{ 3dx^gd- 0Lrstz{&'WXz{DEijoooooooooo_h*OJQJaJmHnHsH $hlfhYOJQJaJmHnHsH hlfhYOJQJ'hlfhY5OJQJaJmHnHsH hlfhY5OJQJ hYhYhOjhYUhY(h\wIh*CJOJQJaJmHnHsH "haCJOJQJaJmHnHsH (h\wIh|0CJOJQJaJmHnHsH $&uu3$If^gdlf{kd_E$$Ifl0LK' t0644 laytlf&'<Wuu3$If^gdlf{kdE$$Ifl0LK' t0644 laytlfWXmzuu3$If^gdlf{kdF$$Ifl0LK' t0644 laytlfz{uf3$If^gdp|3$If^gdlf{kdG$$Ifl0LK' t0644 laytlfuu3$If^gdlf{kdG$$Ifl0LK' t0644 laytlf uu3$If^gdlf{kd>H$$Ifl0LK' t0644 laytlf"Duu3$If^gdlf{kdH$$Ifl0LK' t0644 laytlfDE\iuu3$If^gdlf{kddI$$Ifl0LK' t0644 laytlfijyuu3$If^gdlf{kdI$$Ifl0LK' t0644 laytlfuu3$If^gdlf{kdJ$$Ifl0LK' t0644 laytlf7-yyyyyttkkkk^gdgdr 3^gd|0{kdK$$Ifl0LK' t0644 laytlf %&WX}~tu:ry뭚tt_tMM"h!oCJOJQJaJmHnHsH (h\wIhCJOJQJaJmHnHsH ,h\wIh|00JCJOJQJaJmHnHsH h\wIh|0CJOJQJaJ%jh\wIh|0CJOJQJUaJ(h\wIh|0CJOJQJaJmHnHsH %h25CJOJQJaJmHnHsH +h\wIh"5CJOJQJaJmHnHsH (h\wIh"CJOJQJaJmHnHsH y2ARXhmnWXĬyyy^F.hrB*OJQJ_H mHnHphsH tH u4h\wIhB*OJQJ_H mHnHphsH tH u.hmB*OJQJ_H mHnHphsH tH u4h\wIhrB*OJQJ_H mHnHphsH tH u.h!oB*OJQJ_H mHnHphsH tH u(h\wIhrCJOJQJaJmHnHsH "h!oCJOJQJaJmHnHsH (h\wIh|0CJOJQJaJmHnHsH -O|mXY&'&(o`a 3$If^gdlfgdn Sgdngdn6gd{6 gdnxgdgd=( 3^gd|0gdr^gd^gdXYok%&'bjt|ͲͲͅjO4O44h!ohnB*OJQJ_H mHnHphsH tH u4h!oh=(B*OJQJ_H mHnHphsH tH u4h!ohmB*OJQJ_H mHnHphsH tH u.hB*OJQJ_H mHnHphsH tH u(h\wIhrCJOJQJaJmHnHsH 4h\wIhrB*OJQJ_H mHnHphsH tH u.hmB*OJQJ_H mHnHphsH tH u4h\wIh 9B*OJQJ_H mHnHphsH tH u |$&'()*+,>ouͲ͚{\XTXTMI9hh)LB*OJQJmH phsH h0 hTh0hdh 3<h!ohdB*CJOJQJ_H aJmHnHphsH tH u<h!ohnB*CJOJQJ_H aJmHnHphsH tH u.h$B*OJQJ_H mHnHphsH tH u4h!ohB*OJQJ_H mHnHphsH tH u4h!oh=(B*OJQJ_H mHnHphsH tH u.h!B*OJQJ_H mHnHphsH tH uu"<KPWZٶ잶p]NBNBNBNhOJQJmH sH h HhOJQJmH sH %h Hh,3B*OJQJmH phsH %hOhOB*OJQJmH phsH 4jKh Hh*"B*OJQJUmH phsH .jh Hh*"B*OJQJUmH phsH %h Hh*"B*OJQJmH phsH hh)LB*OJQJmH phsH %h Hh HB*OJQJmH phsH %h HhnB*OJQJmH phsH a+5= &'޶ޣހ|t|tpt|i[E+hlfhn5CJOJQJaJmHnHsH hlfhn5OJQJaJ hYhnhOjhnUhn%h HhnB*OJQJmH phsH hB*OJQJmH phsH %h Hh5pB*OJQJmH phsH (h Hh,36B*OJQJmH phsH %h HhjB*OJQJmH phsH %h Hh,3B*OJQJmH phsH h Hh HOJQJmH sH &'4:r}kd-L$$Ifl0LK' t0644 laytlf3$If^gdlf'249:;NO[\]pq67JK񵠔vivihU)hnOJQJaJhU)h*"OJQJ^JaJhlfh*"OJQJ^JaJhU)OJQJ^JaJ(hlfhnCJOJQJaJmHnHsH hlfhnOJQJaJ(hlhnCJOJQJaJmHnHsH hlhnOJQJaJhlh*"OJQJaJhlh*"OJQJ^JaJ#:;O\rr3$If^gdlf}kdL$$Ifl0LK' t0644 laytlf\]qrr3$If^gdlf}kd]M$$Ifl0LK' t0644 laytlfrr3$If^gdlf}kdM$$Ifl0LK' t0644 laytlfrr3$If^gdlf}kdN$$Ifl0LK' t0644 laytlfrr3$If^gdlf}kd%O$$Ifl0LK' t0644 laytlf7Krr3$If^gdlf}kdO$$Ifl0LK' t0644 laytlfKLcirr3$If^gdlf}kdUP$$Ifl0LK' t0644 laytlfKLbchijz{"#ϺwbIb0jhe0J-B*OJQJUmHnHphtH )hheB*OJQJmHnHphtH #heB*OJQJmHnHphtH (hlfh*"CJOJQJaJmHnHsH hlfh*"OJQJaJhlfh*"OJQJ^JaJ(hlfhnCJOJQJaJmHnHsH hU)hnOJQJaJhU)h*"OJQJ^JaJ(hU)hnCJOJQJaJmHnHsH ij{rr3$If^gdlf}kdP$$Ifl0LK' t0644 laytlfrr3$If^gdlf}kdQ$$Ifl0LK' t0644 laytlfrr3$If^gdlf}kdR$$Ifl0LK' t0644 laytlf?KLvvccccvv^gd8x7$8$H$^`gde x7$8$H$gde}kdR$$Ifl0LK' t0644 laytlf \IJKLR\~"ɴ}r}eUC"hh5p5OJQJmHnHuh`VIh`VIOJQJmHnHuh`VIOJQJmHnHuh8hNB*phh8h 3B*phhB*ph#heB*OJQJmHnHphtH #h_DB*OJQJmHnHphtH )hheB*OJQJmHnHphtH #hjB*OJQJmHnHphtH #hi}B*OJQJmHnHphtH #hB*OJQJmHnHphtH  >E $Ifgd] $$Ifa$gd] ^gdYN;  & Fxgd:xgd`VI"=>HK "$FMWʸܦ܋xpxhxx`x`xUh,Eh_OJQJh!OJQJhqOJQJh_DOJQJh,EOJQJh,Eh,EOJQJhYN;h,E>*OJQJhT5OJQJmHnHu"hh!5OJQJmHnHu"hh7~5OJQJmHnHu"hh`VI5OJQJmHnHu"hh5p5OJQJmHnHu"hh(5OJQJmHnHupqr:;=>CE;<³¤¤jV&h}B*OJQJmH nH phtH u,hkmh!B*OJQJmH nH phtH u&hi3B*OJQJmH nH phtH uhah7tCJOJQJaJhB4h7tCJOJQJaJh/:h7tCJOJQJaJh7tCJOJQJaJh7t5CJOJQJaJhh7t5CJOJQJaJ(jhh7t5CJOJQJUaJ rf]] $Ifgd] $$Ifa$gd] kdMS$$Ifl4FY ' 06    4 layt!:riii $Ifgd] kdHT$$Ifl4FY ' 06    4 layt!:;<CDSfrmmhWRII @$IfgdTgdkm SS^S`gddZgdpNgd!kd5U$$Ifl4FY '  06    4 layt!.<BCDfg~IûûzrzjzbjzjZhDlCJaJhqCJaJhTCJaJ *h $hTh[7hTCJaJ hkmhkm hkmh_ hkmh_D h?h_D h?h_h@ h_h_h_hOjhkmUhkmhpNhpNhpNmHnHtH &h!B*OJQJmH nH phtH u&hpNB*OJQJmH nH phtH ufgtyyy ?$IfgdT|kd*V$$IflK0eL'e0L'644 lalytq a/E=>?]ɾɫɫɫɫ~vvhxCJaJh:6hTCJaJhnaCJaJhV]CJaJhhTCJaJ h(hTh(hTCJaJ *h $hTh[7hTCJaJhTCJaJhOhOCJaJjVhDlCJUaJhDlCJaJjhDlCJUaJ, yy ?$IfgdT|kdBW$$Ifli0eL'e0L'644 lalytq yl ?"$If^"gdT ?$IfgdT|kdW$$IflK0eL'e0L'644 lalytqyy ?$IfgdT|kdxX$$Ifl<0eL'e0L'644 lalytqyy ?$IfgdT|kdY$$IflK0eL'e0L'644 lalytq>yp ?$IfgdDl ?$IfgdT|kdY$$IflK0eL'e0L'644 lalytq>?H^yy ?$IfgdT|kdIZ$$IflK0eL'e0L'644 lalytq]^_'().2bjtDFGMµµµ¥paOa@phB4hJCJOJQJaJ"hahJ5CJOJQJ\aJhahJCJOJQJaJhshJCJOJQJaJhJCJOJQJaJhpN5CJOJQJaJhJ5CJOJQJaJhDl7hJ5CJOJQJaJhpNOJQJmHnHuhJOJQJmHnHuhYGOJQJmHnHuh[zOJQJmHnHu h_hThhTB*CJaJph^_`()tE{{{{off $Ifgd] $$Ifa$gd] xgdQ|kdZ$$IflK0eL'e0L'644 lalytqEFGM=riii $Ifgd] kd[$$Ifl4F 'er 0T6    4 lalyt =>?E5riii $Ifgd] kd\$$Ifl4F ' er 0T6    4 lalyt M>?E67=;AIby{ɺnVn/jhwHB*OJQJUmH nH phtH u&hwHB*OJQJmH nH phtH u,hkmhJB*OJQJmH nH phtH uhH+5OJQJmHnHu"hhJ5OJQJmHnHuhpN5OJQJmHnHuhJOJQJmHnHuhshJCJOJQJaJhJCJOJQJaJhahJCJOJQJaJ567=riii $Ifgd] kdk]$$Ifl4F ' er 0T6    4 lalyt riii $Ifgd] kdW^$$Ifl4F ' er 0T6    4 lalyt {rkka\KFgdJ SS^S`gdJgdJ  & Fxgd:xgdJkdC_$$Ifl4F ' er 0T6    4 lalyt  +,-.0]cdepyиvrjrjfjr_r[rWS[_rWrLrL h?hJh@hlJhH+ h_hJhOjhJUhJ,hkmhJB*OJQJmH nH phtH u&hJB*OJQJmH nH phtH u,hOhOB*OJQJmH nH phtH u/jhwHB*OJQJUmH nH phtH u&hwHB*OJQJmH nH phtH u5j=`hwHB*OJQJUmH nH phtH u%&3<Odz =H`abp wgh !#꿴ǔDžǔzhOhOCJaJjQahxM=CJUaJjhxM=CJUaJhH+hH+>*CJaJhJCJaJhhH+CJaJhH+CJaJhxM=CJaJh8 2CJaJhhJ>*CJaJ h_hJhhJCJaJhLo hkmhJ-%&3<abp"gh${rrirriirr ?$IfgdH+ ?$Ifgd] zkd`$$Ifl07Q'7!0Q'644 lalytxM= @$Ifgd] #$%7F{|(<bcdlstxxxohy>*CJaJhJCJaJhhJ>*CJaJhH+hCJaJhhJCJaJhahCJaJhah@CJaJhH+CJaJhCJaJhlJCJaJh@h@CJaJh@CJaJhhJCJaJ h_hJhhSdCJaJ*$%0{{ ?$Ifgd] zkda$$Ifl07Q'7!0Q'644 lalytxM={nn ? & F+$Ifgd ?$Ifgd] zkdeb$$Ifl07Q'7!0Q'644 lalytxM=(c{n ?"$If^"gdH+ ?$Ifgd] zkdb$$Ifl07Q'7!0Q'644 lalytxM=cdlsz{{j{{YPPP ?$IfgdlJ?z$If^z`gdy?z$If^z`gd] ?$Ifgd] zkdc$$Ifl07Q'7!0Q'644 lalytxM= kyz{ȼȩЗЗuh[Nh8 2OJQJmHnHuhlDOJQJmHnHuhJOJQJmHnHuhhJB*CJaJphhJM~CJaJh,hJCJaJhhJCJaJ h_hJhHUCJaJhhH+CJaJhH+hH+>*CJaJhH+CJaJhJCJaJhlJCJaJhyCJaJhhyCJaJhhy>*CJaJ{rrr ?$Ifgd] zkd*d$$Ifl07Q'7!0Q'644 lalytxM= ?$IfgdHU{{ ?$Ifgd] zkdd$$Ifl07Q'7!0Q'644 lalytxM=QR}}sjjsjjegd,^gdQ  & Fxgd:xgdQzkdXe$$Ifl07Q'7!0Q'644 lalytxM= .ARin򹧹th]U]U]U]M]M]MhQOJQJh COJQJh h OJQJhYN;h >*OJQJ"hh7~5OJQJmHnHuhh4K56OJQJ%hh5p56OJQJmHnHu"hh4K5OJQJmHnHu"hh5p5OJQJmHnHuh\OJQJmHnHuhw LOJQJmHnHuhhOJQJmHnHuhQOJQJmHnHuST7GJLPQR{{{gOg/jhwHB*OJQJUmH nH phtH u&hwHB*OJQJmH nH phtH u&hQB*OJQJmH nH phtH u,hkmh,B*OJQJmH nH phtH uh\OJQJhYN;hQOJQJhQOJQJhYN;hQ>*OJQJhhQ56OJQJ%hhQ56OJQJmHnHu"hhQ5OJQJmHnHu   9DUиvkg`U`UQUM`M`MFBFMh{7l h?hkmhkmhOjh_hkmU h_hkmhlDh h,OJQJ,hkmh,B*OJQJmH nH phtH u&h,B*OJQJmH nH phtH u,hOhOB*OJQJmH nH phtH u/jhwHB*OJQJUmH nH phtH u&hwHB*OJQJmH nH phtH u5jehwHB*OJQJUmH nH phtH u\SSS ?$Ifgd]zkdlf$$Ifl0Q' 0Q'644 lalyt|w| @$Ifgd]gdkm SS^S`gd,^gdYN; Rhkmtu`   l m                 u  ļ{sļhi3CJaJh(CJaJhhSdCJaJhOhOCJaJjgh&iCJUaJjh&iCJUaJhkmCJaJh&iCJaJhQCJaJhhkm>*CJaJ h_hkmhhkmCJaJ hkmhkmhkm h?hkmh{7l(      {r ?$IfgdQzkdg$$Ifl0Q' 0Q'644 lalyt|w| ?$Ifgd]    {n ?"$If^"gd&i ?$Ifgd]zkdh$$Ifl0Q' 0Q'644 lalyt|w|            ! ) 0 1 Q e              $ - > L Z d e g ~         45㿷㷯㧯㷟㯷ӌhx+CJaJhIhkmCJaJh0KCJaJhq)CJaJhfCJaJh1C>CJaJhkmCJaJhhkm>*CJaJh6CJaJh&iCJaJhhCJaJhhkmCJaJ h_hkmh6h4|CJaJ1    {r ?$Ifgd&i ?$Ifgd]zkdh$$Ifl0Q' 0Q'644 lalyt|w| ! ) 0    [  {j{{j{a ?$Ifgd1C>?z$If^z`gd] ?$Ifgd]zkdEi$$Ifl0Q' 0Q'644 lalyt|w|    4{{{r ?$Ifgdf ?$Ifgd]zkdi$$Ifl0Q' 0Q'644 lalyt|w|5  #U]g}~Ӥ}}pdUFhB4hU)CJOJQJaJhshU)CJOJQJaJhU)CJOJQJaJhU)5CJOJQJaJhOJQJmHnHuhU)OJQJmHnHuh4OJQJmHnHuhkmOJQJmHnHuhhkmB*CJaJphhkmCJaJhhkmCJaJ h_hkmhhx+CJaJhx+CJaJhfCJaJhx+hx+CJaJ {{ ?$Ifgd]zkdsj$$Ifl0Q' 0Q'644 lalyt|w| g~}vjaa $Ifgd] $$Ifa$gd] xgdU)xgdkmzkd k$$Ifl0Q' 0Q'644 lalyt|w|68BEQRSijz{ôåÎzfzNz3zN5jjlhi3B*OJQJUmH nH phtH u/jhi3B*OJQJUmH nH phtH u&hfB*OJQJmH nH phtH u&hi3B*OJQJmH nH phtH u,hkmhi3B*OJQJmH nH phtH uh45OJQJmHnHuhe5OJQJmHnHu"hhU)5OJQJmHnHuhU)OJQJmHnHuhB4hU)CJOJQJaJhahU)CJOJQJaJtmc^UD?gdi3 SS^S`gdi3^gdi3gdi3  & Fxgd:xgdU)kdk$$IflF '+8 06    4 layt] {@AN\ѽ}v}voddXdPdhYCJaJhhi3>*CJaJhhi3CJaJ hkmhi3 h?hi3hfhi3hOjh_hi3U h_hi3h hi3OJQJ,hkmhi3B*OJQJmH nH phtH u&hi3B*OJQJmH nH phtH u/jhi3B*OJQJUmH nH phtH u,hOhOB*OJQJmH nH phtH u-@AN\- {rrrrr ?$Ifgd] zkdl$$Ifl0Q' 0Q'644 lalyt|w| @$Ifgd] an `*2Zѷ坕啝yyh,)CJaJhYhY6CJaJh4CJaJhjCJaJhfCJaJ h_hi3hhSdCJaJhOhOCJaJj~mhYCJUaJjhYCJUaJhZCJaJhhi3CJaJhYCJaJhi3CJaJ/{r ?$Ifgdj ?$Ifgd] zkdm$$Ifl0Q' 0Q'644 lalyt|w|{r ?$IfgdY ?$Ifgd] zkdn$$Ifl0Q' 0Q'644 lalyt|w|{r ?$Ifgd,) ?$Ifgd] zkd)o$$Ifl0Q' 0Q'644 lalyt|w|Q_awxy.Cijڤڕ{nbh{aCJOJQJaJh{a5CJOJQJaJh{aOJQJmHnHuhU)OJQJmHnHuhhi3B*CJaJphhx+hi3CJaJh`CJaJhIhi3CJaJhjCJaJh&CJaJhfCJaJhi3CJaJhhi3>*CJaJ h_hi3hhi3CJaJ$x{j{{ja ?$Ifgdj?z$If^z`gd] ?$Ifgd] zkdo$$Ifl0Q' 0Q'644 lalyt|w|xy-{{{r ?$Ifgd` ?$Ifgd] zkdWp$$Ifl0Q' 0Q'644 lalyt|w|{{ ?$Ifgd] zkdp$$Ifl0Q' 0Q'644 lalyt|w|Cjp}vvjaa $IfgdSd $$Ifa$gdSdxgd{axgdU)zkdq$$Ifl0Q' 0Q'644 lalyt|w|jp!/0[`alm8 ɼwwcL,hkmh#MB*OJQJmH nH phtH u&h,o,B*OJQJmH nH phtH u"hhJ5OJQJmHnHu"hh#M5OJQJmHnHu"hh{a5OJQJmHnHuhe5OJQJmHnHuh,o,OJQJmHnHuhU)OJQJmHnHuh{aCJOJQJaJhah{aCJOJQJaJhsh{aCJOJQJaJ!riii $IfgdSdkdr$$Ifl4F 'er 0T6    4 lalyt riii $IfgdSdkds$$Ifl4F ' er 0T6    4 lalyt riii $IfgdSdkdt$$Ifl4F ' er 0T6    4 lalyt   rkka\\S^gd#Mgd#M  & Fxgd:xgdU)kdt$$Ifl4F ' er 0T6    4 lalyt 8 : D G S T U k l | }                  !wlhaVaVRVNaNaNh#MhOjh_h#MU h_h#Mh,o,h h#MOJQJ,hOhOB*OJQJmH nH phtH u5juheB*OJQJUmH nH phtH u/jheB*OJQJUmH nH phtH u&heB*OJQJmH nH phtH u,hkmh#MB*OJQJmH nH phtH u&h#MB*OJQJmH nH phtH u!!! !!!#!;!!`!a!n!|!!!!!""" "##w$x$$$$$$$$$$$$$$$$$$%%%%ļ߼߃x߃xhJhJCJaJhJCJaJhhSdCJaJhOhOCJaJjwh)tCJUaJjh)tCJUaJh)tCJaJh#MCJaJhh#M>*CJaJ h_h#Mhh#MCJaJ hkmh#Mh#M h?h#MhJ. =!>!M!`!a!n!|!."#$e\\\\\ ?$IfgdSdzkdkv$$Ifl0Q' 0Q'644 lalyt|w| @$IfgdSdgd#M SS^S`gd#M $$$$${nn ? & F$Ifgd)t ?$IfgdSdzkdw$$Ifl0Q' 0Q'644 lalyt|w|$$%Z%%{nn ? & F$Ifgd: ?$IfgdSdzkdx$$Ifl0Q' 0Q'644 lalyt|w|%C%L%M%Y%Z%%%%%%%%%%%%%%%%%&0&G&H&I&Z&[&\&^&`&e&&o(v(((((((((((夙{{{s{hpCJaJhx+h#MCJaJhCJaJhIh#MCJaJh hMyCJaJhMyCJaJh#MCJaJhh#M>*CJaJhh#MCJaJ h_h#MhJh#MCJaJhlACJaJhJCJaJhJhJCJaJh0KCJaJ-%%%%{{ ?$IfgdSdzkdx$$Ifl0Q' 0Q'644 lalyt|w|%%%%%%%0&H&{j{{j]] ?h$If^hgd ?z$If^z`gdSd ?$IfgdSdzkdDy$$Ifl0Q' 0Q'644 lalyt|w|H&I&W&f&&({{{r ?$Ifgdp ?$IfgdSdzkdy$$Ifl0Q' 0Q'644 lalyt|w|(((({{ ?$IfgdSdzkdrz$$Ifl0Q' 0Q'644 lalyt|w|((((((((())))))%)))))) * * *µϵϨώsdsWsdsJhNOJQJmHnHuhb45CJOJQJaJh%hb4CJOJQJaJhB4hb4CJOJQJaJhb4CJOJQJaJh5CJOJQJaJh:6OJQJmHnHuhw LOJQJmHnHuh$WOJQJmHnHuhIOJQJmHnHuhhOJQJmHnHuhU)OJQJmHnHu h_h#Mhh#MB*CJaJph(((())%))}}vjaa $Ifgd] $$Ifa$gd$WxgdhxgdU)zkd {$$Ifl0Q' 0Q'644 lalyt|w|)))) *rf]] $Ifgd] $$Ifa$gd] kd{$$Ifl4FY '  0T6    4 lalyt  * * ***[+,-rkaVaK@ x^gdh x^gdf x^gdYN;  & Fxgd,uxgdYN;kdv|$$Ifl4FY '  0T6    4 lalyt  ****%*s*t*w*********+++++++ +)+N+Y+[+q+z+񺧺ߟ{i]Thf>*OJQJhYN;hf>*OJQJ"hhpF5OJQJmHnHu"hh{7l5OJQJmHnHu"hhh5OJQJmHnHuhhOJQJ%hhIe:56OJQJmHnHu"hhIe:5OJQJmHnHu%hh7~56OJQJmHnHu"hh7~5OJQJmHnHuhIe:5OJQJmHnHuz+,,,,,,,,,---K-{---- .1.i.k.l.m.s...ļvgXgh%h:6CJOJQJaJhB4h:6CJOJQJaJh:6h:6OJQJh.OJQJh:6OJQJh:6h7tOJQJ hpFhh7B*OJQJphhpFhhB*OJQJphhhOJQJhYN;hhOJQJhf>*OJQJhYN;hh>*OJQJhpF>*OJQJhfOJQJhYN;hfOJQJ-{-l.m.s...//e`W^gd]gd]xkdL}$$Ifl0'0T64 lalyt $Ifgd] gd7t^gd:6 x^gdYN;.1/2/3/4/5/=/E/F/V/W/X/n/o/////////////zcXQFQFBhOjh_h]U h_h]h h]OJQJ,hOhOB*OJQJmH nH phtH u5j}h=ZB*OJQJUmH nH phtH u&h=ZB*OJQJmH nH phtH u/jh=ZB*OJQJUmH nH phtH u&hhB*OJQJmH nH phtH u&h]B*OJQJmH nH phtH u,hkmh]B*OJQJmH nH phtH u////// 0000%0&0'0(0J0K0b0f0{000b1c1y1z111111111111112(2)2*292:2B23̼̼̼ċ|hcCJaJ h(hfh(hfCJaJhOhOCJaJjhfCJUaJjhfCJUaJhfCJaJ *h $hfh[7hfCJaJ hkmh] h?h]h{7l h_h]h]jh_h]U-/'0(070J0K0X001e\\\ ?$Ifgdu,zkd{~$$Ifl0Q' 0Q'644 lalytf @$Ifgdu,gd] v^`vgd=Z1111{{ ?$Ifgdu,zkd$$Ifl0Q' 0Q'644 lalytf111)2{n ?"$If^"gdc ?$Ifgdu,zkd&$$Ifl0Q' 0Q'644 lalytf)2*26292{{ ?$Ifgdu,zkd$$Ifl0Q' 0Q'644 lalytf92:2B23{r ?$Ifgdf ?$Ifgdu,zkdT$$Ifl0Q' 0Q'644 lalytf333-3/35363T3U3V3j3k3l3m3x3y3~33334444ű{l{]lNj>k>>>?'?+?6?ȽعqZFq&hwgB*OJQJmH nH phtH u,h[7h[7B*OJQJmH nH phtH u,h[7h]B*OJQJmH nH phtH u"hh[75OJQJmHnHu"hh=45OJQJmHnHuh OJQJmHnHuh=4h=4h=4OJQJh=4OJQJh OJQJh[7OJQJh[7h[7CJOJQJaJ *h $h[7CJOJQJaJ<<<j>k>>l?m?,@-@{qlgVQgd] v^`vgdgd $gd]  & Fxgdu,xgd $gd=4xkd$$Ifl0'0T64 lalyt 6?7?8?N?O?_?`?h?i?l?m?s?t?????????@@@@@ @*@,@Ι΂uncnc_cnXnQXnXnJnJn h[7hJ h[7h $ h[7h[7hOjh[7h]U h[7h]h[7h $mHnHtH ,h[7h]B*OJQJmH nH phtH u,hOhOB*OJQJmH nH phtH u;j8h[7hKfB*OJQJUmH nH phtH u5jh[7hKfB*OJQJUmH nH phtH u,h[7hKfB*OJQJmH nH phtH u,@-@O@P@]@g@k@@@@gAhA~AAAAAAAAAAAABBBBBB B+BNBOBPB\B^B_B`BhBBپͳ٨~vٕٝ~k~h(h(CJaJh(CJaJ h(h]hf*CJaJh,]CJaJh CJaJh(h]CJaJh[7hSdCJaJhOhOCJaJjLhxCJUaJjhxCJUaJhxCJaJh[7hxCJaJh[7h]CJaJ *h $h](-@<@O@P@]@@A{rii ?$Ifgdx ?$Ifgd]zkd$$Ifl0Q' 0Q'644 lalyt2X @$Ifgd]AAAB{n ? \$Ifgdf* ?$Ifgd]zkdɍ$$Ifl0Q' 0Q'644 lalyt2XBBBOB{n ?"$If^"gdx ?$Ifgd]zkd`$$Ifl0Q' 0Q'644 lalyt2XOBPB\B_B{{ ?$Ifgd]zkd$$Ifl0Q' 0Q'644 lalyt2X_B`BhBoC{r ?$Ifgdna ?$Ifgd]zkd$$Ifl0Q' 0Q'644 lalyt2XBBBCCCSCnCoCpCCCCCCCCCCDD D D D D˱uh[KhwghwgOJQJmHnHuh~OJQJmHnHuh7~OJQJmHnHuh]OJQJmHnHu'h,]h]CJOJQJaJmHnHu'h,]h:6CJOJQJaJmHnHu h_h]hh]B*CJaJphh(hx+CJaJh(h]CJaJ h(h]h:6h]CJaJhxLCJaJhxCJaJhnaCJaJoCpC~CC{r ?$Ifgdna ?$Ifgd]zkd%$$Ifl0Q' 0Q'644 lalyt2XCCCC{{ ?$Ifgd]zkd$$Ifl0Q' 0Q'644 lalyt2XCCD D DJD]DcDD}}vocZZ $Ifgd] $$Ifa$gd] xgd\Jxgd7~xgd]zkdS$$Ifl0Q' 0Q'644 lalyt2X DDDD$D%D8DIDJD\D]DcDDDDDEE E!EHEKEPEQEEEEEEEEFŸ~~~qi^i^hwghwgOJQJhwgOJQJhwgOJQJmHnHuhwgCJOJQJaJh%hwgCJOJQJaJhB4hwgCJOJQJaJhG_hwg5CJOJQJaJhwg5CJOJQJaJh\JOJQJmHnHuhwgh\JOJQJmHnHuhwghwgOJQJmHnHuh3cOJQJmHnHuDDDDEriii $Ifgd] kd$$Ifl4FY '  0T6    4 lalyt EEE!EIEriii $Ifgd] kd$$Ifl4FY '   0T6    4 lalyt IEJEKEQEEriii $Ifgd] kdȓ$$Ifl4FY '   0T6    4 lalyt EEE.HHIKJKLLLrkkfff^YO  & Fxgdu,gd & Fgdu,gd*xgd\JkdД$$Ifl4FY '   0T6    4 lalyt F1F2FcFuFvFFFFFG(G0G8GEG[GcGiGGGGGGGGGH-H.HSHZHiHkHHHHIIBJZJsJJJJHKJKOKWKy"hhomV5OJQJmHnHu"hhv5OJQJmHnHuh*h*>*OJQJh*h*6OJQJhwgh*OJQJh*OJQJhvOJQJmHnHuhwgOJQJmHnHuhwghwgOJQJmHnHuhOJQJmHnHu/WK_KKKKKKLLLLLLLL1L>LLLLLLMʸʸʅvqdM,h[7hB*OJQJmH nH phtH uhvOJQJmHnHu h5hE5OJQJmHnHu"hh`5OJQJmHnHu"hh5OJQJmHnHuhv5OJQJmHnHu"hho,5OJQJmHnHu"hhE5OJQJmHnHu"hhomV5OJQJmHnHu"hhv5OJQJmHnHuLLLLoMpMMMMN @$Ifgd] gdE v^`vgd gdxgdv  & Fxgdu,5gd M M)M*M+M/M8M;M*CJaJ$]Q^QiQQQ{nn ? & F$Ifgd[ ?$Ifgd] zkdi$$Ifl0Q' 0Q'644 lalyt2XQQQQ(R{nn ? & F$Ifgd[ ?$Ifgd] zkd$$Ifl0Q' 0Q'644 lalyt2XQQQQQQQ'R(R)R4R5R6R|R}RRRRRRRRRRRSSSSSSSSSSSSSSTTҸꤸ⭸Ⅽҭzrzh1qCJaJhSdhECJaJh x'CJaJhhE>*CJaJhxKYhxKYCJaJhxKY>*CJaJhhECJaJhCJaJ h_hEhh[CJaJhECJaJh[CJaJhCJaJhhECJH*aJhCJH*aJ((R)R6R}RR{nn ? & F$Ifgd[ ?$Ifgd] zkd$$Ifl0Q' 0Q'644 lalyt2XRRRRRRSSS{j]jjPP ? & F$Ifgd ? & F$Ifgd?z$If^z`gd] ?$Ifgd] zkd.$$Ifl0Q' 0Q'644 lalyt2XSSSTTU{{{r ?$Ifgd ?$Ifgd] zkdř$$Ifl0Q' 0Q'644 lalyt2XTUUUU VVVVVoVpVqVrVVVVVWWWWۼ{n^O@hB4h\RCJOJQJaJhsh\RCJOJQJaJhG_h\R5CJOJQJaJhx75CJOJQJaJhi3h OJQJmHnHuh?OJQJmHnHuh?h]VhhECJOJQJaJhCJOJQJaJhhCJH*OJQJaJhhEB*CJaJph h_hEhhECJaJhECJaJhx+hECJaJUUVV{{ ?$Ifgd] zkd\$$Ifl0Q' 0Q'644 lalyt2XVVpVqVrVVVWWHWzzszg^^ $IfgdSd $$Ifa$gdSdxgd?gd]VgdEzkd$$Ifl0Q' 0Q'644 lalyt2X WGWIWJWWWWWXXXYYYYXYsYtYuYYуteSt<,h[7h?B*OJQJmH nH phtH u"hh?5OJQJmHnHuh5OJQJmHnHuh?5OJQJmHnHuh2XOJQJmHnHuh+iOJQJmHnHu"h?h?>*OJQJmHnHu"h?h?6OJQJmHnHuh?h?OJQJmHnHuh?OJQJmHnHuhi3hB4h\RCJOJQJaJh%h\RCJOJQJaJHWIWJWWYYuY Z Ztohhh`[Vgd?gd? & Fgdu,xgd?gd]Vkd$$IflFg 'i7 06    4 lalyt YYYYYYYYYZZZ Z ZZZ&Z'Z)Z*ZYZZZZZZZZ[[콋~wlwlhlwdwdw\Q\Qh[7h?CJaJ *h $h?hIhOjh[7h?U h[7h?h[7h?mHnHtH ,hOhOB*OJQJmH nH phtH u5jXh?B*OJQJUmH nH phtH u/jh?B*OJQJUmH nH phtH u,h[7h?B*OJQJmH nH phtH u&h?B*OJQJmH nH phtH u ZZZZZZZ\[\e\\\ ?$IfgdSdzkd՜$$Ifl0Q' 0Q'644 lalyt2X @$IfgdSdgd? v^`vgd?[[\[[[[[ \ \\\\\\+\K\L\M\Y\Z\|\}\~\\\\\\\\\\\\\\\𿷬𬥬|obhIOJQJmHnHuh?OJQJmHnHu h_h?hh?B*CJaJphh:6h?CJaJhICJaJ h(h?h(h?CJaJ *h $h?h[7h CJaJhOhOCJaJjlh CJUaJjh CJUaJh CJaJh?CJaJ#\\$\L\{r ?$Ifgd ?$IfgdSdzkd$$Ifl0Q' 0Q'644 lalyt2XL\M\Z\}\{n ?"$If^"gdSd ?$IfgdSdzkd$$Ifl0Q' 0Q'644 lalyt2X}\~\\\{{ ?$IfgdSdzkd$$Ifl0Q' 0Q'644 lalyt2X\\\\{{ ?$IfgdSdzkd$$Ifl0Q' 0Q'644 lalyt2X\\\\{r ?$Ifgd ?$IfgdSdzkdE$$Ifl0Q' 0Q'644 lalyt2X\\\\{{ ?$IfgdSdzkdܠ$$Ifl0Q' 0Q'644 lalyt2X\\\\\\\\]]]}vvqqlgb]gd>[gd5 gd5 gdVgd 3xgdIxgd?zkds$$Ifl0Q' 0Q'644 lalyt2X \\\\]]]H]T]p]]]]]^^__oasaaabDbNbmbnb5c7cн{j{YHY!hi:OJQJmH nH sH tH u!h QOJQJmH nH sH tH u!hOJQJmH nH sH tH u'hh5 OJQJmH nH sH tH u'hhOJQJmH nH sH tH u hh>[%hh>[B*OJQJmH phsH %hhSdB*OJQJmH phsH h>[h8h5 B*phhB*phhDB*phh%5OJQJh7tCJaJ]]__aa}ccccc @$Ifgdlf @$Ifgdgd v^`vgdgd5 gdSd  & Fh^hgd:gd>[ 7cf$1$7$8$H$If]>^fgd1:z"2Zd(($1$7$8$H$If]2^Z`gd~Vy^d(($1$7$8$H$If]^^gd~Vy"rZd(($1$7$8$H$If]r^Z`gd~Vy  $&,.DFTV^`ďƏ̏ΏЏҏԏ֏؏܏ޏ $*.24<@Nh1:zh1:zCJaJ h1:zh1:z@CJOJQJaJ h1:zh1:z@CJOJQJaJ h1:zh1:z@CJOJQJaJh1:zh1:zCJOJQJaJFޏNsX=XG^(($1$7$8$H$If]G^^gd~Vy^(($1$7$8$H$If]^^gd~Vykdn$$IflFR&qq0&    44 lalyt1:zNPTVlp~Ȑ̐ΐԐڐܐ 048:>@DHྜ#h1:zh1:zCJH*OJQJRHcaJ h1:zh1:z@CJOJQJaJ h1:zh1:z@CJOJQJaJ h1:zh1:z@CJOJQJaJ h1:zh1:z@ CJOJQJaJh1:zh1:zCJOJQJaJ h1:zh1:zCJOJQJ^JaJ6ΐJgd(($1$7$8$H$If]^ggd~Vy"(d$(($1$7$8$H$If]^(`gd~Vy"Zd(($1$7$8$H$If]^Z`gd~VyđƑȑԑ֑"#%*+014689:<=>?Pij杈(hSh1:zB*CJOJQJ\aJphh#h1:zh1:zCJH*OJQJRHcaJ h1:zh1:z@CJOJQJaJ h1:zh1:z@CJOJQJaJ h1:zh1:z@CJOJQJaJh1:zh1:zCJaJh1:zh1:zCJOJQJaJ0 sX=q^(($1$7$8$H$If]q^^gd~Vy^(($1$7$8$H$If]^^gd~Vykd $$IflFR&qq0&    44 lalyt1:z =>?SUPI4Vx1$7$8$H$^`Vgd1:zgd1:zgdkd$$IflFR&qq0&    44 lalyt1:zGgd(($1$7$8$H$If]G^ggd~VyPQRSTUWZ[bdefghklnopqsyz}zizXzGzGzXzXGzXzXzXzX hSh1:z@CJOJQJaJ hSh1:z@CJOJQJaJ hSh1:z@CJOJQJaJhSh1:zCJOJQJaJ$hSh1:z@CJEH OJQJaJ hSh1:zCJEH OJQJaJ$hSh1:zCJEH OJQJRHcaJ(hSh1:zB*CJOJQJ\aJph"hMyB*CJOJQJ\aJph/jhmd`0J-B*CJOJQJU\aJph’ÒϒВْڒےܒޒߒκΦκκκΦκκκκκκΒ hSh1:z@CJOJQJaJ&hSh1:z6@CJOJQJ]aJ&hSh1:z6@CJOJQJ]aJ&hSh1:z6@CJOJQJ]aJ"hSh1:z6CJOJQJ]aJ hSh1:z@CJOJQJaJhSh1:zCJOJQJaJ/ !"#$%&'()*-.234<=>ABCSUVYZ[~ʹޕބބޕޕޕބtbtbtބބ#hSh1:z>*@CJOJQJaJhSh1:z>*CJOJQJaJ hSh1:z@CJOJQJaJ hSh1:z@CJOJQJaJ$hSh1:z@CJEH OJQJaJ hSh1:zCJEH OJQJaJ'hSh1:z5CJEH OJQJRHcaJhSh1:zCJOJQJaJ#hSh1:z@CJOJQJ]aJ&“ÓΓϓѓғՓ֓דޓߓ   оКxgxggxxg hSh1:z@CJOJQJaJ hSh1:z@CJOJQJaJ hSh1:z@CJOJQJaJ#hSh1:z>*@CJOJQJaJ#hSh1:z>*@CJOJQJaJ#hSh1:z>*@CJOJQJaJhSh1:z>*CJOJQJaJ hSh1:z@CJOJQJaJhSh1:zCJOJQJaJ(  "$MN !")wdϾ$hSh1:z@CJEH OJQJaJ hSh1:zCJEH OJQJaJ$hSh1:zCJEH OJQJRHcaJ%hSh1:zB*CJOJQJaJphhSh1:zCJOJQJ]aJ hSh1:z@CJOJQJaJ hSh1:z@CJOJQJaJ hSh1:z@CJOJQJaJhSh1:zCJOJQJaJ'X,+, v^`vgdXgdvYgd5 ;x1$7$8$H$^`;gd1:zx1$7$8$H$^`gd1:z x1$7$8$H$^`gd1:zVx1$7$8$H$^`Vgd1:z)*+,-.34567<=>ABDMNQRVWYZ\]`aghnopqvxyz{|}s{Ϭϕ-hSh1:zB*CJEH OJQJRHcaJph#hSh1:z6@CJOJQJaJ hSh1:z@CJOJQJaJ hSh1:z@CJOJQJaJhSh1:zCJOJQJaJ hSh1:z@CJOJQJaJ9™ÙǙș˙̙͙Ιܙݙ    l)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph-hSh1:z@B*CJEH OJQJaJph)hSh1:zB*CJEH OJQJaJph* 4589:;<=?@CDUV\^_abcdefnopqršÚ׭׭)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJphDÚ͚̚ΚϚњҚӚԚ֚ךؚٚ     #%-.456?@ACDEX­)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph@XYZ\]deijtuxy~ӼjjjjjjjjjUj)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph)hSh1:z@B*CJOJQJaJph-hSh1:z@B*CJEH OJQJaJph)hSh1:zB*CJEH OJQJaJph-hSh1:zB*CJEH OJQJRHcaJphΛЛڛۛ  &')*./3478>?׭טט˜׃טטטטטטטטטט׃)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph)hSh1:z@B*CJOJQJaJph3?ABEFIJKLMNORU[\]^_abdflmnopqstvw{|}œƜǜ˜̜МќҜ­­)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJphDҜӜԜל؜ٜڜۜݜޜ  '()129:;<FGMNQRWX_`abpqvwxyz{­­­­­­խ­)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph<ÝŝƝǝɝʝΝϝԝ՝ם؝ٝڝ۝ߝ׭׭׭׭׭­׭׭׭טט­׭ט)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph)hSh1:z@B*CJOJQJaJph<   "#$01234589:;>?GHJKOPQUVZ[]^_`bcghmnqr~׭׭׭­׭)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph)hSh1:z@B*CJOJQJaJphDž˞̞ҞӞԞ՞מ؞ݞߞ,-.­׭׭׭׭­׭ט׭­׭׭׭ׅt hSh1:zCJEH OJQJaJ$hSh1:zCJEH OJQJRHcaJ)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph)hSh1:z@B*CJOJQJaJph,.0129:;<=>@ADFHINOPWXYZjklwx|}şƟΟϟПџҟӟן޼ͫͫޚͫޫ޼ͼͼޫޫ޼ޫޫ޼ hSh1:z@CJOJQJaJ hSh1:z@CJOJQJaJ hSh1:z@CJOJQJaJ hSh1:z@CJOJQJaJhSh1:zCJOJQJaJ$hSh1:z@CJEH OJQJaJ<ן؟'(+,349:>?}~ߠϾϚϚϚϚϚϚϚϾ(hSh1:z5B*CJOJQJaJph hSh1:z@CJOJQJaJ$hSh1:z@CJEH OJQJaJ hSh1:zCJEH OJQJaJhSh1:zCJOJQJaJ hSh1:z@CJOJQJaJ hSh1:z@CJOJQJaJ4   !#$%-./78ABFGPQTU_`tuvwxyz{|}ԗԗ)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph)hSh1:z@B*CJOJQJaJph,hSh1:z5@B*CJOJQJaJph;΢ϢТҢӢԢբ֢    !"#'()+-./23׭׭)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph<ãģǣȣɣʣˣңӣأ٣ڣܣߣ  $%&'()+,옭)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph<,1245>?CDGHPQRSVWXY\]bcefjklmrsvwxyz{|}~׭׭)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph<äĤŤƤǤԤդ֤ؤ٤ڤ  쭖ׁlll)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph,hSh1:z5@B*CJOJQJaJph(hSh1:z5B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph*%&'01256=>@AGIJMNVW^_bcdeghklmnopvwyz}~­)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph?ŦƦͦΦѦҦզ֦צئަߦ !'(+,îÙؙؙîؙؑh+=B*ph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph)hSh1:z@B*CJOJQJaJph%hSh1:zB*CJOJQJaJph(hSh1:z5B*CJOJQJaJph3,cʧ˧ӧԧ$%'(Z[\|q|qmq|ia]aia|K"hrhvY5CJOJQJ\aJhijhXVUhXVhOjh_hvYU h_hvY'hOhOOJQJmH nH sH tH u0jBhrOJQJUmH nH sH tH u!hrOJQJmH nH sH tH u*jhrOJQJUmH nH sH tH u'h!b\hDOJQJmH nH sH tH u'h!b\hvYOJQJmH nH sH tH u¬ҬӬج٬۬ܬWXZ[^_deopvw˻˻ڋzizizizzz hrhvY@CJOJQJaJ hrhvY@CJOJQJaJ%hrhvY5CJH*OJQJ\aJ#hrhvY5@CJOJQJaJhrhvYCJaJhrhvY5CJOJQJaJhrhvYCJOJQJaJ"hrhvY5CJOJQJ\aJ&hrhvY5@CJOJQJ\aJ)>kd$$If4srsD'`'4aytX$<<<<$1$7$8$H$If]<^<a$gd~Vy<<<<$1$7$8$H$If]<^<gd~VyĬɬ֬۬ܬY;<<d<<$1$7$8$H$If]<^<gd~VykdS$$If4rsD' '4aytX$<<<<$1$7$8$H$If]<^<a$gd~VyT­.wx?kd$$IfrsD''4aytX<<<<$1$7$8$H$If]<^<gd~Vy<<d0<<$1$7$8$H$If]<^<gd~VyЭѭҭӭ֭׭ޭ߭  !#%&3467:;?@FGHIJKMNOPQRUVbeijnoq hrhvY@CJOJQJaJ hrhvY@CJOJQJaJhrhvYCJOJQJaJ hrhvY@CJOJQJaJKqrwxŮƮ̮ͮϮЮӮԮծٮڮۮܮïÜz hrhvY@CJOJQJaJ hrhvY@CJOJQJaJ%hrhvY5CJH*OJQJ\aJ&hrhvY5@CJOJQJ\aJ"hrhvY5CJOJQJ\aJhrhvYCJaJhrhvYCJOJQJaJ hrhvY@CJOJQJaJ0׮";<LWcl]kds$$IfrsD''4aytX<<<<$1$7$8$H$If]<^<gd~Vy    '(;<BCKNOPQrsuvůƯǯȯɯ˯IJIJ hrhvY@CJOJQJaJ&hrhvY5@CJOJQJ\aJ"hrhvY5CJOJQJ\aJhrhvYCJaJ hrhvY@CJOJQJaJhrhvYCJOJQJaJ hrhvY@CJOJQJaJ76ưWx]]]]]<<<<$1$7$8$H$If]<^<gd~Vykd$$IfcrsD''4aytX˯ͯ֯ׯ   !"#$%&45?@BCEFPQRSUVWX[\efhiz{|} hrhvY@CJOJQJaJ hrhvY@CJOJQJaJhrhvYCJOJQJaJ hrhvY@CJOJQJaJKðİŰϰаҰӰհְ  $%'(6789;<=DEKLWXeϿ࣑"hrhvY5CJOJQJ\aJhrhvYCJaJ hrhvY@CJOJQJaJhrhvYCJH*OJQJaJ hrhvY@CJOJQJaJhrhvYCJOJQJaJ hrhvY@CJOJQJaJ9WXfرOx]]]]]<<<<$1$7$8$H$If]<^<gd~Vykd$$IfrsD''4aytXenovwyz±ıƱDZͱαѱұӱԱ    "#%&()+,-.;<=>@ALMO hrhvY@CJOJQJaJ hrhvY@CJOJQJaJhrhvYCJOJQJaJNOPJ2x^F^AA6gd{7d1$7$8$H$]^7gdvY7d(1$7$8$H$]^7gdvYkd$$If'rsD''4aytXOP̲ͲβIJKMZ]^ghmntƴƟƴlZIII h_hvY@CJOJQJaJ#h_hvY@CJOJQJ\aJ&h_hvY5@CJOJQJ\aJh_hvYCJOJQJaJhOhOCJOJQJ\aJ(jhrCJOJQJU\aJ"jhrCJOJQJU\aJhrCJOJQJ\aJ"h_hvYCJH*OJQJ\aJh_hvYCJOJQJ\aJhrhvYCJaJtuxy³dzȳ˳̳ͳϳгԳճٳڳϾϾϾຶ hTh,h 3hD h_hvY@CJOJQJaJ h_hvY@CJOJQJaJh_hvYCJOJQJaJ h_hvY@CJOJQJaJE1234HZӵյ,0;>gr¶$ƷǷȷѷҷ׷κκκs___'h!b\h9OJQJmH nH sH tH u'h!b\h$OJQJmH nH sH tH u!hU<OJQJmH nH sH tH u!h$OJQJmH nH sH tH u!h9OJQJmH nH sH tH u'h!b\h0OJQJmH nH sH tH u'h!b\h!b\OJQJmH nH sH tH u%h 3h 3B*CJOJQJaJph hTh,h0%23ԵյcdSTؼټڼ13$If^gd~VygdK,c SgdK,cxgdT6gd{gdFgd!b\gd|0׷ڷ5JLQh(9bd sRS׼ɸkZI!h0OJQJmH nH sH tH u!h(t~OJQJmH nH sH tH u'h(t~h(t~OJQJmH nH sH tH u'h(t~hJ{OJQJmH nH sH tH u!hJ{OJQJmH nH sH tH u'h!b\h0OJQJmH nH sH tH u!h9OJQJmH nH sH tH u'h!b\h9OJQJmH nH sH tH u!hZOJQJmH nH sH tH u!hU<OJQJmH nH sH tH u׼ؼټڼۼܼݼ  $%&,./0178MNPQfzlV+hK,chK,c5CJOJQJaJmHnHsH hK,chK,c5OJQJaJ hYhK,chOjhK,cUhK,chFOJQJhOmHnHuhOj hK,cOJQJUjhK,cOJQJUhK,cOJQJh;WOJQJ hTh`{h`{hr h'T hqbhF'h!b\hJ{OJQJmH nH sH tH uǾrr3$If^gd~Vy}kd$$Ifl0LK' t0644 layt~VyƾǾپھ349:;MRST^_def|}~Hp䱢~ncXh$@h$@OJQJh4h4OJQJh4B*CJOJQJaJph(hlfhh)LCJOJQJaJmHnHsH hh)Lhh)LOJQJ^JaJhlfhh)LOJQJ^JaJ(hK,chK,cCJOJQJaJmHnHsH hryhryOJQJ^JaJhryhK,cOJQJ^JaJhK,chK,cOJQJaJhK,chK,cOJQJ^JaJrr3$If^gd~Vy}kd5$$Ifl0LK' t0644 layt~Vy4:rr3$If^gd~Vy}kdʹ$$Ifl0LK' t0644 layt~Vy:;MSrr3$If^gd~Vy}kde$$Ifl0LK' t0644 layt~VyST_err3$If^gd~Vy}kd$$Ifl0LK' t0644 layt~Vyefw}rr3$If^gdh)L}kd$$Ifl0LK' t0644 layt~Vy}~Hqr{h|uupd[[ $Ifgd$ $$Ifa$gd$gd$@xgd46gd4}kd-$$Ifl0LK' t0644 layth)LpxyKgqrz{givķzkYF%h5h$@56OJQJmHnHu"h5h$@6OJQJmHnHuh$@>*OJQJmHnHuhB4h$@CJOJQJaJh%h$@CJOJQJaJhsh$@CJOJQJaJhG_h$@5CJOJQJaJh$@5CJOJQJaJ h]Vh$@h(;1h$@OJQJmHnHuh$@OJQJmHnHuh$@h$@OJQJmHnHuh$@OJQJhijbc|-^tmmmmhhaZZxgd'xgdT6gd{xgd$@kdӷ$$IflFY '( 06    4 layt$ _`bcdef|,-~4J]^_`abcrswwwowhhdhhW h|0h|0h;WOJQJhyfOJQJh|COJQJh+Oh'OJQJh7hOJQJh,OJQJh+OOJQJh~VyOJQJh`{ hTh,h 3h$@B*CJOJQJaJphh$@OJQJmHnHuh(;1h$@OJQJmHnHu"h5h$@6OJQJmHnHu!^_spq89qM!"55./ 3^gd/ 3^gdRgdr6gd{xgd's$%0Qopq79uϿ➉t_M"h/CJOJQJaJmHnHsH (h/hWCJOJQJaJmHnHsH (h/hRCJOJQJaJmHnHsH (h/h|0CJOJQJaJmHnHsH (h/h/CJOJQJaJmHnHsH hCOJQJmH sH hrB*OJQJmH phsH %h/h|0B*OJQJmH phsH h/h/OJQJmH sH h/h|0OJQJmH sH !"?%&';Xîî|p|g\L=h:hCJOJQJaJh:h5CJOJQJaJhhOJQJh,OJQJ]hhOJQJ]hh,OJQJ]hh,B* phh 3B* ph$h/h|0OJQJaJmHnHsH (h/hWCJOJQJaJmHnHsH +h/hW>*CJOJQJaJmHnHsH (h/h/CJOJQJaJmHnHsH "hWCJOJQJaJmHnHsH /%&;aX $Ifgd{}kd$$Ifl0dK'1 t0644 layt: $Ifgd:gd,gd 3^gd/ ./6<=>?pǸӝӑӝqbSGhi CJOJQJaJhi h[w!CJOJQJaJhi hi CJOJQJaJh:hi CJOJQJ]aJh:h[w!CJOJQJ]aJh4CJOJQJaJ4h:hB*CJOJQJaJmH nH phtH uh:h[w!CJOJQJaJh{CJOJQJaJh:hCJOJQJaJh{CJOJQJ]aJh:hCJOJQJ]aJ/=xo $Ifgd: $Ifgd{}kd9$$Ifl0dK'1 t0644 layt:=>pxkkk^xkkk  & F$Ifgdi  & F$Ifgd: $Ifgd:}kdֹ$$Ifl0dK'1 t0644 layt:   PQRYejklm廠rfZfrZrh*CJOJQJaJh{CJOJQJaJh:hN=XCJOJQJaJh:hCJOJQJ]aJh:hCJOJQJaJ4h:hB*CJOJQJaJmH nH phtH uhi h[w!CJOJQJaJh:hi CJOJQJaJhi CJOJQJaJh:h[w!CJOJQJaJhdnCJOJQJaJ#QRktkbb $Ifgd| $Ifgd:}kds$$Ifl0dK'1 t0644 layt:  & F$Ifgdi klxoo $Ifgd| $Ifgd}kd$$Ifl0dK'1 t0644 layt:xo $Ifgd| $Ifgdi }kd$$Ifl0dK'1 t0644 layt:7V>c:BCD񯣘}pcUcUcUcUcGcUcGhh5OJQJaJhh>*OJQJaJhhOJQJaJhh!\OJQJaJhh,B* phh 3B* phh5xB* phhh,OJQJhh,OJQJ]4h:hB*CJOJQJaJmH nH phtH uh:hN=XCJOJQJaJh*CJOJQJaJhdnCJOJQJaJh:hCJOJQJaJ  rk^YLYL 0^`0gdgd 0^`0gd!\gd ^`gd,kdJ$$Ifl0dK'1 t0644 layt| uwSU?A~hx^h`gd,xgd,gd"$a$gd"gd, 0^`0gdgdt9=Rstu~deghzog\TIh2h2OJQJh2OJQJho h2OJQJh,OJQJho h,OJQJho h,5OJQJ\h"5CJ\aJh"h";B* phh"h,0J h0Jh"h"0Jh,OJQJh,CJ aJ hh,CJ OJQJaJ hh5OJQJaJhh>*OJQJaJhhOJQJaJef*+z{lm;<56Axgd,gd, h^h`gd,)+,hjyz{m6@ABCDE}p}}hashL-0JOJQJho hL-OJQJjhL-OJQJUhL-OJQJho h,OJQJho h,5OJQJ\h,OJQJhehe0Jn6OJQJheheOJQJheheOJQJ]h2h2OJQJho heOJQJheOJQJ,DEQR^H+gde++gdMgdD%XTx^T`gd, h^h`gdL-9:Foqr"$%NOPQRSTUCDӸ||hlDhhlD0JOJQJjhhlDOJQJUhhlDOJQJ!jhhlD0J-OJQJUhaCJaJhL-OJQJho hL-OJQJh,OJQJho h,OJQJhashL-0JOJQJjhL-OJQJU0]^_`GHIJùîùãùÇ|gOg/h+hlD6B*OJQJ]mHnHphtH )h+hlDB*OJQJmHnHphtH h+hlDOJQJ!jh+hlD0J-OJQJUh?hlDOJQJhBPhlDOJQJhwhlDOJQJjhlD0J-UhlDhhlDOJQJ!jhhlD0J-OJQJUhMhlDOJQJ!jhMhlD0J-OJQJU2KLbcst|}Ƶ~mie]e]e]e]eRhlD5OJQJ\jh5Uh5hlD hOhOB*OJQJ\ph)jhlDB*OJQJU\ph#jhlDB*OJQJU\phUhlDB*OJQJ\ph hmd`hlDB*OJQJ\phhmd`hlDOJQJjhlD0J-Uh+hlDOJQJ1h+hlDB*CJOJQJaJmHnHphtH  only evidence hierarchies relevant to this review have been reproduced in  REF _Ref270797089 \h  \* MERGEFORMAT Table 17, so tablenotes 7 and 8 have not been reproduced     Page  PAGE \* MERGEFORMAT 1 Page  PAGE \* MERGEFORMAT 16 Page  PAGE \* MERGEFORMAT 47 ܴݴ)$$ & #$/Ifa$gdy/ $ & #$/Ifgdy/gd ´شٴڴ۴ܴݴ޴ +,./012589:;<ɷhaCJaJhD%XhlDCJaJh5hOhO5mHnHuhlDhy/hlD5OJQJ\hOmHnHu hhlDjhhlDUhhlD5(ݴ޴ߴvav $$ & #$/Ifa$gdy/ $ & #$/Ifgdy/vkdh$$Ifl4F($  t 6  6   OO 44 layty/r]r)$$& #$/Ifa$gd  $& #$/Ifgd %vkd*$$Ifl4F(   t 6  6 OO   44 layty/   vav $$& #$/Ifa$gd  $& #$/Ifgd vkd$$Ifl4FzA;z$ t 6 6   OO 44 layt    01r]r)$$l& #$/Ifa$gd  $l& #$/Ifgd %vkd$$Ifl4FzA;z  t 6 6 OO   44 layt 12345vav $$l& #$/Ifa$gd  $l& #$/Ifgd vkdX$$Ifl4F &$ t 6 l6   OO 44 layt 56789:;<zugdD%X dd$If%vkd$$Ifl4F &  t 6 l6 OO   44 layt =0&P 1FP:p;. A!n"0#Z$% <00&P P:py/. A!"0#$% <0&P 1F0:p}A .!"#n$0% 50&P :p;. A!"0#$% 90&P P:p8>. A!"0#S$% kaDd 5] 0  # A"`(AyjF`ߵ`D@=`(AyjF`ߵ|7o`x S?k( D2OI2fLE"RM3eʐ9yeDQ)Ou{ι^w=<{^{<ߩ OS v3Æia[gu juv4#ևNnذ96l l'q70 0l%VY>V?pdF󡑟EF~8=,ҥ7WϟҨ!h4 @C!h4 @C!h4 @C!h4 @C!h4 @C!h4 @C!h4 @C!h4 @C!h4 @C!h4 @C!h4 @C/rrmVri4^. 7PrWG$r}k矟::D}e/#_宻Ph40׿YgU^zw/zYc5ge-oy/~1GAWYdEʻ˗Ç|2˔'}Xx{~/QC!E]T[r׏?\>?OGI7?={D%pc%Xam 83|XeU;FFvE_N;4`4u}0ϔ/^ؾ5 GuTy^9ʗ;暫X+ 8}٧u+x`_G>򶷽uuםhK/T??KcSO{ｷcC?/J߻oG\/{I7|'_seӟTq|k-'-ڊ|t/СZ7'mB4;| +rrV[Zӟt~P?5}m~ qˊ+X`w^y{[j2 3縮'(˻ϯ}ku#g:cZa;\ܗgN>Kֺ'?IM3VZiF]|I?<(SOX3Es1cN;ms9˗*|S9CئuYO}+Zs)0^h|r-4U[nYfm/oʢ.Z?(o~l}@2`fm 0aomeͅ|~z9?_n:fsdxXkB6 O$կ?_Dz뮻ۅ^b_6}|~XcM6U}c" _s52^ցy;bn]wQYf.so}p eyy鲧vZo~3JWoS7} g%3Y+;nZ2sV~f~;zWo-/6`Fk+'tR`ȳw]qɘ*}5֨DbbM//~`[KjzxGE~,6+:˛WAduwso 13\pz/^=^^UkC]/N;-#:d=崼Y;9mꩧ90k-X#8w_:Ye^e]'M_1`=1ƍ\mU`DxxsY>[`|#r>sl?ak#e9"Gr>3Lfizi:k]מ˜u^Mn;;oSnׯ{:b>i\rI@>ɯ?#sYD1iK-T;{ѻ/5{kuZ;QvCg}Vjz|ty$ LԍY=S.R?{gCW۞׻:OOQ/DѦM7T[?q2?siS#ks=sI>>c~ո#<<8#ݕ<4MvZ({sdo sE=S4?g:KƤُyu>2yg;Xc=G(:bĈ^^9|rx<">v)<:|}:[j_ rby筲;+Dx8&ao4T"s>~⧜/9Muh/"\sͪrO}Sg>=^趑f~LecF|q۾e=;}<յ;D>W̍z3U>X Qƞd>'$w=>efiޙf㑟Ur==zȚYuU{}T^etT6FYwaҎyrz źYHo蹢Ɂb{(fy{b-6*r }={zD/^;Ǽ;Ab/k#>4e=|%+9u|+<^xa텾 CKaD#ͺ}&C^O2=]%(0Qխأ˺!]0|.Yg{:G[mUo,9נ<3YWUQBs 9yNy]1+e~ 3ezqވ}Ss>{PĞmj_UY:lo#>5TzZLN|DĮ] EZ֟i\{vz~OYYxLu:#\:}2>NcΛўkgBry}-9tЛuQ~;.=3/ws`_iCf3sD@lq jL޳--WY>ne+{~(l[޹Rg׽Ϣ!%ڦ;[lF?w~?FyׁvB{vL{6ho(z>rΟl{c+j [Eߡ{{;>'?| PF}롿EYʰ gb09$Þ_14!o ~*}!Ǟ@gt`˼힁 ;bSp>t}k} Ɩ /+ː g?+,({\G<Kvo|1z;- >/%h}+eǵd^kLyއ*$afWImD9qqq'O3R?%s\rPwU϶@}߭qs=)?G( =#Ezsc38Vlg3FG[Q| } jη r {u=عj(>kQu᧐G?Zskܷu1T{Ne{iѸKck |B'}0}#>qe~h'wV> ;ስ}x^1bقL!&攌5g">",|CsԐ]Y0|g|7qY46Y{>( 2YFkqnQO_='I?"Kl۠Cg[ ﭑe:/e ic߫3ģ]KE{}AuEZ䤇!lQ3σېucR#彳B~^-JTh>qD~yC:؁C398udyuQ~]?'>3_Fw?Gq[\?ٔ0UqE [ ew:X񍩼L ]nu&;sľl>2~A;#5ƿk\ |ׇ=>Xw%;2aa"׿9/{tOqY8y>Et~ykٛXe+3mWg[Y=GkNfmGųtHwNP2);FL}l!GJ!G [0"WsP!%x$Dy4SxǗ&Sy?s%_|.#17k:k8wܤΏy _y{qe1{:#ц=XP3L?Yǁ}7>ǺdyV3!oɩ 'MW㳱6j3*_.aer~w_;j|k>BFOsJv8gCxr}֝#_&xQ/{}ϠIk&d?q!vf 0f#C~{}>]Qg;ƲW}!Ѧ6g7k<̵g(7]90sU1ȾJFSub=9_ر|cng'x!o_ǭĎdME6y~zZ2 <|6~R Eޓ9#-qcpr͹.vOk#kG{Yg#ˈ5Od}^ɽ<}֏/a],##=g|iY%c_c ?pse8f ֗\.Ρe.:=.mHo}\{ug17\7q'_Y[1?t~2C,BG<6Lμ(/5_b+Gg]Fٸ:󊛈 FS~/AwqW`;f?kP=ž{lCD򓳼>4ع)cөڱr;}$mh(gqPOw-9xw ;zUZJӵN O]kc>˲aǚ @gOȳQ%7/︼|q^[Dmgf:RdyoqĤlKo<313k~,H6ß?71wL>붍i|ak3 s6RWu/(U}{?lebLɍ{sD7c뷃x3C|6 @C!h4 @C!h4 @C!h4 @C!h4 @C!h4 @C!h4 @C!h4%x;Ѽ+$>{\s5һe˗|ԓw{w_P|ѽy:P9_;2V\[& {k"o\#{Q>e.o]Hk1k{e{rZ^l܏nݼ{=Q@ѕ|=w킉Iow}4<}~tbwR{WOà@Czb'nb-Z @C!h4 @C!h4 @C!h4 @C!h4 @C!h4 @C!h4 @C!h4 @C!h4^< /,_~yꪫW\Q?z?$^K/+r?j_׵ 7P>Owܱ~/KyW{y}{套^'?)w_9CfmV>OO⟧z|('|r1bD.E]T닾^po_~N:^s=WSN)?O}OcW~r-/>'_*]vYmk-/rG}q3,n_|޺tAG9:R1Sj:x纞y晲~U~|Gvء|c^m4!|/Æ 7Uz?>&;KG9mݶʠ:L34},bU>O;}/^fi|ӟtYhj^|nя~Tk>l6W^Es=zg_y-W]u}Y}vkߚYdEO7tuZ\v%,7e9y9WV}H}Ҥ> *ywAguσ>~|}kw{wv+_Jy[Ze/O?}kHs}rk "|GYowk=ur^߷r"M[n~ǯ꣤uϵ^2}{_E2Sv*N0<}9#x9q]k?\.x뮫5묳NxLy|k_{vpRT\wuZ^wwy<~V.zZ]jzsN![D2wg|_̜s٫K:yX{1E]GgR{|&[lQ[)mf{Ww>\cJo{dژg?ĝ'r|fFۮdo sj˷馛/ڋzjt&P,R(\4^U E+2<߮k"(Ws׆?ꑹ+A,3_㬓viyMlnW9;l{`Хnڕ϶=k$i YJ/8_|JP_ u?tu}f"l,aOFOⱕl>q!G#KԽ ~-4=m8I"1c <^:1 -?^|իeL}_ec l\|T̊+9ywF.l-R1e" >z#r7('?`dy|^~66>ΨciozcWW^t eʳ)rN;JežÖm-'l]Hd_`׿n#' :{9R^ FE0>>g}E:*[yeFu2O|t>}>aovF?g}Oy{[`l觳lЧʲ'ezW޳g_(qd݂nfs|_W>{l\ ١+%:PRyc@+mVo~ x}ܧ_4F3fwl=@oي",16^<\/D]G֌x܋ OJޓvXKXo7t|n|M.ç|ƻ!=>v9GA0@cWu"r]Gw='{2r "Ğ׵ߏ~ߕby}4?vi~mC-?D&z8.'cS"fl:nW9fH|It븐IOz9#}l_#VH9쯵N]-(弔+2C@e>nl}!߲Эړ}C,pĔt}%Ο~/>'ٖ͠gԵ19ЇjQq|;{㢃 fHsS9ʞ=o3_~Gk+|1za{aS;x]v ^w1H%>gKօ#^Kr_N>1g]LqD9Eq!YneD ?=W>%i`\ QOxFn<&;VPsEٻ|9rTAtH;CvīS{lu/sbu}"pc.ޯ _^yׇrAg-zF/vJ,9N'sy.kȨ'ן[Cg loo*oؙW]=NGk|*{t|#N@CkPi~ qZAxGY<a;c>ouXwzuEϒU9dk=},AƳAddȺ;=^gT<＜A ^W[kң۬ҽ[]X W&> tf}E!V;@؎ck87xO~jiǧ9bYKY'b5 gNIc_Bln\ڲ:ύ^7S/ @?}ؙ={WFK}u kz7zU/].ÖyBmmtgg^v#R~99Ȼd1!!<'9PypDYl|9] ވlwqX=}"߬We&{Gz뭋r{kfߩ(|p-V[}dlCC!h7Xsβߥ:e{ +PB]+w|Ou]L5Toԟy晵r-^/|@C!zA6QGUs-fg/ktM^Ow})R{L]}}o7l=o+^ml4,~[oP>vYgn;~.z~.w {Iֱ@C!0! -,堃*o{/~o~tMW_Gg%|wfmujh4&u28yr1N|j&.~U扷d7/yְdzs#oL%K9^KlX;׽^xs="aW.;S9GkXQct19[o 䂀誳2K qWL?r> `'xb}ۼ={ݟp U뮻;7޸Z.eZ;K;X1e9󫎿6ڨvyn~}٧,5.4=tC=4nի^GAZvm4:bgڳK/]v(Nfxitnv?{K/T{loʎ;XZ1){[OmggtX5 /}9T] }\5wb-fKbrn3Ħczgk4 Ia4wȗJ˫x;*T,"MzOmM?pͣ~\KC!0![ Bd#;gf-*3S#>\^Oc%Ź{7|y[{ [̊+Xn-}m28xn}.oB_ݞڻW_ C z XH8 hà [A|E4 (0á=F\ϭsL/kc5\si@럍vwWK9c7s:"PY!0:18V8׈ى_<\2F?f܁}.m]K\jr6=/֊O?ws8/ |?Δ^˛L܇}ܹJ|1qmⓌW^V@x&?kğcKI#^7W~+<{ )ro_-?v5<;>%}y|ϽLvS'}HLKo`_)Gp֭^ǽm{__|ii|>|s"PWt+eeķjXҨe|GD<Agƾ#v^XWпܼys]˘Ի|ڌ+Yi v>3y!_$+7q1H5p@Wol3c ӯ__Iw2_s&XOa9[(9S0NؤTZ'J #HWG9qڜ>h7şjshLE x-^WsO3uP|Σzb-7'0г@m]{O'|z Lh6j37qa!k]R>hRާǻ/DzM1̋h\m_<{eyvPO(ZD\WyRU_NugT4o53V*jGz5Ҋwgf3zC1 /rOn!Ƃ,w7wW_suxG>={sZ(E &(;mcr8&;)g/,|!%~^o5YKsgh=5;|m\ >є'$Ff3 ;2/o9l~Znn2\NA63u6*uw$ZO#5-Er ;u?.]S&w16‘ךR:->X2jN/z0 1)^t5mN #jY֙PSr^\?ߘg& y$F,q ]H}[w?x=z'~Qy5-[gA"P.4jEz@x>[2V.VLNGŰ6ke5éyؔ+uzkcS4#n^kN.;B'q<믿]eq9MǜD^ ''fkӊȡsh`֊-| ݛ{0NF׊@<$V8Rp cրwkL>ҡŪtI/~&[6ns<4T#nתMkCW8x6IwAlNg͙ZN>Oo]?c2պ+<Թ:Wq[0oe1LCSy?/i:qmLΔ~{yyqV :3u1֦<9Pk_E?u>\?wY'oV-u[GOeIjBngmS_{C|9EVqp%x~4FXw[ZH 2E5.5bf#5wp~sEkO܃ISe0`_H06Xx9nڏYQ?`Z(E нjdh15s] F<>jjOQ''c8H/xz!3Z>ųpՍ=ҟAMzQf|܃d-qGm1Ԍw1wa><-985e%`CHs>n69x׊@( O纑X5-`\9k4z&e2:]\Lk?g}hayֲҠ ʭ2>IOAf>Bug|Fݓm̽wFr/&=E]?M>e?͡>sp)ECh"8\HV+  `V|2tW. ;+ërj`R;4Q2b<֤2^LO26.C۶u(q? ?Jg2"P z n{ߤ]%%ֵx:/OF0bv=pkY*V~8KS1~gh 5E|G4{ Ҵ~Gcl>޽36m=}(Ei8Z-<{1\t}^bSI3 ) BtT^Tz+PGs3<|oOyu5xܾIq~Z{Ɲa~wRІSw>}942^ieLwƩ>̍%ʽx_doyGOCK /D9%rԵ"P.&bgcpru#Ceu(j[$԰kROh^B3ݨG%w*WIO8VP_8 /&_k.0aW{C<BMP3)O쾌oxg[7Xh=/}ѯY4ԖZ iOҷ-x}_EF"~WYKn5mݦ^oz98^̣AVwz]<.j>`'Nb~wq|\0b[~#&U[gyU g7FqfM΅5GiGzp|-|k| "Yh>K-؏vEM>AXF c\:\0&51tmO)ʛϲ>Z{c/<"P't]|^:4m@~1f^ kz; qg׍<(1qQƇ\h}*x29[?OGZ92pgz.ߴkR?3ssl20XefM T5_/x`ӿAV@@S7"^UH+ZD2C^|?zU^W̡&O´p>|-]47P4uwhja$`Xo܊9>>8[U?/ǚq[Ϡ r0zcE#jE\ p4E+֑555C1:@`1'=^q]|;^d~;cwWcFwRe˪Uq/?$8piՊDZʓsq:s[v9  31957gjlg?+<9lN>Eo"P.MͦW="{E*q7v<;4&f㯳1Y_ҳ?ܳmϓsU-';5רۙ{W{+E|! 6e6!W{"_4 NM?h9d5V0?6_깶#_+շ8\xgIK3dN߸få|͒sūL>ls>w3KK8GyE˳ȟj']ϙc8/~t:KS1XOt[=PW % ޳ }.ϳ'/o'6&\Z!x,ў@hth5t#ܹheCsxy\/3?q}h~~K~QMk+Fڸsqr|aMBjW1Z|ckH.S"P;rj3q:Flt1<5CbpD >>ƛlǾ'^14j2ixN <.s3g?2#~s1$.blO+R2>WR[wi?&t~~ L-ԓ߬+7O⋌k|6/,,Xs-֦Պ@( E9O_.i4uFYo-wi8~]z5/zZMjuhGZMםr4"G9_sc|{Vx<-~9:1:twO/㣙ș`j!Gc"P.7Wqzp ^WԤ18 yh/x׋,dw73,_lχst|l>|͍d?9VT?k?r:8>8ȩ.}=?,NOkEV AZt\it{p*킞b1{Ŀs8_ ֟UASЌGzf,Ѥ\C=<~7./wqQ6לeriԊ@(7I Ndbn8ug_Opx# e([4Y-<4~ux֒~c>a#m}TXq/X]\.9ܬW6i4on+E!nq\Cp${Bϧyܧ.o{{9|+8^|h{s=547j5]bu.3ʭZSk4-1sW}`uy5 ~@_kxݜco"PNmN}b𗜥1оsk4ܦg4szΜC,7*bjz1Kr's?8[:F?yX/eQO9#Bɏz$s ߹5"pЬc3ZS߉cn8(OWA2 F2p[KG MLVNl+߲&7?US+E<(V*uΣUę٦}ls∡#+880s=^bYEwu?Gݼi6s >mo=|~.E@@ >QON=>nUݸ|~-voY?q?xGu׋^S`?d߭_J}͹0Ы!tr;;~IQT|r"jPh2y8QƚHG[r(e=gw,[zko્&Ku0^s|uWN~yMzij3SrϢѡ&ܻ5 {"P.-_M !U(nZי>b 2Kklꉼ/9[;^m=qǹCMr#l>T i,&uյϫy-E@ u5bhz}EuVE/KMwq~sV)浏5| !{Fc:q<'ЇW ܯlI~V/~gC|>Gt3'~"hj`c&}tdͱyų><\EKRי8_|q3@wK\\Phga躭U\`8q}kgy~7 =)7`.Yurz ^( |˝nUXxx_?5A=}}Q_oүV@895g>+SOcwy&_{zk"p0stmrsO_9Uz0u;/kTt84joƤ.U+Eo.Zztq{>!k{0>OW_JvX/bЗ26K/{"Py78zq>I?gǩW~պanջt~q۩h"PG/Ukhd]3v"PE@KsZq;w3}ܔ'|r#O8cE#ObmU8j4υKyNsy\ӃYZ(Eˆ=?ꫯ.߽|;x&E"prcSʟ}94ՓfC2sjc^&_X/keC31wmoɡ*}-[_eu\эҩ6^v2[^ClfmYOb5_WNwK%8>kq) +̩L-c7l1uzg3mȿab}4} bJyCiaYS4U}vV^3,>Ye~oW2|#(9?& ~zl?W(S²C~qosķfcJoYYVNELΩ2̺Y]5V; сN&ElwqOf]VdTGul{g7/)<U˝N.g=_~}oZj e5Vϴz'; N٦=~d]oo @ y cxB26%(O踽k66=7fs}9bkk}(\nW^v]C/0?utMeUߧ~ו/JON{ӗn̞mnkJlǧvgOV+YVݗvpͶKeuz;-m}A=]}V9t[OպEQ-L~C濝~T&Λ$b;7ŵ62^_9jW+/ֵEWv} m+ّa̾溺ru6[e6euWTP]k}䲢*6>u5[PmߣdK]8GS)M[z?]~6Mc:n;ly8w~YFܚqꪟ^k6뱲{a鮦u{}ٔV/Q=S'>E]c]XOUm1}vb}f?c`tn[͕bT+sqecӫ~nMޒSbUWXYaS{?K+rg}P3ޫ`/4[E5U8VmRIHe[.ֵklwuf{$JЧauLP̦l`6kYtz:{~f~i6]÷Yf>UPl_ɫW޳N48:zkc.cɎ?'OzWz?,a]i49K-&-ػ+=ǯ~u ̀(.L88r3wSk}\wuzl]MtYeQakqobGb/ϳ}[~)kj(Y[Gz: erzbWU_݃u^ٷV_u:k%ή[mPVV㺷Ue-r8rA$JB_/_՟%>9- ]g@E8 r2vCNsG>K꾚f \ۼ塒6c \H}rPwQͧ%{Z0W[q9To[cw=_Oєnٓ1ǃ!O.N.,Tba|I${I%)$IJI$SU}i )I^lR??X}qnzWIsR]Cs?CC>xqTʩ)HTU$TU$TU$TU$8BIM XICC_PROFILE HLinomntrRGB XYZ  1acspMSFTIEC sRGB-HP cprtP3desclwtptbkptrXYZgXYZ,bXYZ@dmndTpdmddvuedLview$lumimeas $tech0 rTRC< gTRC< bTRC< textCopyright (c) 1998 Hewlett-Packard CompanydescsRGB IEC61966-2.1sRGB IEC61966-2.1XYZ QXYZ XYZ o8XYZ bXYZ $descIEC http://www.iec.chIEC http://www.iec.chdesc.IEC 61966-2.1 Default RGB colour space - sRGB.IEC 61966-2.1 Default RGB colour space - sRGBdesc,Reference Viewing Condition in IEC61966-2.1,Reference Viewing Condition in IEC61966-2.1view_. \XYZ L VPWmeassig CRT curv #(-27;@EJOTY^chmrw| %+28>ELRY`gnu| &/8AKT]gqz !-8COZfr~ -;HUcq~ +:IXgw'7HYj{+=Oat 2FZn  % : O d y  ' = T j " 9 Q i  * C \ u & @ Z t .Id %A^z &Ca~1Om&Ed#Cc'Ij4Vx&IlAe@e Ek*Qw;c*R{Gp@j>i  A l !!H!u!!!"'"U"""# #8#f###$$M$|$$% %8%h%%%&'&W&&&''I'z''( (?(q(())8)k))**5*h**++6+i++,,9,n,,- -A-v--..L.../$/Z///050l0011J1112*2c223 3F3334+4e4455M555676r667$7`7788P8899B999:6:t::;-;k;;<' >`>>?!?a??@#@d@@A)AjAAB0BrBBC:C}CDDGDDEEUEEF"FgFFG5G{GHHKHHIIcIIJ7J}JK KSKKL*LrLMMJMMN%NnNOOIOOP'PqPQQPQQR1R|RSS_SSTBTTU(UuUVV\VVWDWWX/X}XYYiYZZVZZ[E[[\5\\]']x]^^l^__a_``W``aOaabIbbcCccd@dde=eef=ffg=ggh?hhiCiijHjjkOkklWlmm`mnnknooxop+ppq:qqrKrss]sttptu(uuv>vvwVwxxnxy*yyzFz{{c{|!||}A}~~b~#G k͂0WGrׇ;iΉ3dʋ0cʍ1fΏ6n֑?zM _ɖ4 uL$h՛BdҞ@iءG&vVǥ8nRĩ7u\ЭD-u`ֲK³8%yhYѹJº;.! zpg_XQKFAǿ=ȼ:ɹ8ʷ6˶5̵5͵6ζ7ϸ9к<Ѿ?DINU\dlvۀ܊ݖޢ)߯6DScs 2F[p(@Xr4Pm8Ww)KmAdobed@      n;h  s!1AQa"q2B#R3b$r%C4Scs5D'6Tdt& EFVU(eufv7GWgw8HXhx)9IYiy*:JZjzm!1AQa"q2#BRbr3$4CS%cs5DT &6E'dtU7()󄔤euFVfvGWgw8HXhx9IYiy*:JZjz ?v*5=?(?%-'I43atO60[\G0ڪ"*UPy_ ?ķZbؖ\U6?ߚYkYrb[W -s1WSK~jef*o_,,]Cc9O-el)%5?w ?ķZbؖ\U6?ߚYkYrb[W -s1WSK~jef*o_,,]Cc9O-el)%5?w ?ķZbؖ\U6?ߚYkYrb[W -s1WSK~jef*o_,,]Cc9O-el)%5?w ?ķZbؖ\U6?ߚYkYrb[W -s1WSK~jef*o_,,]Cc9O-eA~d~b~f~I~fjߘ}a熴Լɪ]ю[eeNL[4'*k]iŸ=州a)-ϫ Y8zWogo_M׊4~oz#OV4Եo:}:< s4j\lAI<99ME'~wuVXZᴽ̾c1[ܻRJ U?3Jo?U>Կ=?I?/y?92h`KK|? -ΪL/PyWqW侑Ť?fy6nif {{x5+UDEPPbW/Q5/[VMO^Ե+^{y%id,Y$Uꘫ~_$뿗>x5̭6Xާu]Kk&_?薟MQmbXѢI ERWPTaZfdY~[~N~[~ayS-疵k&[23:$'.u7=7r{PxiRͺALa?4?~uM?)]C 9 o1N*?>i⮓~f>jKY][wځ9PD5뼥T}Zث7v*~ayq:Ϟ< n+M yyVO2^jzw~`o5RR8KFAm|y?qi˿ӟ_fHտBzXz9W&8*rr?$4$T<۬ڠ?%.6 4hncnKm`B9#c~J2?1?,$,oˏ>T_j^[.FI-3'% ĚTx{g?̿~e~hy L$a6%5[ɥҴ銾y^F1O˪?_wgK_Zd76) ; " 9'7zayz}c&y"/S_[o+?y7~@GCcXEƛ[k92zwB@է6]~MϾ.?;rB<+.b5ơk,V 0Z\UWb_75/O5yXмթ[[yʺmw qKma$hxQnm h0_շ&)vx,2և;+\z_NWbYZl *#~g%g~\yRީw\Mo6OFIl剙9(n$ҠثOGW䗝/o:Dԯt2kkzƍN^O*,3 МU?捇_&λ/ .ɗ>cG:q讜F^\ʵ|?,9+IpW^RYiחz~9aa47oעbG$ovYXAc/NSWum'Ο󑺞wVM A^/Dߜ?y_n_9hI;65XBgF>\?o_S?[Dyw7Sj?/)}<W;ϏdQbƝTAڏKp2_gw1NxGE8?/TG}<vR̗*#_xӾ?;QNKn/i|O|~Կ%~ʈ^4o>?o_S?[Dyw7Sj?/)}<W;Ϗd֛_]GU0c{+㼷I^hu#)#+yHH=38(/i|O,AڏL?NKn/i|O|~Կ%~ʈ^4o>?o_S?[Dyw7Sj?/)}<W;ϏdQbƝTAڏKp2_gw1NxGE8?/TG}<vR̗*#_xӾ?;QNKn/i|O|~Կ%~ʈ^4o>?o_S?[Dyw7Sj?/)}B?OilOduv2'! nkxroJ 5`7ҬW*UثWYc?t똫|q/O_*U1B́oq$k,*z*,y6t=s~ϕ?U懊Q!SN㊿UثWb_?e ҿb?5_lW(?lo]L*O\W_V_v*&󂺯>hg. {NVāk~(Iv_ϟRq[ȑ[u' UG㊿}W$GlU*|u)WO' U??Gg}'>󎠺T7l'WbòJ_ϕ?U懊UثbU_wOj&{*srGq!G\]Ck-5)kKVx$'#8ߟgqZMwtyj!DcUXWY-1WcqnB̽rn<$n}DҢ|r\}WUv*!?~x7nqT:E'37{U?yN砼CWb]v*UثWb]?q`<}r.-uk-HggNpp#( ZSLZp;;&?,ܟw>vЇ/ȰN'{A2)z  {YٟK{Ksx!֎WG㏖?:*}V?q5D7P((Wkd@>/Ǣ\yg:/.- BMs%лDY )*HŐd@;L9`%݊v*UثWb]r5OMc꿹Oݧ>>s[K_VX{v*UثWںWU>mָԿ_?{v*!?~x7nqW}8 ?5m~@<WJ?ʟ~UsC_`V~GU_?ϐj~x)q_*UثWb_ǐj_C1WX^]N&_~ϧ./\⯈?;݃e"_~g;yEՑiCyD ˒lU}8Yz ~L]7VpE5E^uhbcQFVhFNױjZ>iyE=k,2{b/H/ʏ tURȟeysO~'$N*x_?{U]v~VʠUn|FHE[}SLU+ϵ?2e~Q\Oqj~KVY+0_W>է*#_̟X_{gņ 9/];q~U>?Ln~gjpkKX8w`]>1ע'v*UQk\F?-W=8m8?z\U*S?7J^[Pէ5{X:W77q.R&<]?5O)*fa CXё[i Wmƞ%Ww+Wէisͭ[}L XIhЦslX {87UoOfMSsW@WO~I}u;HguǦ7 ^Wr")PVVb6IK@: &ekc[qZ Us 1E{j_[[j sXhPۀqW$GlU*|OZ4#3ԘثS|+ qTb~`&4ҘOp#_ϳ9G}?H7~O -,m)grlLe0$3ZSC?qqɞQԭcC_ OPDal}Un*v*!?~x7nqT:E'37{U?yN砼CWb]v*UVf+{xyu#RƊM YHd~r_/{O9^"k./4YYc5RC#')1 'Dl͂xfa1Dtb{SWbWhWA.5"F-<4#൱d4HPPPNs~G#DcՎ`~Ci`VGyWMX>_y{K罎5%ۯN_',^:J8`.@tSi~޿^|rZ絊%*XPUثWb]v*U.?㑪$mU~?(^%̀J_ثWb_?e ҿboƥY?SثW9 6sWrXt]c)y[KDI)ow/V!TS+O^pUK<~^5u86;9EͪXԕ4=WOj?⯰?+?#*bO_͏Žkz=g-?VmJ/P W#}gEyߕ׊9W*D^likuƱ5"xomӄJHQ%qW8WYc?t똫_Ou[,U/b_['[WA/gĿ?ծqWu| _6*|?[g&d#ҿ1`_/yhkZl5CJrN +⯾ҿ'[q?ZB44܇Iʊ[(b-̀J_?ώ*W?G,O}m]C7_Yys״ۿ(&7%KiZF@(?!c4^L46חbkb0o sVS4H:EC%+$`b?w`_󗟜?TUw^z|p:ኾdʿk]Eyߕ׊=?ߘj O)ƹ-BZC`bCs[Zr76Qo~9+9u/)X.O-.t .k 0dK՚w 1T7W7s#F!io:zX]J(BJxdCߗgBjRZ,c_ Չ VHbjU*àJ_ϕ?U懊UثbU_wOj&{*U?q~1*y7RGj[״2*(1?s]'5.OjU[rt^$3PU*}8'֋k^WIn{%RG^Fk$`9늿|Uثv*!?~x7nqT:E'37{U?yN砼CWb]v* p_L|2RKut."ZZ2Joe bw]ع5(5ZW55M ̷:Wf'.6x1PUsi`D.D+f *}=rqNrDO.\Xh^^+_#wO r2DrZ冻l|ggvd lA ?:<>_]Em7򡑗ʵ'˰ig8!mY)Dy2|O_众zt->]!.VR ^5W4qV.[ EPw#һ|isev~1|{LczϜ|ŢyW˶OaKN4j{Z;RvVl9[1bYDY&?>$wm~uc7.f8ofIb8H~Ҟ>kۡrߨ=ٱp]v*UثTXF0ɶ}W3>xo{| _6*~b]~@<WJ7ͿkgUOb_'Of*?$|5I_Yuszj){: fȔ 'zwߕLW~d %<ʿaӴ[MEK)t^w;-$۪USZ_hxJ ?w'ޕ]3Zv&RGdi.;]튿t@ "f@ "f_$#Vg>ZzWQg@ "f@ "f+c@W4_)yWJCߗ,= 8EQA*0?5?#`k22\䧜)0>]Z֮s1@]Ȑ ث|>7X(}<2&O.]YY2U,ѺbCagg?^eӭuRҴ}װnQ*Z늿o Kqs/[q6o.[pP-iy(^IvmثlU*4->2iZ@ͭ z5ߖ９KFּV7a_]eq& S~Gٝf bt%#:h4f=#y=S6DԚZ%TCTCQ8pde_Gt^]7ߕ~lhZg|2]Mu, >a#d #3R3W/&1anN| ;;v*UثTXF0ɶ}W3>xo{| _6*~b]~@<WJ7ͿkgUOb_'Of*ϿA~GҭW_ǐj_C1WSZ_hxJ MO48>]v*U!?noUS//KeHo6d 0 *ks?ȟ4)qFhxE5dִ*~ϮUnoDwY7RȟeysO~'$N*x_?{U)״M7f]`u[V-M k_F*"#_\BK;L>_/`5+/v*|*~kj'徉~nzx$&$_-\Uп.Ah8DeH6Yn/l*~v* ?_ثWbs[Zr76Qo?coǿa⯯W?͏bFleQ@^].Go3}WM>H"X6+G ˪G_D:'<4+_'>D ޏ^jnxmM'u~|CB>xpr\п5ͤz~K:lZ8}bIU* ~OJKR's BZui$ t ԫ5 U[W&|izƥ TI-5M0A3)\}gAO⯶ *?`/үqWOj?v*!?~x7nqW=88ɿC^v*0??!?+LŊ/^⯷Wbv*!?~x7nqT:E'37{U?yN砼CWb]GiiZ|TW1>em(i8dF̕0~'BbF'e*<ӡykOO[>[]Ҳzƥy6yj. s!s*voki2F8譄O<_ig<݊;cr3w]^Ͼo,>XVeGhWIOfC:fcYZ}.%w3<_~co6/ʯ,yGZZ-K$G%7&>nք-}Sgņ0!)v\92aOCp݊Iqq,pC,I ؕY@M$w5 $(WOxQpjUEMrI$P‡=N^^-6Wu(ɥ۲jj5Di_eٮM|tZye<.9ݝ09s>C7[iVzu, "cB ,器ܒO|HȒyԣȥ9?ei4Uϙf8AA(u?Ϊ8ǞhX?Gh(gKu:UثWbRc9O&1_n{xߟ9⏭_H/ t,U=v*U?Xm]+z*6\j_W= _?{?J^ Aͫ\_Oj?⯰?+?#*b_>9 <;vtdt[\w=WpO/>gN**?_?6|xU7ϓa'7sëNƳ}#r=^|9%?7n0rM`WM/lйB"fثg1t[ ,Nk]w:x;]CMFRїB(ڌ%%~mh~ߛ:/ֳ<@VZ-Ŝy/J|qWem7;zg<SeNJW~}81WϒA~koYbU?V?_zyZwFȅ}3WZ/xbmR?=Wf}/[{ M&!8_|u)WO' U??Gg}'^_ hh8' 3'wpO/>gN*Kȟ>Dп2-5/|КnoKe?/be4 ҢA*/okE*OK_M?s ]]ѮAZӍ΅N~H_gVMSpwi>n.t zڃğD/=W{V͌o;]CDVz:dIbT'*GƓ_ȿv({\^_oI0^\EVwrD9U_Zw'tg_KbӮea}mI#|U?69yo˟Qxn_I6\Ioc@f [|iZg`v>d/)yyqsL5adu\U?O_W?Uj\W _?u]+$rwńJyOj'?hk7j Ps" ˮd:(#7KC Aᗢ^|?~glR@jˣB*+1>q8|-!/1d=ƾ[~un]v*Uت*K+q 2GZmDH1̏,QԭΑ%ò^XM\CZPVx%/=㣛OM9&?_r~tymw7s{q=@V9w`v?9s?SY@OyykKSSE{]ĭcgCE@bEhNoǐ̠2l]v*Uت]#TIf>Tc{KegWb]\疿.<Z+?2\_kf[ٴkhnePb??__qϕ|ŤyfD]?F7Mw5' UmcqWbk?|̯?:E󇙵mn?Z(u ncI8YUBEzUak#~Z^y+PYtK~^iq[H Y$TNg87[~Nyk~ahr%niFVfZHߦ*p }8_:ye&ynD7..u :do¼ٰ45u^?@/<3h~Y~u_On!Uj_ U,UDZb%~~;q{"ޗ fYԵ'ts11޺(q?!MU*Uث/s'}m9=~ay[X7kP 3XѰ(6^*<>. 'Lm;+\eތWQM;QR<\kv|k7oKWۢC=:LFņ*7z~W%k!/Zyo 2&M _;nJ*_/_?bʟyWu )t_K}?.T)]Vs>N/寝<_1e/iw p;{nn\'aJS|U*lhloeJ7Fee$zUy|7<7?4+YOu_'{*\i -ͼB[HӔ@Y*qWb/1O+ʺ~:n_oZ ԟ*uC_ U,UDZb%~~Ik^hմs]wj_m%!1~F \Oo~7I癵oN[Q0LҢK:rb=WoOn'aSzm4CQOM"hTGUXs}93y=yg˶:ΉY~oD^WVLf (J1(53hi[k#]2Amwon[),,?lmx憎stbՖ-GK7Ђ>V]WooB.&<?UTy]MU`񔸷n+Մ^:bKj]ܤIд^]yOh-8OYjoZ:7|};V-E0"eM*ז/Ti-~;Eaxq%'yr~JW_-_k[HEŷS7.S+*p }8_:ye&ynD7..u :do¼ٰ45u_XW>tWt"Xyڶcipڟ:1,y*"*Ng9Mq]ꟗM|_ZsVC*h^@uzf*UثOrW};~c/IѼɩivڏa,/U8AA>[~QySu%Y][_zomein.$o@j|U&*Uv*!?~x7nqT:E'37{U?yN砼CWb]v*UثWb[[k++io//%H-- FYe"(%*NFRv hs}/+~R~bq`Uk2~^d($WV"yV4]S6.<7x^gz| WbߗVмkӬair/@h*EIw(LRُK {z|ZyGQK@S22޾ 6>s[K_VX{v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uثv*!?~x7nqT:E'37{U?yN砼CWb]v*UثW?ouMV0>h/- X$@O'&W8h_SS=x5x,5̎%s8 Y{_8GɆ0#}}ys|-̂$Iq#*P 9M_nXaռϫy5Qvp4`U RIsw-nF{VKZL31?[G^B?X~kL뽚L7[;BG#2O5 ĂTetrO18wuwzP >O?= ᝊv*UثWbRc9O&1_n{xߟ9⏭_H/ t,U=v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*!?~x7nqT:E'37{U?yN砼CWb]v*UتaiZXh5OZ<ҰT4PK3@Bs"e#@s,2#d_0B~W]hl1R5ivm#yɼNP~o/gGg#~'w]7|O$SQ?-F87{[JrK)yı~O\y'OQ`% &%Rdv#42?R!bQ2w1NgF2~whby;Ko9yZM{%u7dI ǡ:gt_( N=F@|NUثWb]v*k?6ُ?sv}m/ϒA~koYbUثW~Mㆥ?7-f]K 4*Gt@B"gˆ*|9%9IۮZמjr3[{Oܻ[iv;tb=ƣ95_52MqsqA$vgv,IN*UثWrϿO5/$S̚tگ-!g%f#B<1W';+<,yPl4-ZQ/mo%xʴr`E$U]<ѠenVF!ef@A"*⯗5|?%*xyZ<ɡn[\h.mH2_'o.U:TD'K_6"?0zu}F~q3yH7%&ƕnOi,IZ!LDH?L T)'tY!6 ** o_݇?-7|/I*mRszJc1Wo.U:W\F`rk_g~럒ߔֱ{6kI9k: %G;;bORqWOr7rnj?Nz6OilneY%1r` 7}YOK3dyVǘcdγu%ȶɣI!'b_Wb_rK_ߑ?>^:n4 ,丼եŽ>"OUo?>*5Ȍ6#vvqVʹ̲E#oA%2iA]W_󊺷.٪y/̑yF\^aWF$n1W[rkr+rȞQ/7]AյKY^ 2X⑊4˽?.<i2Y[nlo!bE4Vrr# +A_o.U:TL.ͯG%`^U<OMW/kn9%gi'Α^yLYgHcAE9)Rͺ,|ekn$K#~'߿<8(<m[/ [n&5ܼYQESu.?#0?9w5؍׊[rb7^*>#KΚ<ϭij3\]\jwq+K+B"a]v*UثWb]v*Uثv*!?~x7nqT:E'37{U?yN砼CWb]v*Uث:m!4t<_yr̚g% ƍyoop@G9 ud$r5}]8ĸO1| a#?,`gIhu/kp/;ёёсWF3ɵ||AR YFRUث66/Cv>akWL 2G7z|U.(njo\]fɐoߘi̗r4}9EP])$ rAZ\+8˄s?]à|YYd,3-v*UثWb]v*Uت]#TIf>Tc{KegWbgξi7]T_zSBmw~1U,~f޻]|n}B^KFrP U!)yq_C֋KB 1#VԵUiNG1ma**gfU޹hf5 zEjеj0Gsks}Udu>b~8ߤ2FP[yg=k;ז)m=F$ Q9ޟDR|ƍWȚ?(.nNFZ+kn{UQU7RoeyO wUv*UثW??ZhI_%yD WY/ )QxGg#n-m^^C|LPjI!xX*ֿW]&uCq>z,Bb K 01B *ߛz'o$5MBWגgxwݕ߆*t\io1WYŔ&WWb_KZM^P?Ϳl g4Uv*I#9%E( *I'`_u'MKvv-yzCI)m(l;b/o?0<~m&|2_YAxPGPqW8i;'?0.}Cyv5]$|:kv,B*s~` <}?sl1&S?*2lU1OR,VO*1VO!~ciSh~^]"u+&[EuY]*Q?G|~W~e\jOk Y/$Nķ X)bs|y3_M69c$GO·6 ?קlURoeyO?_DW˟cP_ثWb]v*UثWb]v*Uثv*!?~x7nqT:E'37{U?yN砼CWb]v*UثWQy (+akZzg{c3~^q?~+E݊~FɧPNH~ؿxk?;v*UثWb]v*Uت]#TIf>Tc{KegWb85i4_?ȻˆȺ@9՞-r3B3' ?7nOMEW /_VA>1ע'v*UثWA~i[~II~h~j+חlRzv07ex*3!.u_Ϗ_˩{Kmvy~$޶p>"ReqW+ʿ/}OH5y,&B[!ςﱗ*| g/v%#BE4N|!M_ ~B+7,??_4?LU_FX?4#CUtȋ [4=|1WϐuVC%ifүM8{g$DzoƛFC~ϛ/Bi{v*U47E|O_ثWb_75k=3'ҍOklfa*iߕrBϣysSk[hKYpD_{*_k+`-դ\y[]ҥ7V!,7Nפ^ث׿w J^,ڄkg|SE--J}IuqWXZAϊ_?nqW;/Mgf_*lbsv*>?gL@ONY*&+N1WϿMYй8]G67^_cJmֽVK?q^c~*?1W*UثWb]v*UثWb]v*v*!?~x7nqT:E'37{U?yN砼CWb]v*UثW_N|Kns;'UI'[~*јZd%Dmgӂ1~Wsy'~5^`yd[ޤc G&Pzف7͌B?OvA)=As~rw˿k:NtSPA{bxm|_da=NMIӘ@;Ow~0sOr+̞aյO;,j_GiiD XP*Ic`{E&Du<^I rOX^pg/_Gי[ZnU~ߢ it84DFח:fmEx2Wqv*UثWb]v*U.?㑪$mU~?(^%̀J_ثW '_Ol kWQ_ojLi5?_gK.SLquh#`HnT/ʣ8w5_.^yvTQ@H=) VKqw]$?!?)?4 oc1Z,tm5+Y튿tH:8 _!~B+7,??_4?LU_&?# )wgeo&f_E"1b_ok Uϟ MoogY>s:tW?Y(Hi q{Kr*,[/ wy UOb%qѿ/P_d}K6P~*^]=oͿjߑUM󯙭2ʁdHz:US?A{-<˚xQpŬCN*~S+Cp?,E @[o|U϶6'uFy+]Z&;q[շs^;~` <}?sl1&S?*2lU1OR,VO*1WbH/ʏ tU/'k*/_Weo.[{;dS]{"WqZlU'Kr*,[/ wy U%~EWۦ#{:Z!]mfrJxāT]v*UثWb]v*Uثv*!?~x7nqV9L൞K)Eһx:o>\)KVuٸ"_w+n?Mfj_:1^nv"n?al>R_-tc%|V#DF?W|[MKzGцK)жw[qe _aRm7.i&1F/BoO?]+n?Mc5͇_KΟĻWݤț(j i?w_7ջH7Q06)/:1^nv"n?al>R_-tc%|V#DF?W|[MKzGцK)ж{CaRJq@M*i _aR}7-w[qe _aRm7.i&1F/BoO?]+n?Mc5͇_KΟĻWݤț(j i?w_7ջH7Q06)/:1^nv"n?al>R_-tc%|V#DF?W|[MKzGцK)жw[qe _aRm7.i&1F/BoO?]+n?Mc5͇_KΟĻWݤț(j i?w_7ջH7Q06)/:1^nv"n?al>R_-tc%|V#DF?W|[MJw-oz੥g;nq11\S({3c%˽^%̀J_ثW '_Ol kWㅛH&*E鱑~U$s RQ|=6XO**vW}-8%9+Wm< >qw~c<~<5>yVv?8KJepJTQjīoH،U*Uث#nˏ667BvוƢx[䉉c*VVߓWhN̝r֙kux]wm(#oW~~A›JUnP?~CǓu};]򅟙.|i70Y~EqnZ6cn'fR61W8?9?'|qtn/FO-޾״Bl]=d&4~~B+7,??_4?LU_7yV#x3I$*M`:Wr'ھ\*%qѿ/P_Vϱ?<]c3-SMVŬo\mbJ+HƼk*oҿ!n*&/X=+⯷W?ָ_bo>YM?~b]ͯ]>z+kW bm/GH4YWܹ=Wq8#_ȏ_?&?CKU%3Hb]iWwHզ-:dn"20H"m_̻??O"?GflgR>{?ZlҿBWcE gyf\#);$O$9hfB? +ɳu{Εdث^ _36*/L_MGɈn&k˷`!i.gm5xm\Uwv-y#Kqa\,4/V;䷰IZd"T_/_c/ҿw X&t&]B? +ɱWнAgJlU/_c/ҿw X&t&]B? +ɱTgR%LxO-j AU?{| _6*~b_5dy}89Egwo ,9Keg%`qhEBz\U5%CEZ{\ԧbZ qRCPi*1Wb;n0!|urXA5-hL`7qVc>8Ю9GyEt#eANi|PT)W'UόI*]v*3~W~\\pO+nIur nIbo5h{J1y_i=_jYM?~b]ƛFC~ϛ/Bi{v*spG4~oc[]3YybRajellY݊M:@'` ?$#Ϳi<]kפx} Cp8@H #1`*Ws'a&s'a&SOGgGPҴ͏"jE-HT7Ы0![c*C^h`v5M']w^臨*/^'~0ϧ./wg%__@͊?)Uj_*U!?eED{z ~8--m؊$i%߰qV>=r^fiBR.碱ai"U_/_Wώ?ơwWb]v*UثWb]v*UثWv*?(c?&"tC,3|Ǭ*h*H{7yէ[KzWySRNy/z]<>Ly~xS;v*UثWߛ?_/%y*ZNV#H  NT랍rvƎ:@H\$$v6)cuAAYvbyxzk][W+)tye,'"6 pߙt]CV"j3}#y8?k^tt_]-n-VjI@;/lS>UF׼֍O]2ԁ%6ʭނVW*̓aÒ"C~Q4o?r{Q/uSC^\!(=~%~k%fHa'5)Po8?6ZVDA!u[O"ȷH۞{e3[dlq|!C_%,?[I_=iVX|-Y'mCҙع'2~˯_CgXW42N{I݉Y>Jzg(eIlDAe~Bo?7/䗒/+Gqo.@\_\K'd`ޜqHTg}N60 ǎn"72.RkwnsKf ZIԞ`U#Grv<$%AΩPy#G޲iy 9 SE٬Dx׊Ogg#?+~_KbnR[ۗ#N1+~q|GW<?VSVlti&DPiPWb]`ߙi?zHZ&g+jPR<_ӗF(?25g; [C35w_XTYku[ޝ[Kij,D4 ѕrc?󏿜^z$3 KJE#CU;,Qy˾K柖|CkۢƗ^aC3 +-^*x?0=?-+sQ򧙍EѼ PL1:()?Zo6k3'?JONܾ!k}u~H/hgӟKw掣/k ХŵQ*^%JEA__J??⬃|cEOW*UثWo 8g}cv!?8}6X+K+y"2[F+!6__/9{cqX^ySa%'( \Bw qW͊~pտ,?cyR,57Ӷvޕ1W>?󖿔>b<:!ԃc*??!?OE9kr+W~rԿCW^pҵO0꾌WWOF%&ǰ_/pO/>gN*̿/⿕4|!t>NIQPQHd6y$0:Wy0`y5<~cjm#OI(ܬh#%݈U^_?hiM[Φ7YmJCqq4X@` 6"0w늿_ok Uorq7qߚ6>NiϠjW,w Rh;⯋?_ &Ǜ v µ,:<1W:~i]o͵Ok0n,7@*1Wbƿy'G4m-[/2-B`z1H{eoW?d^WQ4OӣX~C_-n'__cmkO>*aOm~\+_I_J̿5 ~^_nl ien1*($\T?l8p6w\1oCM?F.=g* &!hH![js*%<9U~h4{v-3ʾWS4:VnYYYPy$~+GbW_}8?6 t=~i_4KON{ y"Ht9T ]XG)W'Uϧ&"gi䋟3:W6דfe6L*u~H i_տwp/p[ȱW@4y:^cmZ9bI)^eI7x~%1Vcv*UثWb]v*UثWv*.s8r5?Jߓ_:凖yTl丅,ìr4J (m98Я=y}?O*K e_䥶q%D̵U瞿.]gz$V+{dhf)@|Wn*UثȏɍYS򭏔2F2h.LFDDZP[}6F__ʏKU9s9y8Ko?-!|yYyzɾYi7:3U+"s;U*UثW9Gu(u-'X햩\ kD;21RPqW߿#'(<s[i \k6a \SA Sk*X~@O~]W$>d_\FhVAalqW_o57~T7z7C/YCG W|U*UثWUk 2Cj^ n$VdiJXUoF;늿UYϟt,?-.ߟoZ\ШW Bqޣ*J]|w9g8MG9q'~z!h|hً^6\ۖ<7 $bU~~bϝ*}pHMX+2ozFIx*}A9\徕X5-"H#Oze'~'ϣI#hе~&|t{koWcKqUW_jE5#OfYi`i@* ,U9>O}+#yR7JL:ֻ#*SUq]sx芟?~UW\*"?Oߕ_?/+H^5Ʃ+&qhqEm+B$lPdeSNt_?ʏ;O4G`򾟢=o+{qi=Ԯ-4˸:k?"?Oߕ_?9OSWu|9/˟:jx#[ԭ5=eOUdcRc!C2#*ͯ/4tO9~]R66G[RXNƬ2M%RjqWĝ{q>U󦥢~xgSAypEogn;(0U*U󒟔CKeκ%uSΝ44GuLU'lU;?/ߞ<5$v[U8cOKSCZ0*z_=G޵jIwOs٤S%Ԝ~#~~ϳ?>??"<6 Uޅe]hW3[FcKՐmҧlUE}̾K,d+0hg,%HQ*C0 M;U?)~xR5m'G0 ; "^ʿ5?芟?~UW\*"?Oߕ_?9OSWu?į/2~C;Y~RyLԼ+mRGidy.T%6`(z}v*UثWb]v*UثWv*DZ?[Ac5[thkX4Ux?&X*궺c@+I&QRGS8o#`;)idv.T|~g/lUثWbo?ȟ EPUוoP->&(*iSd鿺}ϛO>~Dq~Ckko{k{_1yP-BZRe` *6/?J O\˯=e.}kN ^kң|=G8w? 5̚wל,2ݭos4X0hRPFKM@ߧU?ȿWZ~hZ[_C5N Ӡ"Hs*!N5'ӼZן|\kA-4 =$K$bӿ˝pGo(fVZkS$$Q̅i*q99ȶmF?u,J|Y2*~>vZ\͝L뺤3@hcԚf U涇_ߞ4L,n"twK;$i" "Y $4ͿJ*鸫/Wf=[}Gi:n_Q'nL=b]l0wyK[V0ɴm'mg?~zQ*yQaqO?UGW_r;yU/'4?)_WNiKÛR[{uE;^1lUt_ Չ+5ޓk$(×{I<>>.N,,RI&g+zBi߈>S?a%$EՅ >]շۨFYוm(,<&BAXjzR${HZWY<٢Xɺ_-u͕ݞ95 c=W%_zw@U۫o_&yV?Yo;;}FbP~ğxb?=eؑ嶛"PT?l8 տ?:t"[?4y_rZ@GRjkzmU^89?ʟ gʞB#@Z%6sͤ g9ȷFE*U9W_7}A?Wqھc~*Z6* sY1_sW+Qysm&6?zov*U=?Qпt 9)'|+Sޠͱ -cr6,aWG?NE]ޟؑS^銻v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*0y, '# h:˙B7{XVoF{*v.NTA/SɌdG☒ jkz>Zڽw}>:`,K$b}DQiPثWߛzjc6Kl`:{W/PuC_RҼߤ?mE)SĿ_ڶ yMzy??c_sSm_ y?GF*>մ pqY5;MH.YVd-)TE1Wߘ:ɤzݫƬiYca4T喻f>VƳۇx屲xC2S}bo'R!_F*88VO0Ay \r%BKq0;?|U?~Ggo.z&ݛq{=&y%e&$ 튿!*`֡ϝ<åV0Kn^ TY6_,Cm66 *" *)]'?ͦ|a+/z64BZiY$L~qWs8ߔ?WZ52H,ڶc9y@?.?9kt)t}r̅ԭ"vBzt8?7_>mG:ΓFCRey!i/U~n_8M__^k˻_1yW2!HtD Eb?_Z'BYM_k:*۵cgG($'F),;hzߓU-W@McJ9Rc%2Ѕ¢oEP_V:ơO/~r-櫡um5%b0V9㈃~k~X}O@?0T4XsRҖ'&6lUU9?ŗ/6=K;9wo3V,K$OU쟗?#yOʿ:ivƇ-οk mtH̑rU*Gg\iy_?Zy|cy}(" :oL;F*_/r[˚Ϛ(6{Du#w7:֙bt!~.lÄj1VW?]}d/O1lY\J(p`SA_D֦_rrrV_<MA4}FHs ͒G-U߾*1W?qw_a򯛴?5 <Yk7n⯘ߝߛߗzǞ?=jmtMd.Uv-*k_s@ג'55o&y;+O/=$kƣ~U<ߤC~Ϲ?>/,yͺ̺oΚS-մWiq M7nXUثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb_v*y8e-^[7V)ƻY]$WMQӍ5}|Ubڟ/2$|3\h+Z K"Dgϗ~Ws6?츞rhm}Aػv*8MGqrnC7,#,Пfa&1G~>2g6Y.> m1X~ث6#6S?Km$>t@/K!@TGl=G$>A?'˭%NuKyAƏ  )LU _=~Z~SSߙ_?r>z-ƣZ4Y&~qIG~PϐUxW _L~sAyiy]?0uI<#R&;e%[c2˳}`qϡ%f 6Ѩ;=klaԉ4$*DxlUBOUkz6ŌvzXPv? 튾pYFO =qϫh756S\Au""#˅@Z U/so_ .?:n*(|&4U!E+{&lU (m#&cVV/pDtǭ.]/t[jS +y-u(%Un,79c0{~s8>ĉ ر>̧]$̯W}o OBZ*ImfZتqWb]n8 4/iɕ꺙[ =׹qpiqW88+{qsF]7KegW8IWW_Kc[^olMh:Si{n[ܺpiUH?_󐿗z'OƵj(>_j9bm"(YXs }m9['u-Ƌc^Ҧil\K=7T*QI⶷qusHAbG ?H^GzWlUQ?Wqھc~*?)Gr"b y>`%̀J_Rε,hfדLJu_Oz{vL< ;=WQ_]EGzث3cҼ1y]hV.}f la{ބO\U R/:`gu?/yXfşNAXN&+J U??_>do=w6ϧ.ieҧԏB{,?kK5Qz~*Wa??'qW/iqW?_˿kY4G+i>հk?m3cYOoʟj^|X\g?1WV~|??(+];CźbV){mI[rcWoݾ߲qW6O;L߼uX<Ȏ5bO$5Yp~Li KfiɭJ]5E7îU5?r/=妓+6: 8?C^~*?OOanGXⳖ~%R=qW2(*Ek*`Wˏ+8m_1ɍ?}~J^ɭ~B9HɘUǹ9ptOKA{YO7;JgN拫XNeqm+{XY\N*?2|~daVԼ:^j72\e@;jȿVGQnj7ʧEwv*Uثe;ɿVT.q1-t6*,?!኿@?(-*)|اˢ1Uq 4S-&8e<?Wc3j#5Ikēfc//Yb? 5`7ҬW*` ?*j#bů ?0l>rTv$,N K|..W?ϯ'jΰGF:ov͌`hq`y_/'m KG斺n)ICϘ[WUZUWeUY;WcO_?_?LUa??'qWន? <e8ݲ$ucC?-9'Tv{lMUk˫E4i*H@ZBpW,u/ a6hs.n"Hc Uj|@ή l-/n>!{@RI?R˚[|S[Sn*ݿ%?3??"|ըy+s#am/J[?C 'I]B#Inc^!|Uso_ .?:n*(|&4U!E+{&lU (m#&cVV/?M.m'g?~ U?EOʟ_yr]l0wyK[V0ɴm'mg?~zQ*yQaqO?UGW_6ZޟX^~]]\Ʋ,mfH`GPF*?+,="n G*ʠt;Ib1v@ށTlIX>AkOfSѿtf$qu5WXJD<[u[_XjHU*d>Og/e?#wO4.eӼ@vyq%1iPI*g!NY`󏘿2ZyiY_740*E»Ƣ8qBi]VFߙ_)v4"MىF ^U$)m纲-xX⹏7`AZu*$%OKCN*rJV?'?(|]~Ogu Ca CYs6G#ZBԪ1W9W_7}A?Wqھc~*Z6* sY1_sW+Qysm&6?zov*dߝk/)NiWm#HηMkb9GZGob6~a~IX__zK4W~z׬Q_ ٶs:6yHҴ,t .? kQ1Tv*Uߜ~p/*?1^aGPem-Vm-UI)k_ 9!#˃ɚWbn%u ,mw! z=_-okqM<2y̶z{{5 QA ,24X;qV?>Ҽ/:?uy_{y}4wMӍߗ N&9{%A8{b̟̋G>]_dNԼAūEjCZ\EWՃbYVo?.y:e_[Lյ mzr!pK,l_\qEWƞ7O",I&ҴUtut$ fTfcJLʪ~8)a95廟:\ju?4aoZۨ/p0d^ YKU~KRy6HU85v(UQH{!P9xw((=?b_+ 3k\s鶬 zFe? l$|n꿨8((PD* ~(=g/$y+^nbۭEXlBEr Tӕ+CH?tSCX6Gմ"{ X v!#yO :4+z5t].[˹/1rFcAN|>tO:ד:݅Ɵ4OQ#6eT T~/2ayM򖋨y\u}Si.5G*?6U'8ж>l㧞<'kLt/<^j6Ηy5eT[I`OU_m7c͞[|yvYtGFCmRw_)p~TO8}>u)5,yuQ7;["yӡ8;|4o~T^Sе{O4nZѯ-E +{Q $-jDLGC.faߙ>j37:3bRE$GByV*?5}_}//!jry_|׶cy(}=1[CIMkUUϠ|{%F-rQSү-n ݤkx&S@jv늾*,?4mkZn"-ұ]BȫqW/;_ď//\ڿemp:L4 Q$J*Km,8O,nQayPO5N[ol!KskU*k U~]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*U俞Zg?>cΟmu(%m WDk\$r*Uƻyk^M<sk:t[J *poG??,W[v K_9_Vk=t/Dz^,G?Ozgb?<㫡$s=>G+i>հk?m3cYOoʟj^|X\g?1W^X|8E/,y>bl4o;F\W3*Gwk,"y$_*_:+Oc侳~e.lUzϟ!59R?zVPlDMA䖠 WlU7pK_~[jc$0Q$կJP|튤~nH k3SF7厩< SZYylAцU冷3K_O0`jPoMݽΡsuiYM#B*!Nyȯ7yZuP~pmL ]DgoN3'|UCp,^Ѽ)nkuoNڊ 7/̏/"_ >YzbH-?$@U$m~s>~_6!VwR^@41j @ߩWп_ߔ>yuʝCs:nBKi-X/L\\+ SFAj}N*cWˏ+8m_1ɍ?}~J^ɭ~B9HɘUǹ9ptOKA{YO70O?/S~]/S/#H#+HїXcY%jF0*?1֋gyOݯ.>:W@>])'v.*?u"yoҍotĹH,L|$c}ɦ5=7i90_^\5h?4yv^YK߄kFF| A,("Ӭf;V|רZ&VB↍B@?gcJ[<Ӿvn /ecɌT)nM_G>հk?m3ӣYOoʟj^|X\g?1WC.?(&?,?+/2kBޟji ĖpM$jV"Uk*4t oPE6愷 v-.n^,n-uǓtzsT$KczzmI~]?SX9=-Zp)iڊVNYݿ/.X_?-jkʷvjU"-SozHa~@E_R^oO̍Av~Ve'h5EX@T"dF_Ϫ?=?* ?=O*Rdl zvy)݈ZU[sk{wcEckF̶c4Z:v,+O 5;vtwIůoXj?č֝TT*)YђJtdp\%T7bkWhmv/M|8aZ f|->-cM!|Uv_˧ ;[D{Iӏcۏӊ30?tɟϏo Xu:yX3aqcjŞ/1)~vƟ?h/֍!?ycU_ÿER~cK?J?5ԯtеeHJP;ҧ3t3?z^1 eDo+'so!'kr=t/Oq:?2~fE 5]TZuiO=(G_%Iuuu"mm ITEPK3@\U~B7<_~Y<mJy2 My4_N]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*Uثkɯǟ9_'O~]ܽZGh# *ܣ=d- U`]]X]\[Ke}e+yg:4r,lUVVEA_֮zB7RKZUx o(=F=s{/צ-g<2?O24t[37&3sh! 8] pe}~jv\1cec=K[V0ɴQ'=g?~o,垡]aaaq}}q" 0{$9 $?l4o¯?Jҿ6<[?C{&S'tvxNϭtnZ?V[M{iR@^4}늴<>5ZoxW6_礦 mr<@;{b7O}||[CKo-y[S_?N/jb>YK%Am;F@n<?n"Ҥ'<.Z~ۙH#U;o2?=#?5?/>=Ƨl{?q.-uPZY|W59&T3#aWwjjҿ--|Ro=iyAE-}8SqwqџRBDVeUC9W>FK[/O$S6eE KNQIΜUF>C[}'o?Uh?6s.A=iSJklt krW OU4_do˶[mUWi̗MoZʤ;{ ONتa~OϳVҼt8\gC/2cEOVkϏ.puϟ11RaZY7esoؿѿH7\HDnyJ``K(X\q늸-Ϡ|ZϦ[Pɸ{2w^4͟oΥe=<"αy' ,Wq\ӹ"o!~E~u~T?^a?8<+6yf [`/\ ⍿bBʪwJԵ;˶W1j7wp٬Ԗ{"JrFUUf +O?$uҵo2\irtfrTGq 9zW1zJm#U~_ B ko0yCtMΧ^RbYƭ'ڕSO'GgϡW)LkVwM^֫RM[|w-oyON- ^T)ZV:m|iI"7rb .| ZC&~x cEOW h*s'ȿ>q)sUk?D\i_X=I}/WÛq97\U~B9HɘUǹ9ptOKA{YO-~qj>dֿ1!o^EGTVa |ٮ+V^x ɣQ?f/őI4䳻^ZIܒLۓwQ(T[*{oWMK1Gʢ{??GG_QZu}s0Z;9+qn䤃29<'ivvj# $(δO;6ږԶ[OCIU}Q-N8'vo }<5:}79)|;UKiU?;MK1Gʢ{??GG_Q=&OբC_ʯ>nZyNqr\",em!_Ж*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]miWw5 (fG 0H`wXn.8Fr"A_aثWb]*_grWJ~q[X~Vm{E؀7i%v%.U+%Xe4e;F*[qAƓ_\ĖU5C#rA{^Wِɮ >Da8KMlw\(5Om5 jt]9Z<+(;i6Ũ;2rk`rdzf#[FR#be?X?齏a"8q1ۊB W}}>o=o%od~oI/7L#p[[&?|{K-Mǿmwĭ_>=?%&VIqnwq[|q+$8Oo7IŻ8-nc~k'Ƿ$#9 888_h`k>nOGjUdVk{ EkOI8OE@ qn8r2)nNfbsɐ䑑M8K8Y~oyYOR4J@xD*..ʔ"21`< ^<. ˞[M{U b(bAʪ*UثWbR_JeQ,'eX4nf'W!V8bH v-6\F2hC!L0v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]օa_iߚwm}f^[HJ}C9Ԛ_?gC$Dc+X>t($bE–7TNMUGE.̠"$zv 3=q3Db_f~_Sokp) \k~X$X1z2p>_?v~S/-*"?4\9 ߣoKG&|̆_"cܳ`?{ɍl❊v*qMKVт?Y5heƣh.$a$naϦYъ:Ut "*QaB;4ڜ!EYŻrأicG2ʞ{OCi痻b]v*UcCY/lD|XOZM^vgDB =܈O_ؾve@c18QݸBT# pCSKߞs-zR{>[G>$^=]ANŪ)Gq{s ]',8cWDn/(/ҟ,y[˞K,=,Fvc;Nuq޿5ϩ,%R6r.Wb]y柑%~ccywʞ]սwcYZqW99w?̹˪74| 7aYJUzȿ*?<~ybyoJ:q[gb6lIp3z換뽍2j]?;fFyKK.PwUt@z4\,Y%.ݝF:hd(78j:sO,{w++.KpscF.fIثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*U׀gN~l}sIpqeO݊}Y9UE[ygwu i+smt'E}b>蟼~O-G~'Ƴ%kZH|NA]ڲڐf~-le|o!(}2{5'_l StB1-c2\[̄ӔrYXTu3X|cS˦,Ya811>`-K VK!4J -u Y! H "bk~!>}cϩ~CJ}$/*ˈ'xnfE&)$r!䮌 *鑜#8X;yH66{O#!a59(g^wYv|Fszpnݗڣ0_C_ggb]v*U8K_}7M&5?흣v*UثWb86;o-y[EJw9A1[D>9  =]y޿,<^BU CU[W7DmɝW>F?2"yCQ8i~b~i]~zlmg3h:oq\:nEeNytgfҭ.};[IխD;eb*Y?_={qYN9weqs剥j-L9O>-*˸ c `̄#)w` GOѯǿH[ oySD~Ɣ?M?;12vtls1Kolc}VWUt``j=9V`Wb]~4WuM0I?lOghv*U'?ϒdwFȞVuW5{BH)#DJEU&>uo1Y$|g+@i@BevPJWy rnO yz>l iZ5sf;*" Ub y3q7-d0Y,^fg|o>P4!"U~b_AiZI/鬾z>\ {94 5 'Pyf.mTq̾g ;G?q?!k_q-B ;PȃPgif;K@dF<叔2{Bgur~[\Ayoowm 4e2 6!(HB4} Zfj.jFm-DΥ%htu$2B1`o=?zzeֿ}Yoqi5,]qhR1W՟^dȳyV8KONw4d+|ڿ`yV<? we=ߩ:cϺ-5o{PF f4i^*Tnnm//.#溺Gh ;U@$h, dA$nI<ƿOMOR^AHꗶռ(/e;4u7kW9wO:ֈNqw?%/#wG2I!,Ƥ$(-.]v*U_П_iv#y/o?[ szUثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*g-/|&Vy;WŒ;(#b#!iX&Mlh;?'bi 'fR;D;+]v*Uث_\U/-~Oy2YXBD#h.X˓x{NJ^o~>nϭ}?LǨr@O\}wC)u\^W:|H-uөFfhOݿ6`J;w=_fv:lb?s‡󟟗Wu͆i5 mH#AE>ˋ,2NJ$X #!lv*UثS}M ԭ=s2Ojδx"Z깒MJx hË ~cw|JҎ.>f0UثW?_YDN[ cJgܛk ݢ^6; /Ooڏ#y!sTҶ`ڐ: Ex_xʯɟoi\Z(#7H?{C7gμT{=?󑿖U)5R{@ߠFMʌ+{&8qHsn^IxuR?9ȻGI/%WY O4pz/0c6aJgNk*#S!ݩ՘9:GSLK*.C'揘;hIiIW.*%E?2ݩOjs]PV(d5jC^hӼwmG>i՟@JE@i qAyQ0Cq }&Ǵ󷙐%ŗez-0#0?鮧c e_V66YXDYPHEUU@@1TF*UثW_[yOҭ}Msb56AytT7>*akqG {KҖ!ޠz|Gq6<Ȉ~fثWbA=[B7[ĥUU$@,g8&R4@>}l`˒u#62 TTVfVx0Z9s|3vWfI40|70[{)'5c'54vmRj m+{w ?>23r'H$q8TE t2=$ev(v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*q_M}R<爡5(T| *.bx2TR>3;k$yuI]ijV.dehH]F+U4YGceAs]#O!ܭyTk`Y4Ĭax ;7/wWEF#JteҴK8,44bb5TPoAUɩ< r2)b]Z#G"G]Tv ָr}A5GMo1qg\ԟ^:VcA[QFaqW88լ䋽/O_KK}։~iQk_Lo@> U$A*GrK? .*t]I5€7%˜Omٝr:~4;~\|_-_O~ZYd+1O庺rVPbE$A5u{7=$$aŸ|R6..P5@*gۯ3kWư9 yuCljkl`Bw*fyjXjzi<M~0Ϣ7?3['|)YG ,fc v!zXhk_-+R2V+u m%䕖SZ Fث1Wb]v*kz6-V5Uu95;72Jٕ@"dlGpOtlzoO/&̞W崂ꢳ[Im)2Bv& ?~{90.R ywnQz}XݽG_]H 0_RVUbkV N՛'S*k uJ5D6`Mou>qz|G:m& 7X4_?h{G$Ӄ0y?|^ӱWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb_v*or?%?'B󇚃NT?KCU9SSÇ}ʞxBb1h*#I$'4K?UO!k>g쭙Y)%4Vp%A&mY R!nɜaC;}s3}[@ԯ4mwLѵ}>C} BWH# Ajqjq.BĢDG Ѝ]~RlyU m=-AE4h()!qQT"&dNcoi?U؝s lJA4$*~Jym䷟ZܼUPNgn{Tc3a.{>Ϲixu0 2}iӡiaҮ7Rnb$,zX;uF!şs)ثWbRkC|˥_>b,TڕwV17Xedu=1WGgK1~EO;iZ$ĄF[|ciF_?_3\Ky{!`#ΒHRo!BXFqW]ט߬wzmRON4io.Uݏb?ǯo'uέVɟ+SMC~.?W Rj!t?jx ?cy_Tru%qc%qWxWb]K5}kGY]Υ+/^Y.nvKu\ɫlto]5H j0C2@__'m|]mmSVIx'5 DRі?k7:Lp?wo~9éǸO~gw e>TUثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWv*y6:PoEד$<ѷ(6>X4i./UcY#Yz )H>>gz޳y8Uo3~F~M6Oln;rc[xy$F2n~;&8AwOl~"'$bn0DK#G?'7.3̚Ƨ02h>mX](` Tt]l:1O vGkPie˗0?Ipى#50)+jLFkFP@l:4bQFx94҄D=mv^ ʥ@q+X7O\WkSUӵymgUaU&)X:mG70j`r@1a*/-y~L|˪ycQڷU֒0SPe${Q#NtxzPH}?rb(5OKt_O[U f'<Ɇ$ykg5qFx$-ψWx_ZC~w˱^zI k F:??G ȎuBc`tӾdGUxM }sJ3b/d~^yD|/y֠ibOk]]\xoa1Ɏ Gd[WbsCR=ZۮQ-|G ]M~BS9Ᏼ_%y~9慚@FU:M5Q z܇ϣO{GR'_ӕG,8~R2|}=ϗR5o5^>F0Mx%f)\;ݑpip{'v,ߖ}F/4T8Cti4*FQ%3@[nN/Y8#~(^8 'ϰiy[Y+M,u*')HG(YO,`fIͦљ H ( DP_?%~^y~#ZEy[zJ6nB\dHF!‚QvQŏ&1)gwb- z=qjHR!bPBp}=؎HQG^i y$x\P>$rC#*4R$VVSB;i!!cp_I&s7'5JOWN#] -i^*>_qz?EeuWF VЃ+b(v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*U|9Ko8yO# V.{浊[ 0\+̈",$1eQ#9MoniW)wzCzX@?\?v?FVJՇᴻu-/^n"b*N3<D: ͻƳٵ\!>O^yf+yJz䈠DB~ ];s+f p[ S}RS5 1 K;X[+%r9Q,:(ދ<}4%) e1*7?=#<C5 [,mm`YJ6XqJ^[G=Ə /2]lwORUثVWy^UMZ(76H@HNCuڞjքe;rorK[~rZ9>ѩzZO,.?]aeg99AbU׻r}cO.6&zCUuuWNzH%?f_?;ro8/SEGxzV8?A̹i}2~gNVdj9d␷_W / kt[e1٘ә{d  Z^ Ap |A_~/{^?|?'!5)s^5f4zۘ}N!"qa> a?O:S/ NI&ZNVg#̗wM>8Wa0싴v*UC^m<3s4>AG(YQ]J024]'f9Y##Byr/?o\Z 凝.ks _4aNP9wZO\[[7^8%Y_=Dx|hϾ|#2h>wK:ONkKʭnW33&1#rgvmieǏ$er0YoS> [^k#Լt֊a|gOGl%ǹװ%Y.9G4'83ruCP^/Bv[m(Y%Tļ8E O" .\E6M9%dߝW{Hy'<[/2ݪyWum ok\Dh@#>.*f ^ ?},\gS/'Wh?+3c>yeľu_үrڱ1f2og^E/.=).8p3K=?/.*52k_ZZ։qd=ZFqv-d4 K/)+Ljx ɋ/ aژ.ab8ޢ/wyC?/4Ly_(^^-iE<ȏn 7zYcE,r!yW_ο3i$7N-CCdrNί=~u]41?m>eyZ_?1]^^aӴNIh_܅cJ)̭_yjhqĜX>:߄GGm1|Gz毙tCQnwM[sg[3ml_Cˆ? r<;s;;;P8MzJEk5%kG[zI| Vv ns#{v+˖}F{WdÄ!^3~A򖑬|*'Cq*5чм"a$!9Nk.,u~"~ ev=U_w?WI.t d˶>4qrޙe ##lXw?OٸGcG'2KSY @-+/?_;cޝk $5XڬwY#,ͽK|Al |s'}^K#/JPB'94mȼs qA͋ZOF&6YjnqUV@xѫJP] ]Ojf~ԗL|U*BX LhHs"\lW'n4h<[I%ѡM7?ompE%(.)N Zu^ /z/neNr>.RW ~V<ڦ,iWMiS֒d%2%_0_-_n꣤DG ·P 4I |?-(6%WIbރ;S|d['-e+/\AOΏ>\>E.CXiȳciq+M=MN,xiFq@Gy{u?#F_֓M! `Tm6r8Twˎ O#g0Y`_o4 XNwjޱ:it4&TND h=^YGYHGȞ@w67nM2DϩiP t٥@O)xlVfά|!/|jV׵,붿Q<s6\_FVxHѸUbbFQ AZ=^-f z'HD(4EȀ{>RO, =VKZ;NTȁ"{_h?'˨2).eC>^O"XwdmKnig.Ԫ9v}?[ݼO~qx&j:ʋ>`45%KK{h"b_m v>хq@?=#)GXٲy=OGT1y7iO$PI BTQМX'wØC KS߫_7&1]cf]\(Ji//`vފ{1p.(䇖P8\/Oȏ=;W󧘿1/Jx2ݕC4wK< rRG'~ccN2IO5˥L'q6) x_~XԴ7*Xgsj7f.MJ,Fd ьg;?P{eG'i8HJ2ocwԷ(_o//б[*e onzk,Vyeɋ5$ Upe,Sg>vggGd>djnwyNwZ"])V:]/<쨀sCl!fR /ƏE};gmk[SRb̕?4w\-'d gc ?}}=~$hƂ8QP6 |MءثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWv*U埚7_-[ uE8ݭRЕF rV^LQ*A={7a|N?!;?_H7:u~dqX蠫oj b5tR?J{+ ?=wg蚄wZF d`Tf>ˏ.=F1(8HlA$>D2w+:\O1hZG[˻X )HfJdIDi; yN\|Xy0d}7??iޛZd1Njծ/27c$u+POsjODR={;/ 7G37]&Kۻ[(s$1(i(&Td.AG_FQkbJV[}6*WM v~X|~){@򌟟?'/凓/-STȗF[gԭG-®Fð,, >즯َd!! B_;`dA 7w៓4oѮ0̩kL 6̫"mNP1Q392<o O}} GR򦙬iV&Rii[p"VrHUP(<<6{')]#1YF0"+3 md6>ͩpq?`^;נ1x_yX0^8r?^p1<}MзT'Ż>R>o?᝟@WAr1{>&qv9u{}O7w?2nGޟXA5ŶYfZ+#@ֹ2pe"\6=ΗU#3)B8@ ![>g9o5y"򧘿3ۭ쩨j>yX0 s9[zOn]>bFvw)s˟<7DK9cⶐɒt& >YOk`ɛ'2mчߙ^~ ?:x?? #i_v<0,p"y1yns,GMKl5;SNݪE" ;uS-%*D+nH͞\~`^c}V{18o?6҈a]JEi[ ҕ_~.5;3ZsvYB2̟xgj:GG䆎jg}k:W $ 2&m 9 &:~ {M_aqBtz`kg!Ջ~{KUk#q H󶝯cj}?I/.5 I411hȒ(1*6(v> ښ-\)x|`'.'clmr?_znZE.1K5s2$2J41J*P3Q9'~`k{ aJ%#H⫐r~lΏy{~wu@ҴYg+i68.z'+YHQ;;k{;4iB2HRLQTG@kkˈm--人u/$Ɗ $s9L@rN7޿_kV>X7wY}̬:ar>?O//'(i@'䆖t!yv;K~c"S W~6X?5{KiCYn]k;v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uثv*UثW~g~ETp}_MnQxk*Pv)(,T+Ɇ3vݩrXP>Ư6?4?ٺ?(<G2 ~1ۧx`?7);O~-񄍏~}~`HlVJ!j_F(5I!$ ~OS8s7}Q SU1y^V.U"H%h\,,)Ы) DHwϯo9T?~q}YZP oVXd؎\͔ucpٯl3fHa LL p `&}iw:'k-Crr73"4kY>"I]FԿs7&')f7.Fdv}e^?X ߝVm>H&Dc%\;ݛX89Kkï#9r`c_No-~j"ߵ 9"(;jt4b?i N5z %5;w^A}4-nuiocnm}DgY)`^*j)ʣ,g^g30X"n<'cAY]̑O?(:v2N6wWmϥj14&{q7`Fq1愥8gSeDrs_^MMwXf3jM`eq ĐάNS?LϙG '={7?"cJQ@b6yCɟiQFoA eyd~.BX0H˷ _s3eՀڃ3r{%ߒ{^i]VL>6X[PKGgǒuih{ Fom/ L*\\WJ;+Ⱦjw/|٧\q4?[Lk'I9 y\{-^:$<<2F4# L8j>l˲~͏+~q~eZ\p:%Ω.mo%j ܒӭY\%Mh=$7.W.I 9Jh?/?&,?"/кk?[j-eY7$SG'5'zOVC3f1ۆ޹~_f_,hmʩ= AZl-chO24 mQ nfr~OV1sKFj`yt6|?>?5(4mmNд+gi#EC#dviT0f9ee?c}3x#렠&?r E]| ,~X[O%nN8w$C^'GaqU_"/>F̥7agxKw'#f' R!n=ȍ3>/5#m~mvmFT{YFf|kp'$xH{ qn:T o2]wI[:_s;c ^0zqFƻgYkʻv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWbv*UثWbT)YJM …X#b)H |8{8\jz&5Iռ[J1;n0;H(=c3˨qÓrY~v`1˟a]yd>ܯl~=O vbGoH|m8@;qcW/cKI=-^1#$LG4~K5+$j}ŘC4j=J1Ow^><Ԕer.تwPUdd0jP( ^j7uXu)yQγ+\k8Vd)*S216 8k:q2CGq;?61bKDJvx00$xsmWS94lxDqWw0<Կ1%mO/~k#O3omcmtPTԮ\uYx1oa:H{?%#//.o- I 9OĒ= d0DyW_?$RܫyWhCOj-8?aƋO 0kin3kwb/}wY.eE?Ryݸ*̉6^I08F F"͚h $m(v*9S`x "zd.B~tzz?(879'"+C~ >5hIp)Y|t%ҞS]갃fT4v;Q?Èx쇯2m-㵵P[B#EU@<#)INbثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UNoGї= Ÿ*Ju,v8y|Bc[X?EIA_c7ҼN^~f_\Kt'ї~ GsޔŐ~-_%<cQ3i_qҥ?e_MmA  ?Ity$?nGCpB-+鋯$4 ONxzO.;'ݨɈ~R;垝tǒa^R)v9{G>ȐFؓMY0rLO-yvs珑rl^vʱؑ|xl|88|o_?&fY2!3/-DFm9 珑hN?{_oE7eN/-U>px'}&}e)9qyxEcƝ*>O&1?{Zx~i?n AUi!bcB W$J(~LCOGtڎs6zϗ,I&q\tId:%iս;{x2ȍ0^PH ?)K$\ʪoz}o"Olɇҟ4i_=-~x~}SۇL|'|`UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWbͽDd F/'0  # AbIW8&N`%%nW8&N`%PNG  IHDRpsRGB pHYs.#.#x?vIDATx^}%U\bɑ!̐rV 9]]75YPQ (A9H03L3_\ν^zlv~E^SU=|G㘥KjR L sR  8>R X 8;MZ @jgg @jk)̓Mnm$TJWOI%N>g2w6OKj)[{ $\ P HEXc&),&{Lcu&k5PY@as除?, &}NvOe ŪILZzܺCYYH" oLKMO%dg'ݎ19$ \l3>]&{RRȔJ<ٌ]w7')~09`O w0`6n/rlܰ}<@ `7(pDH--xs@ B",+BF1 3e+VĎp!T`+PK8;Y.6=R4V#QH /G$!tS2;`לΛ6ٙ3Cmv4Hj)`$“I ] ]uVǜ ekSY^izb`ʹ_ &Z @h-0C."pNb XVM@P8˝Pc PWp@gC8ȨkPL}ޑxr,6P҇m?tI-Z`-j7 GQPmG g*,tY1`ZP ;s ٳcGp'>A~ rۮ TJ~ QzL 8;YAd-J*x-Wȱ|L MfI, " GJk,?%(PK[pу,Y|"W_S,Jz4 8;YYFɠ&8ӉBY@[4>s}pX&ϲ9A2( W 9D 7 >l7BU7D`P,~ibHd1_z&R,7*G*$ b x Vm3vlۦO:װsJ̷BǖG~ϗ5 twl{l'Qb 8;y i&!"'xQedIcܻ㧿}q32 ȎU\ ^-<_ᢶ~Fk.÷un=?nvE3Mj:N*s'Z`rX q( fwbB+Ux95V#լL(T@Jz$;gD`+"IetYOc.O/_BeP\dRW8 Şy<Hqv܋f]/_K5댊1ն9G/aerN-‡%Pq*k4&ͷ-Ƿ U(-;c(ܢϿ=ԛDQz*)N{B%@C$A,Et>fvxZ4 RsA3_w." RRT5ʄ"G?PY,"PP㆐5\'G ̝USMM559) K&˃+)NC 6/ZK'z@+>x3;PAT,% Ri7YЭSsĝוC㏹sr: ߍbifqR8M)=Ico0Yn|X*k: srvm sȎ8,'7dQTImcۅXwHscE÷nit=awƩ-"2L r(^HЛgꄜ 6 "8M"]R og'M,0޹T^Z@֋ E.:uB>Kal46 ^'uRrh"o#ޅq$nF&<ơ6Se]f+徭:)N'=Imt7YnXj tj!lAy9vkLՂrߪkY8C H*I=7@WI>y6oeM`,τ̮8A0jjdyfxX rxp@6 .]$aNZ6:I4&0T6^.GVc- .B ,F2zHfbDH- qm%I Q.a G#/Q,ԫMBL W,L#$@747 <~&~R\'K3V5'`5Fx܀8PSo\{GR9C@[ѭ * j 8>PMpyxHIsp=ok@Usy`qJJY (mf$Wv;Ө RD rtdwm4Y(tMevivzʝ4MO$_?Ó"s RO4dR&MnQl3F~^F4Vbk aA.-JCrTmlXg؈2 ]_MV۴"a=Y<&R,x}0IfR'X[RհIA6rY $mq傄%P5@NLt1DNfkJ6nc˞^SOC:rck ڪa5ɷg a@p;,)Mqvb#j@\"CLEa  J>2 Fj?<^vhW|^פӏ_/cymۜlS,OPzi4m#lʮ}+?Q~xv~hga(O EK<('xQ(Eŀ Ip\Qs~@Gx]9ơWo*pJHqb 8;S񿴳TrGŮ_mZ0Q4dƧW*5QeˊJ$cRDDVS5K̚]STmA\4yMDh͟v5p'МS R-D9P{.Libf4Z3r`(B ׌Զwg,?-n`SeQhc* %)YD[4fـSe(2nl-4TYFt<3 " o2LZ+7_B`H0}[ -+O0PO5l3|]7GH&!|MNc1KLbIT 6SWӟެTIl9o|T*p763f@$aJOGUw.=r1F"E{i |]-DAmd%T@B$zv\E1նL{r!5RwQW=U^0ۦXBA@-V*2-Zo ^3(:R\jT"Z(x x]4:QF)N^%Aqb? ?3{X@B!|ޚ:kU!BtjM[+s;v"˂/0kV0 #ֱ՟/۳ L>gtT:h*}Jd{SOXNC6D(wj)NMn9b> Lc/GfCȚ}fd>o` zTAF_W㹵aBW=0foтqutڠS{.R - M 3Q|3Ǖ뫤+W*(PrO6sg5 =7mFyAY򢅳9[8j~,*'{S5'k´e*M-Tkʕ+˧`*"j 8<) +y^NGoTby /Qw.(86o!,,t=⢲$#$^@DAc9pqR'$~cg'VW=I^pfEA#H s!Mi@@uC 記p P.a%Wʚ$޳y.r~zCQu kgB1GH3;o,jrZy 6&8hжeCseEfBB8%R0R݈IQK35T2(%?VY,bz/VcAhnKL#%ԓ8Вț|-Wc48uf'Hw?Y ۄ$ B.y [4[ %t2JPr ~\fZ 5YYaچ-Y4ET66a'HwZ @C]B7+dÆSw5ܮ NeegηOյwhd+¤HQ/z*& %YaUn˛jDR&P՘ *ۢ??: &7!-P'#~gy[mk!`s%l shA(M-W*S]&B s%]/=E-[ˆ+>+AEkABVuue )/G8;΃M ~*gHߨ j9Bn *z/.\ی`}Qx.(˰9sfynM  nî^ٕnpK.<` %1ΛBmx;IZ`@yy*r*:_e7{cY{)JdV;EQvRhgٲ">'D~Ѽ.`(6F_Xt|9,dтWZGĆCG\s? zT٦8JZ`@vn3VI[ۍ}5fuwY?Re9=(ϖGӏ~e}7[zLeHHPB؛`tqRIvV yLT)١SeU_:`v/m#ÜZl}@{kWdftǩ+ z]uo6x02CEEj(pG*FƚrlɑlN/Rꚜe9TxAm HWrCH&+p$ x< #V n^ůH&;FoIcS_ryg1i5PHx B,]R x-oSG rS .25MmfkFgL\nBPҳv"PXU.92@ B~?OGnE˽>hVhBVviYY#aډz:_Hqv7Fv(#e0fd5\Jf>nk˱jGeuFR(wRw[Q ƁdtD qlՆݺ}g2ۃYpgO,хAtcyŨX+`!!Gt;ޯ,nP%zגjL?+P%4\3)vPΩ2ְV`@7p!tSdVSIw[ŀ?)*2ltf.Ve YHp#ha@[Ʊ2 uDx]Yo%JLeje).飔nY =LX|®2qxsOjE' *pUB~>xCTB^V]$4s^.Jg% !r68$C5qQz^lRʋgʏ? _{n/W*:8ilOtic/n(¢jR:1#/rӂ *e> ɸЯhKf&DZ0>)#Jr]ojkNz~u1 ,I76JXOl9O Bd9n XZz6$mXy[m^X44~aԟ݋,t1eryB@D,t 0E4\Nr- EQG8B. m3/ <~k ZnFEWs#p;nM[6+gތ @ӭ&mm. og j6pX]S  #1PZvp3TfMcl3.LsCvGtC>̳CQ뎠srg~1c*3 \VhMJ!@XDDNc!a-S @{z!)sP(x$bjSAv=vÏ75+:pg P'Lij>7Y\7Ϧt3_Q w><W\}ퟖ=# 9q <^Xg _Y?00tnP+[mZFiu5x<&!m^ %=}3 87K". `',SEٖWlyj*#;,HpKrB_W)F\4k1";jZq$@sR"ĞY|_wba B[/WtUS5>~;riᜎi]CYA,<[ G֎4$p=,fYD )n?Yf-3:p |0 Щ_{X.iR{bLGfF>ѿV!t?Ak ,'p--sԀ&Rh6/= |I^" Ljϱ@{PR~dlqo2sg^7ʄ҂Bw(iMmg[YFU"68 v[?eGj`4гV[   pԗw6PǺnkyB(GR 0=Q]W/K#h82 erS 2ϳu EC8rmԪv 8wةFrcļS ʞ]g.7HyyB 0dZJsaTz+F!P&QBEW?jͥ v&cLX@{ g_-ķu-5^+J<Ȋ Ѯ[bUmVlb%U-R,. $'.[ksH-{ =~2+ExX=D,.pw~й}{_e5p]4X+e4;OB %fT3~aW6ggnwά9(ZQcjqh9dCԇ/x) QK `,.7)`̊C>ӫ6n<\*CXϙ;ӎ?a@ctnr/r%Kv@ǏJLfhSϮ,V9)Ɔ*ItfK/HS](zx>ٺXE1lr]` biE}WYEh\~TzjP2vId@+mH;"$me͇ͩemgMW_xFke;m\O.ty38"ti-(EO4 Se4n(h@DWa=buq-)=?! A`rxDE9Awd)3U5 Ƶ !btOLى svÍ5M}!tD|!8KdZq_vu3vFAƥ$e8]K~xq~}jKLO*HC1;YM)nIgm  ۞Kj@{d ծƎ,BCt[ٕ˕m5@.:{XMGIX~ݑB,[xH\I$ Ck,֙G >":%kӛ~-|ŕ)N @D[ p@\v\eYA 3H+#g~^nS͎(m*yZDًZ~]HA-xB7nY`l37-'ņi9wjѶ/ka j~y;/k9xaYb|k;"|§2VULpNTD\.4#uYv-,kB+s,|̀]۶lݾ똒2Z+#0 j6& W0rVqަ)j m괤DKi߷K߼`*^X=iF(vHbd%%3 nMA J 'ǜ~Ad& @Nݒeũ/sYpK91$…xUSTp&}toC h_6љ4X8ծ Hɦtx:QvPq/Lq~2T)&ʳU*4"҂#HzR"‚U8(qXlRT|5@JA $Aknj};{+*qM +9PL;AX&t"R [>CzGYGTT<Ȳj?ܶ _@MQ } L#R(#߆-1B9/{l\ΣF,:5tkN0Yݎp BںX NCQ0PRA9bMnEcl@Z`_,?ړ& ؘb՚*m8Ne܅<Ϗ#I7%8p-aIX'6!"o*WIjخ*dr+9$3Og]L1djK$rcv׽j ~m#ChCC-"X,rYؒ.}巐kj__ɖ9-ʫ~HoFrt EU$1b|Bu8i*q|}WNC3;" .j|~McH{Z`,(G@oOÌOo%~D1 ](D9"!di2 pO`A|FO|@ S.G]cpVEBt,FnE F@#~Wkz=Gmd@R\|FO 2y58nqQmEuCTb<+шķZ+hs 1wEԣp3y]8nUoQ0u兴(B3nKʒ,J H+B HCڀO#&r$%R i|b&x(o.8l0\_&Zy{$R4n)SP /7N@@0St%S08žY[ݍǝ=Ãv%PK[QC U彴#E,:1dՄd٪-G{n{hӆpA]Ѱ"Z41pĦy kz/?+2d9rr$rM8H(zITL6 =V*ifvM>&6  ctr|C$Js iP|%@cJr/+3A#(Е؏P$^GշeM#;:7p.ˁ,lj6_1;u3GBgTׅSN`\i,?Q*5y9h*C 5}q;:Պx>-}21uLW87Po?[z?ϟODȠeлDc"VEֱAWL PN%&8؜?rʅ%oxHÇ'Lį\^Mrqܟg[Y"g%UU50?{<;fi,?*VT`O2loUG->c tk4Hvjx]/ /)*&wri8.hH+8ମD l{l`= %ʡ~-)p@| ih;\ėȷ mڠ! v_~fseÔ2t拏>S>q-)ɇIr$/HLGss~Ox)؇84PJ(қb|  )l;ȊzPF 2c  (`'\''KL[bAhfF1Lو؀ :~Y~s2n/ (gLAFԍ+7 է޷2pd@9(C|\DZqWůaG|ROL@ݤ]#z|r ȒAn斻w?bCw~QP9R_7ꐙqƘ:7Ώڶ)/%O>Y\fX"AaN&VއBBƥ| 'Ux+ C47NpdJ."[^\x<gaӨib~lza0whΎ|QG|׽!u.4Mu؇ <.?%Cd'@@eQTmܼsT CϵLq~R oX1i:Į;3?7 U6tq2cJl:L ݙ# /28fΑ!pxōBHB8Og0 RGc_Di"/ H CmNU,I&KA6V) K`+^߂.|a#GXUGʷvFR d=WdL p ;TwBPD؂zເR"]@is]|Ux=SF$Cred+욺C36f3ENí*Z 3#VJF2v-q2pSx^C! A+ɵ, p$*=>E [lgsD[aigV{vfB5<^Q? \wC붰 9hr!\t"2KYaMp <'nTLdI A@ |[ZYqq ||͙-9"sRilj.,G(Z,IJ{ p|?=l7]@WC ޜlY |ַn) a?*ISaeu4lpdv1|Copxc(cƶdKzfIt*Z=R%lLs!C.|D*4FT5:-0#[UkvWWNf#͈l6QrhS {Z`⬰ȝSRKvHsS++?tjS@r\VhA'|O~9|==ٿشi/NG' u 4դ*e[P9 fL8lb, *OK|"OZBq-="- HqWSqgL% vu+7Z]E93NoB & }!Ϩݿs}Es+<3Z-5^VaTpB;-7@ε >Z9 ;NEu0mM<;/sU~|fl]vp2a{PJM |RFy?39cp)Zg<׿eW*4wqYU9r7[`xIHegȄ7U _ukn6m, ,Ae;œWڼ ٜhu\niTr0`i &]2FD-Yne77_n-~G}`t#A2e- u j7sߔ22jJ$ु%+60'׌$g8 7\Y=]#5v_Y`9@v0t̩ }Esd3r,b=)>o̬g-1`Sd%'-9đW^# ?@P@HA-%xvnJ*2,s|C7õ Yd4؇:{Zgƅ \o]j}\G<\پs` 8 _ck[m;^R,7/@ GIz >0T~/eOd{yb@_`KUdv = yRcrݡ<†'fOEpQYYBE_ݸgUͮ8֎юa̺O<ՇV4"fX[ٍj;FH!@Gs`F[pN::2l赐xk!Vۇ644cJX,T9_i/xzڟ OXJj=SIG93󧟼goQ(K(2[njUr ]b!4Ttۓ<37uezXFq]?/ ]-AEkaԠL<*eTD{ryhZS\D@*_2b[2j 9$}Ќ3Ij_/O:25,mǎc,<+VMj!'+A-^scN e/ch:TXU+rKN[zp<0:6,fC,΋x\KK1$ijF2mäxғ,O݊ lxj{E |1eDoQ;b6f*~d烪cK5K# >}29*c@򝊶 ŝ,6)ϝrQA] ;,@2D ' nj\3A"S7̭5=Y~#OJhTq*Fñ1, l2 x6B+,jnק8 F<6OlOyg݄֭ΜYpƬVUM/%j C]~㾇V.(` +#m䷾ܣ'Q1b#_*ǍА3=k]Pwp}(Бc٠8~!F_ptO:"~^r'5 #2I:䒪*E(8+7o_ܨMQ'@֎bǻ/kwng?5j eºj<Կ(^x($Ђvj ;U,W`h(glAW?Tlkl6oc۶V:͘JXPsY\$ Nj9#4\\ JXbӆ<*'=mu^a J:>"l?P JH6}@qGpT &<>B ad(R4f5xp0 UV?ctk_u,Orla"!4|p3P PE"~5/>O|Sd84!RЊXyƍ'/=3jB+#5W49x kQ{RwI_ا8%Pa,Aw5v-p^?{Ʒ=Q2yb-Fd?;`5~w"IӝAL4*X4Rd੗ŧM׳|Fd2\*m1+0&RU_}4EYk]7:񝗱3Nba$X_A .pӨD K.ępJ8*D5amSmRB4+p7rH~'2ve2;b;Ym{lSΐO dԓ?=GZ6աS~j L"gHm/[4k57n:9Z'>cQIԘyҼTǏ@[^d KwOg߄z&x@'Z/=|x톼,9Ά sw]^}Z` J{YuAvB> *st=U}i%<݄⫄Dge\mزerۻw Cdz4U+Z n> B/8K'gM/hfjlԠ`~ftP X8+`캵W_۴5?0s(1"UyصZE*םm;¦|8' bI'L4*ώY{쥥^!B!xoXIk4_ SCS؅gǿ:_ϰK^;ulUX1@VUK:}"Zbiv`ņ%csgxx=$Re7ծʫWmFq`z xTA$eZN7gZysT{f5[q$B$) TEF,T Z yH%qp˨!SE/69flMC ώ4zxy]0@GLr9FƋPfAGgC'D 0t?67x InLum&2 B*6?&썘4¨҂p1V !sguơUX\/CksF )jij9ta !gsJ.A9Y E V5Ö(+9r*\6PxF6NI㓵Xd 3"$(=U zO](||*% Z`A՞PGdq!ߩ/) NI */~~47BPUb(>-y-y(6"MVQa43X'4R4ĨAn%1m-Afj"W4QFL^ }Ψb$RY,9/ڈ5lmG B-=~m}7~\ۂd9{)6R.p-)@\Rxӣ}З D@]gt;H#o}#ltf]E64< n_۰=!蛼:04xH+ r' Ƙ%>ss9\t7ؔR ۷po)=m4(W[6 ?\w|oΒ+ڿЄM&]R $og8Ġ7^87Z."T+^k ϶ Ƅ>}≋߽5WIh̊A>ˑ6[d7+ׂyK_섣$ibK vuwԧ#Иe8;\5~2$oȵK度m2:pG8K`z `Jv( Nc{P\\λ7y} `/r15GFHJA_מzkeF$V|]@4Wm|dFS$.DT60]^C5ǂ UwZ"dQx%5]N3ۙ/X;/"QXMqv遞1l9C5޶7Y̆J\mJ"oHy3Gt8K@5JEP ?w1z#t-굕+>u^$@n rtIBq&"!/ am%BC'֖)v 5="/ZP?'Wv+L erpvJW =z_]oBI'.Jnl#tϹ- $"%k]DHfl Q= oYAlG =Zפ=po<䍴awopWyB $T1_m,KkzĊ%T MK%S<uthn\4c)\8g%f!ixj=zmW XG3յ;KW €!▼{a5DUt:҉h'YC\K&^:@J!.IYp'6w_G_@'6/@ُ߾rJgV†Ms>H*bͮwwwl2ؿcެg``K"o&v&g'θ}m:qSHUMҺ]C >d&1F53D)n zNFz-Г9"s'ǫ~d}ώ8v6A^VcpB(X e|HY O8wvjW842`S*TCG p,O8gn\~ Br@JXܲۻ5 I\ AWM5AEVB-v 9iL=w"z"!J{4gvm_9,QklN ȅ ъ bbo~?oH35_L d5$9tQt@M8}O\sMw*,8+q/-lM)Hbak uFQ\!).)(%4H`O~ICIVte |P88GqzalOsj3kxBIKY fp?F}C`Kw{yq2 yhA|klU_za[ ټ)HI5" :~69vBz?崓*vr]bu5aBA\TZ3l*rQӁ>#kuvM^۶ $(@EŴO j[J3+U]`Cs+n87+0JݎBqĨ- (<0N]Py / KԋbQ*Q*:O-=/5}6@Mߺ׍fȉCm*FK@e;VC֤L%hvf >.,A ob@BUg/J*ܑAͺtߴ mv"Ϡ+V 'e' }[.L &.CD奏|_.Z[Z!yqk]Co%rWzPOgDdJVOL"",?pV,Lk}@m1[91ƛ>ug_ش0n <Ȥ-C@^"7; ٰtGQwW\(lVHi^Gt]]sM?W(rrӈ {+XErQnT'U43@wۋ )Hp8/ztBBhKYVD2uCʫz'egP!2hNă@ ʝQVg+(V4S9Ƶݰ֤7.2-o;5!06&Y-* = L2m+VI=}Ag^)‚Z'^46Ά= ~fZпjE\ZԠVw膋͉HpCUjR%!+i¢81V8Xo$̬E=8 ~Yλx 5&x,>a&dV"&i+ 8B/2Dk.0lBw!wj^1~779f 鋺ߨr?_>i5/k/IaY*{,Y8c g8=62y<.oㅄ6v}Ŗ 0/R  J۟XR1(X ơ*]wPKIm\4rg"kKNZhɼR.`J]C_N$jXX#JEiA"id=9ﲬ pYNQ˻#y$Ѣ*2 Xesk 4 0[ /C#|f+"%ܟ@sv*b//$@FTag'a7X+*N(@(QQ/vBgzIY^S ȩfE,c(&nw {"uAxvuTS-9lч/Ur08o`2%~j7{=䣴דe)Ūo^[ Bjo3+s*ADsO>Bn‹SM;zE42qߦvT VMPGGůE:M_biJmD@@!gD'slfpL]}# a.%c 3Pi@kݶ?Uyw䜯dB5z͑E(_;0z#kX$Ԓkl!ٽ鶯| DXQY8Ua#oڻDVdu&KƢPÅY3:w\O.Z.L.z̲J9;0(X/7o~-:9 [J EO]5RjӻoA+E[uEc?3kvuЯEqH }r1jP;甥zqrC\SQQw7]LՠP@lڷPG;"]#|v|_utL{P?x8*z*U$.NS L^,MQɕiHFmϵX8oGLiwQ([Ee_yꉧWU92@:GORŪNzWrCEƤUMP/" @cOm?>qj3-E*tXŧMJ4SSR:5hm쓎={UMs&F%`9cG//%E(mA-poxd2!" PbY;>`^&04uP%ak}͝Ž:Za_U%!j]1:r u^ os^/pr!حybml_tש&/)H H1k+E'(bb<^w˓۬AZە+ٝJ^2-^hULTijV!pmy{RB}q($@hL^i~h(Ȁǖ>9Dǂc/}Haׁ<LERоPmjv98?s`@ru5PwĊe'|7lTi `tvL8%uYhFøH3A:`O??yE5JRVgNqvr]k&7,/h`5c~u𼼮N'.0 \,"g;-CFHHcЕL[؎B,2@!l9+u4N<ڶCm28( Zp%)E%a,"u dE=ڤ&_/g8K)G|pAeŎlAna @n 2tQ@4i8#ǎqȶ7|sѓk7·UCGGl-rI.?Ud|ߟxvda)žFB}%Pr^%Tk'<42[qzq#LCpiqP+8 4[<d-f=?\;ˀ~E4v3NȋUXw\tDx̦}'>?俽~v[Z'c& B'!+cJz}tTi)UM3DIJU+'q8䀁gA +Kj(!0I`' TGѡ&;JA0-RU<-gYF7X#svb{)0wϝplKCI( (Ca_5ȪJhJ:mx>1mp[^w\5"Rkk_=b5WM} 7pw"g&.( lS}hO9Fq8I9b1 )؂瘺W5н•`VR"3tg^QCYT#aRqYPyҸv#f}b#)zSk`*"SC3lC ṷۤb.mdx?6R]ȆŻLfZWo tu;ô"U*"s-A@d "/;_vHncBa֬ԓN\r8!uۡ(Lk&Xb\yaiY-MLyoc 9^A4Kob,`+"0~I0Wy;v\gg#8bC_ ;Sr.N'$:쿾|t@#YU[S_w|3`/WpI7u7__G`A,DIeUd娰q #pmxZ`"qV^k)HA<8A lcCQj7b)׍?{|w |S 2_^"ɔ߫JX_b_(75вdE7@GE3Cf~者3( 8(ZH$d(?}rARLQj*'Lo{F& 1p8\.̀.ît~v6\{@2spQ ݖ]Z-^K.<#V9ζ웸gD.J* q@8G]dBkTl{hYw=. hM+m]"11ahtʻ~ka _{G?*~(ThpBZNM@ |8~c9&3(E1Q<̈́kO_U*f8biH[}f~#K}"ԚTa@q4-'4֐~ݤ+-0x1]ǭR*R, qYgQ JFxYD_P)pNA3w Sr ^?k7;ز-sxC_xQ=YJ1Dbc/kv+ՠ# qApDP ;kTRi0GG\TG.c7j BEhj1tpa$5'<` *JĮ噯|緡65T  LHnʑL%0d8I*ֽlL{'o*%e3ۊc0$$Y5d_}?h`0h-dCڡ4B4S+Z?!!& ֻ]vQ@VR+ k6H:tW9*S|EN@ 4"cu/pVM7 dyb)xnk3xeWZ_c?*uf#}Mڜ,w IrZu:TPȳ;!{ROמW6b.@0d4g7- [#/ DR@?(4Ay/D p?>Pze\jJk"HM ȃӑ~sBx/W Tod$Ε\}-Dv y~N9!fH宇29>hAmmhKٱ*nBb?B`^f*^T8b+W(Pgtz_t5E _励v-t*W94~!0*zu4 ^S~1@jbIA6 nY9}ne'*niЌ=-;7mK/|Ndn(B K(eO\[sЂN.eVGo+DuɢY,sC"S78+`H ??\12JA$ ,(ՐB ,yP *EQBX"," "" !.R k LrM2 3zFR-=rΛ^Ӌf4fO.Me zE:Vp/6׬ cZY.f *}&Ӣ*ʈ)HO& K+3ъle gwd`b3cMJg@lSgYЯfWHKJx.g B=/:% e2)B.R { %mfDc+=gg>ދ_wօɏ>㏞B 1 -7X.Bv%C5,B059=8@M.9ȪA `[u#F\+\Aaaitwv.hB\TEjϳXeA%_>;_UI@li|0j=c4:Yȼ(Ã[]zQG&]R 86c=kMW6. ^'A"X2oUvW@+BDč\.G{Y}=D07`q(/Wn=Q  Њe^ {ဓ#H-WisH+We㋤}+bͦRbsHJq^oxK-@XupT̯:R6FC^:qɢBs0േJr wINM %gIH,[Z8(󅤮pA닱S#1 :Zqc&IõKQ4xٛ/ZzTO/}+ؿ,qqA!)g p zFyKqj׮r\fإ_O50SH$<_1Nsg!>/ Ob|VҥGugwPЭ[/%ȣ W5j%/iPX\Gs&jyCS^mj}k?OT ׷Mؤ70YyЀ&&$R+B$E D)~z!R2>cZOytppF9sP w^?΄7FY.8`T-[`A@w|v= %JĸB9 tБgDlXScϩN;xΉ0.o:K{z&B$Cy.+8N[5~wNEI=9mܶ R YhK _MH۱(6ݴa ZgL5  ̬ylͽWNK[-ߤ)>OWP+׃iwl=H-(`h` d@ͫ:H̛;/|e;zq+le[`drC/@J6W Zi/8띗#b@XPx9({lo&?m:My͸m 5_)*X4 CԮTȝYej5;Fx 7&MH"d7X=Yzݏ SFȨ*}\Hx;to,R.7K@wBc$DZ-@͔J-[v="]E/ ^{מyܒE$T*:ɰNrRY`r>1H΀exq梮M,h+s-fd.{ 2.ˍ1a fB W%fMܾbcz%X)/pqd##;2Hi_1dWAc4kD[/-o|yE+.a$]AcI-?Z`r &d*ĔM 8 gB_*o`@~x՟sv ֭BcENq.--w2SM-=jv^FPP}f3]CB9\G ^ƽVoXv5(Z8cw̢YSS54}.^D;md&ަR ogŸ8IІ"8߽ogR72uڋee\2d"S>%SQX`HԹюI qBB9L b6庋5Yw83mb/.nǞ/,R s 8 `^م5 %vp.+F3Y_-˞|v3lyVțGqQ/:Ϥ@Adw FIIdV,?-5Mu̢z7 Ҡ 򊱀B>-_l; +ϋc Y bf#x\e4w׭߸{>[xҵ3o2&A%{FO$8fgRM hۨ^-lMh2SΨ*mmkxHqpagΠ (]E8-!,A=?r0x[q2f?TF6iw?H H1c 5st/Rc;_ ږn\Wr eO>/tF?ydi2y\|' B֡ }*?'cC '$,PMLY07;0igƚM4GBM;SȻP[U2IM:]B>V&= z->:&&fK1-8k$?Apqj~ۦxy,^ jS j:#-?Qb< B#ͦIN)hKn&AĚI,1dԳέ?x w'. ! K q!0.\A^t/RS[ʱu0ۼmB_oMG =oxc@R%V=xh(Kyَ4K.9{V]m:zrnEG3PP ]"ni]y󕿸q.:bG~p`Kf-_mzzW%@jRSx?˖ %Zg2Zy@G6ן}'ugEC\o1PUVC1c4g?ꍥ󎰃Leʕ:Bm/Ukwz~6`Y#aud?lD3]ZSK?Qx[{7˱+qB$# lp9)}oؿtOfc9c!V7ORkr`>L}KNMxPPouϱUɸkC~"B9ϢZO~&T&grவLZb}_L$ñ5 {svl,mHΖ)%:o~tt$fhg%kQWkoh ۺcȅVkI5.41}'>Cp8'Ҙ̅x2#&OuB@IS?`ъL@\D9)BsoLټב @7ϓ/f~r u|MZ{J@TߍknouԁmO}79+B37%FxniZHJXRZp`t'$&Vɠq:fɯR,2WbkrG?&SB hw yY&d/M Z7Lp܁dbBEC-YzǞzIigT#Y`h cŮX,_ȸN؛I>ZI0Eu¨h\>TfeME YpFWGC~V{|NgoNN*p0LWA%N^BdmP;e"~5elsm\blbNpN"yN|Z_$'daBXZh.4]Wɟ;n>~Y~oz+و\Nk(ſ}l٧Ήؾn?c+mkE$?g͕ K1ɵē>Xf %A^m j5Xx !LrY:N{s}d6n٪fX1EeZ޲P7Fc/gҳ2 8Mceg1!I%u&xjd UW}]z64v")vf|l!%N1.HMDQXiXڞqcX5H϶IƋ YDir[ 9D׹A3|EzCWdHr{Ww6ޯqvWkͣ+׎ٰ= H[RN@^-f^hjCZ)͙5ō@lhxہ4c*EuK=0ouх.IC9"RSDM<5xgwon/Hk?ښdV!3@7bYEG6ա1XamO&$+, b4w#`HfCLOp転;=xɼ 1CA56*t<Й1۽u}6V)v*Ui *V|=yE gVP1n!Љo۴Z`˓ƻvg]Q&GUc1h\!oO"V͊Hl+\s1Zh;ݎ{xMҲ2ړ c׮9N@'"7yrZّ;uaNw """e__IGENq=&,8= O{aL钟͛x2eYY^j''W3~z$~<1Zw}w=ƕ{q]Z&fǁd>)Yv degM]?=[?Wx D}1z%zo|T!Ҿ|ز-Z(溊̰"aKfI@dσT?BFINbv;iƋhf0{ef!pNcH/CgN܈;ΠТ5.9$NQh]Rm404\22Y(3{;4;z%ɗɪtϥ8$)ٌc$eqV<M+YFꡚW߼ާ4XhUW-W]wv9 j[Gl vP<zߣW\}>\rL{YU=.uIO\s /t6RV/ͷ<4Z9' /ԾםK. |4ri?؜A1je %.wy.lp?8f30 0ͺ(Pˆ*ݾ?1< jgn-j%"n>J}bf.zWbˆ"ZrFV-

߿ ZWh=ch-V@0q^CSvN2sc5Be֟@'  L 4qՍzg2Ҝw .sqg_Aa=J7!+}m Z)iw*QE҂ެלۢy2w陷]9C< l?6ۉg<g#CbT/~wڭpB/תvutс3cǞD=rvY^9ѶRDZᢻ~4|CbTl<.cާƾ {g ?!$5bqV q0遢P)fW_|L7 ;YGu %Xq3e%,QtO [ `:>nhJ6*쪖kݞua_eS;4C1!,~<#1o׿ݲufqK\a<jP?KDxz%oiNm`)?K^̤¥Mαw0]2 yĺ&!b򷯽[<eU3k;Afy|nƩ|>~ԣ~߿"+<#h m>) 9 |c/_bՔ^ʛsʺ5 Cڥʻ.tJ'BVmt:ۅ0jwDCw Qڛm;Tpl#<_\W\笊Fji,~ՆJ9tY+_Xgy$ {)o`>,mi-)`}b8yio}ǿ~ǐfzCyEL_z뇱ne2^wN?~ɢ,oQ{RN잞 w$@xϯE:f WLۇOkZw~*qlo$4;> Os pp};p#Ϭ dG \:D) R1/3 T_ae OQRaÆ0p8 ߼L&dH᭶Zz$k)7~=<@sȣe8b8(Bj$/mZ:d:PH T|;B8t3GOܟhOG|ɷV9txx9[.=v)'/6qi?w%gKu8~|ۇ=0PMf]\ew]LH!6qLYܼm ([$T(/vN%h&_fhUBk~붨n_cxczW-]RTdMTAB 2?&{UDGn:u^ÖFF\܊痪5Yr0x$x Ī'c 3~y᧮mGPT5 Pt3F[VL8{b5]6:z75?qKx`zo*OX?L]55jcǍ?)H/({b٦|thԉ%N >BaC|wn;WV xmAGȊ'sz?n滄6tCL+7?zϩ' 'XȐ7zuhSo?;o6<$o/q"Ou W!ӭs wL)IB&L*AYYzTJepsͼ)DyhcR}=j`Ś ۷o/r0of]MTj U=hvWғ KxgXC5^T78M"5/qy Ɵ8+ԳlڥHCs|$rzDB(3"o9u7o_}lgB(;F }4PьD} +$!)Ec̾{zz Ⰼ!|JHQ/9/;eHWQBVͷ@B]Omr 4 5YM[xh|Ǟө\񕏝xxZz|4+]U38Չb~ozH8ݑ:*И7"ЄjBQԶbϾlDVrmZtwpB# :ן2s|e<;}D:CgH!6DʹoQޕF̙E^U^3­x D]yP(%6c i&Gb0S<Yo?4DCAEa)`[ mMZ~ H6 @-ɮX uHX4BM9I$f9~}@?%SE0T7a_*F Y$|š R,7tQh rC;Fi'JH%V<@ZɽX%bT wPDȤ SLVtz `j)M#oJH$#Uf1vP93" <.p]%seJ%XxXPoMC#ZîiޠlA'9AF9( i:RU [T" U$BӲsl{fv;9]E:7VUn!qI! wDI~1v@[ضY|&6i )!w`!L/zjXGmږ0 &}݁ ! P~Q0x(a|>mꭈ m`S&$,D6H,(SNp==iGXD޺Є1=L rvE P0 D)c QjI' ;rZl,xXH׆t odmͣYib>WSQOy)>o: naL CP0U:ǫ` ¡ Q2Lg 8WUh+qt=<(T/4b/ѣ@BΘ9PX?uqUas&7v-v1wI<ˍ\"g@q0- qg; y?)jaXiEE'W}ʟ;w~yN*iv%|/ͼ77o{k&xNoi烝=}['ÃC 9[-(Qr %= L:}J83]̲qCl$А2z÷)>Դ)Tc( Ncx,kh' рl^J1Sz꾧̑DlW<(扤h Q. b-H蕅F˒FF4wvZBpyҎ%!fo^G%pAw(g.%:x80K7B d|%,N)^ǧY# z!k6`g6%Jg} 8F$mY S:B wP"#4X~yg@kd$=2$^x_2<2Y7lHAۏ)]OFb7jPeX9aD_F&ph"%Idž cĬkgzZ&}E4*AԄ :g Io̷Ӛ}T }X $~" #%6f >(=utty8Kc T7Dt W㡗w??}n_|XiYH$ar։qϣlpvՆ~ek*Ő.#VbcbQ"ctH)&a W4eEbz `{LrHItd4Ro fLf'*[>EkVYAt{Ud+#8ȫ:u>>қ<3b;ɺe3BIJPNj6S'p%{)C2'l AV9̓oZ_b>2xfLJˌA!ヒeh)OM NTr3ak 73-J1yɎZmbgr_։< FCY]ǔ?%*a{:LL|zٓ,T}1#զ`F6ִoq&,)vYIfqb ?}9XxMJH& ޾!jSNu(՘lr a;`Wz>(`ˉTcSX>NuBDR0k-k$eh"cܗHh,$+>zeIq|^"$ *—N'+ ( O'ʙ!߸KϚ E>,8sLϛ@V>zս)RHl͛~ޯ/J,.0i Im(k$\@@mWWQ}GSKMf ;Tl,I=S,r)MƼ\@6ݧhb#v}'a'|pkTE*w z'cfE3R? {)0l>-^) ,4J`4(]ôSFt5HZHK{@Xֈ59蜷o,6n#:[yA,՛2?qPhd j@a{p l*l:#vK[?a^H1ќ44㶛> Hs],|oNYh @~7&-W W$̒|AYXI-$zROIz?E㞩vҞc"pL)\~nm6WElZ[ʑlgрo,FB`g-@9Nh{CE?C9| u$H x|.DAYͿ3,ycZ3@(3c-|$F&2ʧ3nfr+)5b+#GYSdid<Ȍ2;GH/yPvq+u(K)r3"o|B/-9Jb11,I?~5 KJ`: ONvB 9JmN(SyOM>L667]@@ ۺ㟏.|}cy ;Ib^F%ۂ_, N=P3ըxR_ue2O *10`dFŗ}|8ڃ#$Bzm79*=Y"b qCIᶿ3"tx8`HB 襁bז%Z'-ϬvKo2H2QI)aVZl3 yW*qaD06 ׊HnԆ-Oae7F e`̘Psd bA)E9X*nTiH—$L^&@Նb|O঒鎶-.VH@xnE2]S@KWU! r? @Op'P@Vf%;LD/`s*Aq7x_Ge\h[~ϣ'TR냹ƌ<4ToxqGD 6#ԒbI#>Ťkן9zr⾌xa*Rw eQkY;W"QՅ223V}iB6ON1w3Fηe<Z(fA.hd8bRH(kgsct"FpkqpY`@֕x%5G @3Bʪ_M=P?tmjiQ7y:ʒ[~<<(. SN,%'ì[w$RYhx@Яa.t|\jS[p%@( : |BN?) [eY"$D"bULVW"o:1A+f@TEeIe>hT->< "cSFD0n7F=Ifñ$mu HP@9%kLk!ۮv\0`~8-ۋ '<cu\)D^yBLܔ#S y\xQʢb`bdm}I1*() #h*t,D&}vj(~ "Dƥ2#g9dq9jVԠd 8CԕytN=j~Y (f2>t f;jQ0 L0K.}nɪM'(cw`K$1 2Д3O=eRl "͗<'9*QDrv286 Qqe/= S5,$y)dTkxNb_|PC>?./g%Z_T~/'ua5d2fb뺈O4wONjE4nQ:旅Ahod+8me{8V]˒=1d,Lw#+֤Sp^7Y.e8͘I9} k7_W}h,R mC +d-uG"-wNxx+ᔠO( TH (BV& 6W8#< !)Ud9#r^I({d`Ḱiv B@"'1_ 5?h#0_dSRr z  |ĥbO1R#'JIM>@2h495' yыEE^$0=Ξ~§]HPcȃ/Az, Nh,VyvtE g?UXxlXuE]O\ |Q ( pPD$U,]rpi?bFyEhᮒ /`sk|ۧq"0_F`DD.U<]SR%es刵.^xJed!\qa.qE7 #FN;vlAcR)s;m@ּ=Q –g*>P9@H^% R/N=X=r>#>_Rڅ d2YR*B {"π0D2eb2PaНiJI",FqWxs|̔va14dBف * 1}Z+1Pˋ)̥],⭩G \IK,/#83/2g\?& =5? #)r,k=Y!|0A7![ KWzDVV}X˯Ltzy/qGcPW%@֕c+Vd*os;{ZoWgh3gfkw09ԇp?[޲g6# ;6Q !M`A\"OJFn\?Y8͎\;DT4mﾻ{q"'Uk LiC9̎@-ѼxV˘1b̠o1rmga h1!%yq S* (VSmi?rIύk͸ gl 6'j;Q94pL.wZ7Cauҗ:Gn\?]RXFhpicO= {揠R1M"2Ĵt?|aEpY@ Gإ0JB@Vuv|SFֱ7Xf-5@v PX*Qչkޮɵ1#)?mCqB6(2x{j+kt8;( κ//'D]-aŊRRt )Q";(fNP' nxihPx;pӒC s^ze 2l94Mbs8utpQ=]D -ctk"œmxB)&-΁N9/?>x1Gky \)tˋȷ}DQTa"3ga`ǚ"{36owuZ;v{"+2X!i“YxDN Um/WS( JZcrՎZ*GdQ1lHARd܉;ȱ=2s܏U2eҍbkB{[ ͈xhd7<0!477C{ x@D3J `%ӯlHQ 2v|EH܇ءM8 j FckC0F+jgfq7ذ:2H5F_X:H߲ &#K.O^":T)j ?y,<|@?b6CQ2dn 7o-P0ӓ"{%ƚHHB.;daD q9FKwqDZV0rG߸a#Dzbau@z>??~J A!; ~0 7t1hglO0SPc=AFh)kX'1ri05>j *gABʣZ]5JJ* 6 V㾧-o]^ f2P >x#yI1CGb 4Ooi#| xBa LfЪm|`#6X(;n;: }ńԣAn%`d?Lz aE0&OPFFϚ(ӟ:6|q^mCBǠ>$t '+>k@hqcN 뻄뇒C"AV| SEa6gHu=HE[0a]¦ ' ]0y 7>2 .^dT(R YAT N_'56LN2PU6Bp"^5īHQavt}_Y-|r0`lkyfex=_ NrPE0Ucσ:[;E!*X`!"65Y W㓍+m}8:Ӑ&!jX#A0ҲRES+82il2TU)`ĥ i`Vٷӆ߂Q S)w*_֭.د{5Zr./$%2(k^_>Sԯg}57 螬挵hT(D?( }̰"iىT _BpܛjUs`q]ߚV[@ v%9uɳ'|T(W F̫I ,l)*ۺ~:HfQ߳Y(\^1vA_fBʞ2i _?.T#., i,;&QEK%#4V,ߗ-y"0[o3caQP*\Ew%>DaYc%^o8JdS:?ـ .X,xƢV3߹Y Pj:Őp%)}!Q n\rb@T,-򰗚+fDKx%,_ $d>/fx'+MɏDXJ͹'-&W^0IX̢L0JHղH2(X2nd Wdyh&.;H唸©d   2l:>.tŧVUP^%Ua_h*qN0Ӧs0 =M̎4v讽y=w03jn YHq"8 *#k*n{z.7 繘ڱ/_PCiE[)VGDTRU`]\KNRH { 2#c"aணxMV;Ccۺu {9􁉰暛  W҈ljjb"&yEڎ- t z3P42*fu$NĸrVQE``D[ I֑d^8/+x)UqYj="[wyGE ) Y3a'=s>0Xn;KL洳1}r0awaGxF(m{7:ܒ4En3J;On;㔣f [<`AYm H6oނۏZw 95xk U mU߽{f0B珳DGoYٌrJ_mf.q1! # /+P}p(eZ_HJ~rق%ksGq@K?KO3OUF59MlHa 3&= T3$C %b Х7QQ R\;5{ &Rj "B6ut-l4 ~@\H/jSÀLe,Zj &f0@Č1V'+RE\+V+dA*e}j]u)dnbi_~sƺd$)f s 7%T96N@&8xvQ, 1пnKOR1L|X9r'9 qWξ. 5byS.^;v) L8%x0a{=hfy? ^]Hu*ILa XUDS|,Nnm l^| XQZ*\ݣlYo˘ dw-t@h\m]|8W'J^TAOcնʄ?{IO'&1EI{PW еA"#9 xnZkVz,S njAL$a !mթ?#8 L"%GX"L& edmrSc:]i̛ X[*Nia\:Uɽ]&xWgq %!F`7ئ"C;9Xb@f[5wZ`rN=t4O>xPӣU. :E>,|$Z+Pz:OGT |",S=c4 ؃tWg?:8q#ﭏ>xxdc,]5#_0Ü&OD*ʶ1QzLoɯLU;ɍY~kEh d.A#0xK☚Tdsg ˔, A,=p|tl=*QgV2 xEtN#̲,ۍBdYG>Ԭh؈XDpRbP*3`D&y1jlEMC)X'gZm D$*3 $ϒ?bQRB/Xa6Q~;dRWd  qf2-y!50:HnsCwRHx}Rey -NI(j=}FnY=4|aARB6FB5|Y'4KVvD GB8TY~!:ssAZbIKX F$k3[xuߕgcBcrSPc#9 [+tPhe{l#UE [qo~ןw?UMoB(i֡)͒ckǟ(0)y@%^ vs (U P OdB>ZwrrD8"f,e& ?j fӂg4,ۘ͹|G;bBI#<-`4](4w 3)*$$a cf&A; @YX (i_@R!;Iad FaV5s%XrysQ0ےSu|Н:gtw6 aɐs]*,Tښj ^O:\=p ;%мOf!<_^r, zE#Mj}ьܵeJE7"'0g; #!K=tqet] Ͳ>Kzgg&;.6a="b *Ϛ$2+x;J|#=,y C6<؛I@}.bG<Û'ɑ )Y<GeU\C&xg0DN3ރ#׮O!Min$9&|C&tDc&f4)2^1Ab )0 d=b#?qNF2Ӷ& EQ 0N)(5?kT*QwqȽ_AUg)E -Q:;(3s䀏vdRFPr$0@2ǎӰYX"}T1K qYGMjm#Bgyت VU0CM`k"guY+_0kfMЪ5!",*$Tp&d׆皪Mr_f+ol*B15 м*kk@Y<.P6cϦknt#BTLv/w3nނL{5 s}]J=gW0gLs1"h8C95?Ⱉgy8MVS!PFe$Cgz^bA-57] Nq!B\>llO ~҃*ad2og+=HsI0f4b:L1QC@H @<ڊWPB*Ga@xCq5_u[ @$ӵhv/.ƽeA1K?Y;kylDJq l"-dS}-+~?J@`mbG.>>XtI'CCH?ˑ 7p(cڅs`P0E~dTQSTN6!(c1#ya~lV1јnG CW S9O^P;>Am k J-8i"sH"h6毜rְ@>jkR;ޓ2+x2V;:Q1 GZ؏NMr(%qFZz7~$IxO]y 'Mi( H*YгA,io@BٽA`) TT54!X–MvcW'G%#0{`5d0 dId6BhX~9' O,WN]KO2 hJՁh}Pp &o xJ3nRGa0.Fޑ쁱=vu;; w 3os\Wj} тӥTB X-zEl! 7v~7e ٔb$zJ'RLBΜ>AE #ɷtykgI@u#g`]Wq 9o9γy d"qmw $5o9Xp9<-Z#8lثPh1VWW環QёG C/¼hmoۺ}Kv;%"@/ r> #J X< 6) GjpHIg_b0mdIZcɉEG1A`]N}RkR%;c0fm22񊂊܏ eB`V>-toN- B)( 9 Q 6Q1Xw9>t hя AĴ+rAP_]EI*kF^zKWADLٖ/x/ZEw21٫Ҩ˂ϧ3p"ҋ0P6thC|K2A`qs S$U6,I=_7WUv%m(+M +ENNQQvӸXQ;LXz6ը0 EWYg8ob!|󞵐SRlo\MzZY XT)P (D|bCMm\֠2\M[E Y>H)lvxs洊ȡƈp72r<5b3H]E.MCg^ *Uho|;/3] %Ƈ^leiQw=D8;&Ahʽbƾ\xּ(t-GW+~GKU<@Ԝ!x ~ޯ|W//N,n0GrfOo<}Nl Yd5.+Dth9f ^mk+׬ی>o Y[n#d`ڥzwƧ}q|{5E#  $+%~䣇N`@QH$aAM$Z&M PNBY\JjiћDIDAT^g%bx Ζٖ|uc%.S< 5q^1M%s?mv>TеBYKK_Z!m(1E~T𒳿WwGIQJq;;47|/w> CT51=˱id|42pЇ9"Y ΫQ(- ZYФAenF4{CX3ɍ QβuW B㛹ov OF: snY{7|Mmm=lȜ%/ 2:*!붻7 *AH DAř)ºYs"0*?$SF"t0a E²Z짚%~ڻvjGRхq4Sv@P>cjإzdu{h*#1֯߈$Vޑ|As&`=x-fCw]aT5N9BEyYFʬ@ad o\Umxdp8=0P 4hleU O~=̴DmIqx7=yC4 l# 0G{L#*A!?2b3Ύ<[3Z>3^]ںu f@^")֤ w%LNdd%.!@^zuE*34x~Tlv^] =PUoX=P_B9:5BD'@H2`vB%jHcj V~S'OeFW8`%޸\t|bh7dn}r CsDUJ*6<Ɩ,C3a 6I 2\*z[JdᤁJd=#VějYѳ.n W`b4Cj(2 xαO Q,nr2kj+"el1%)h-ڍ-WQHƭm̢ +(\+2LnO?;;pOֆ-۰GWȯ[C3Y4[fybC"6n7bR"aa_{TOTQPYc(΍E$!oe90:(J;#/kNu9!eyn'☼XZd.lΎwt>ZAĔ>}1Gs֙gv?A3=QCWZro`e|FR#6F6eX0BɋaZtq=\q䎚 O\T[]yGgl)&R&I5EKDI%5gx Jp5! Ѓɍ_(YR`#~3}ꃨ}(hT:XLa(WD<5 -*y/Р@Γs#{AіYh=n{Tpff|OXcDA+''eUpsn֌p yĎGRva4wvt'dQVG9N\T_]V_<2Haݡ.SnCHg6 (R>LTg2; &qoLLvH}mQV2g){hт`{l6=u<4'TKAA#~(ZL(H@yG(CA$M<"# _RhKtF;L[Pw좖d%| gd6=1v@C<Ĝ#sȓh;ܨ \PҐ5`ALIOI䕆Mh+0.).iSORN'CtpBKvF ʡ ~C zP& pS6ZOxtsfe2(%әd v,eB<-u·9$P9(hl4хDYP= wHFB?#N _`eA/HAe/ `( \񢽉`Sp (*rq>j~τ\،V7|Ri`1Kh (,9ހՇ"bFj JYzUtD*p2gY2l)A(2 Kd MJ LlL ?v~_]wɮXPA^@-~2S1'DLt{ddIxwˋW'O INPC!NA|0pW62h̤O{j%%3.ÒWOfZI5K3g@z쌭TA TQ b6)U#hfDF'xpioߍ<f}T "%n**SBX@1)䒸kn#>ٱhRTtDiTwuB1F^ptqaõy _ހq gW t H'he2ҩ1)-kVQu}- XB߈B'o?Ci>y EVNA^Rj+|l̺h%$+![I6=^1ڑ -MDdP_Xj؄U!ƳevB/neΉF.PٽՙX-IжXl,|PmM 0"1f.fGCQ!s]AňcgG^e~37"\oFW7_3ʽ"j a҇ s:3VX~ ʲ& >smav5nr08$AE=)c-p `'9u<>m :mRwӃ /Y&8|(8fs㞯w$y{{/HUJU4$R+ED ͇i&|5NC@hGyA F<-Ȋ;cQ񡪰WQ]x|401O> 1Ԑ^/efunjPuJ4\{G)Oa}S!<2fwP >q6+VZ-R҄[v蛪")Hs0v{L$ZQ>G6¦^}{0~m\-^]lfj*'S- ώs:rW d(, :94As,X%l/ˁl611b٧ d)OnAط ]+u000԰RVP$4Ն/Բ2O T !M1)JŋO` )C=TOc`XP(`ЈN:*A uWXzf#A4͹/Ύ: gGGq.7/NdDhe _~G_:FLarӧRWđAijxݷfNgCi}RWrM / P?yǟ3m- uM IQ;Ljw> #LvYR>m9Uey; |X'˼8؉fD[(syYn% P8Z|V'BPhjA--`;s*|rj{n\s'71W,:(h5P]qL*z$ȄG "荘VdZ?|F%GW bLrf_L9ZlwAbY!Q yq_2g JًO9ϫ*+L–3,|˿\jr!S`0DqXv .gcaжKD޾0!OJu#2ad>T;*\0N )[|e$ZP SdUM59'Y?{2+`6`_ 2Oѯ@̺rJ$^w#ফWJc &t!t ,$UbD"z r *] +݁k(/NR8.~L)"T8.ud]ړP $R,m<i&R*1}< SJƖ/ORy &(eX8w t-SO8|1}_h}0sI|h瓐 aP E&ytj |-`h޺^lL{lOc1;'' (#6M㧐XY.~٤|I>g9O(QD#O~I3EpbC( SHUh|i@,!l+EQFUE&(Y]H_pQVsn`'#wƫ}"ON?` H$6stUg2w b#Ÿ-)-ƅĸv8cDVCD2EnHt"et!HXP|:}!N<L-laԪ|S?B~-> 9"c#Ġeb:Ѳ׏6piJ8]N VNзv}aH+` c9x1H!gٳ4GYd\q3d#fs@ b$_JIcL;9g&&T!!HfZͅl#3 JH9s8I27)hSuΛAMJɭ-YpUDDlf9|,3Z/QQ<${gqbB_0cey^ FX<n ]κn@wnV:ݫ|m1~aW ^eVsByP*+*+80BtlOj @yZOA^2s[ыf!j m5Vzp } S+M VUee8! LJVC9|=Wwu܂9>tt4H@ĀhVCȠ*B5-!2<1t㎣ﲱ͗ek%ЪR ^f>t`Jm+ya.vS>d^ӷ'd$l*xqWc}Y8l%-3*Z])6pV{1ySQ;zBָ43` A#j8); Nn%I|675z̛0gXHP!]@谐a@>", l$l ̛*A]#P,@|1rI*vk }g(89*X[z!F%.WP9K4IUɐOG|9&M ~::k}"B|)*6镙@a/ L>(MэJL:! _uԳUPq TT2A2!󲏟-cqDROS5ksbEPbtA[?NHE^ aI8aa5(ԏo%݋N԰T֎FK4q(AEB (FʨߛM7}!=΅QOFrT;abCGOB P%= :=MfWhnS=t +嶙ד)(>0ݫea-Oc'i`%SY+a'Nhْ -`)U֓}\ 9{JC }ǐfJEUQTl|^)T0];)TFRLk<-DX #&CG~& ~[<*ڹHPLN>c(% ;UhPmo@ c8- FP&k겆RJIjjeB1 %KnjV N%zW h{93[۵ ޮWeSm@\2^W֕; Jd#.ָЈC:5 BCuY43e2X Ou3CeK;}y#kTrWc >7Z֓C=([ֳ;䀙lXYQlDIo?qxߋ IokГ?N}TJ6ڹ؜[-̙5fx3~A!u#3$椣P.vsG0?s83eA@؉XOtm88$znՎ̜S>%1mCxHC[-=ܱI։d'b{!B;y5\3J{m(P}!=6ǐ,"O'3&T|3?}.D瓜2Bs ]$ @`ZpӜHC<>xxz`_Ϣ`_5ѬcfPfٓ.>ċ= %HNIk—9Ѡ<G[7ӵ ߓLJpā3?s9yx`(-gvlb*yq0z|e;P;sbr Nۿ=GB4MuLvuvܑ?v9sg 0 9(l |3HYMU$ B-W|C_3&Fh8?MUX7Rp$pcT\*!P 2y3>tg<`]|_CDgYTj{TDQ.nkiNo) Dъ`uIY8gݥ멦X6W 4iz_G'-K +0C~y:,ňZYXyj4=H&ːtb "QAI]cԆ9>xe`Fhp&yi[0ϕeT䩫dwvtH ^p6ub'.#<(y4}U(5ތq>5+;N29sA`VϨv&&5V{.& ]v̦ iokGmg, tҧkZ&\6/JSv xhQI%YND,FF'HoЪHD޶-'>Rm@1# GO^r!5CBbZ uQKο 4U!Q7!:e[glOPX]!^ v7BT[*RlhD x9/@aHA7,,y}u<2W]^6m&?F9p/8F#<!BbC;Y:Ɲ~̍GZ5J"D6!baADf!1`LPk^A$'Y&̲~1cVֻ\.0X⁆ a;!ɠ1Y8\DF'r1#<^,c$<0@W/βŦ3 0w`Žy`Cu JH6). 3Y“)\ipoGPΔs`,6dOqLlPىhS8[x,T0g1@" 5Yz$ro*/ ?+cֳ\B|ň,Q Ą8+88_Gϋ˃CDbAaъaGUݩ;iZq`ySK^welf`H2䝘l&,2|Ǝ : D SY](U"@ 98ƹq( 9Uuױg"!Ů&;"S%Ԯ Z{pk ` Q0>!yM1@Tr}Ly3<0rCSwIRBdo ,GF?QF:/o97t'A "Ƕ$6+ʳ$q"+P4Fl'ţ+%}:/ud5 Ũ2ST + >tnq1I\D cº4]8\[\ o,̞&&,K\Fd²H#eupxX촇$@Fy`vj? / `<ۀY%P~ ;u ֢udCkXKy)Zva,x8|qwYAu࢛aQ' wNBaDL= 3G q:{o<<%}9@U3R`>rw|CQAݢIMYW`aFZbC$ܴڹ󂦶# ,ZrũDKB;rlH︩ 0Ƕdf啶,2 sDdzq-"}ț8˺]wWAٙ3?j sE7NE8;:uMuF  u\.yd#Xxd`9'.$dqK)g;}T潃~'!%CL'#Iw$50^L2uUfl 51MWITn-mrE7t{k( YE'݂lp4b~?klSsO17[4uے"!F.iCx+Nv_  "4 St4l_ޢ0=0 3*\ QqliIgO/Ȯ3&a fbƏ?NʾSat{g1ovIwߦZ\>S[GsӢ-<(FTx{f&۞—\apGO:c|6;] R;as0 {MvKCv=ٜ ߛ(tVJ=P=큷mK+@J=@ g.=hJ=?:tRz`3C]zRz%u|鶥(>%g(J8?mK=P}J8 uAK=PQpۖzLpv҃z(K-@(>3ԥ-@G=PQǗn[R3=Pgtogҽ-]KҀo#M,_wo|;R-V>%wI*@ݎbBBQ챻o.pa + M%f~[vp}yQYym-XDNE*:mYo1t AܕD-;\C(=}tUGv[éή\P0niqC\^;YcRJ8M G]}([qvg9ytWsg7G1Rd4 KB%/=p꟣8+U CB1zFܝ,wG%݇QK8 #^ af"vTI}KoL\u\ IZW$!F \A]Y%pc8΀V爄>ڝlӞ3O‘Ʀ>i,v@ ?ׁ2opGmdg(쮃#?C*4O{f-zKJ'z`W=P}h^TFy`N9r`B&/&slCd3C.4gR049Ύ07D%Ec48K`MedPIVD FkJ8b]{*I@j DEM0 a݆dOq]3A^0JcN&L KHdFRfffX'`t~!16mZ O+.hm`)u:˳c0.@ g1| G^#Xey;TOTB Fo+. *#emIISBOBuWUA`* [;2`躍m͙{0>tl #Bb&QU\y) GyG?~]pQGs`TUӜP`’k)CT5 M Q"Jtӧ sA.ˢAioJ8Vz]]p( rڿXն{QUyɛZD`@VNG%]'y+*߼U9!b̼"ii;0p=e@j_y 4E&O&>_Vdtdģ 9vaNVMWP5=s_ !l:$h'DVYoZ2@yx˸{.1!u ox4@5wvƸwdak (X6{ɉRO0O~w o5_bkK}q/?i~fY*!rgeV W~S< }N<"T( a __֙J5>Q &'^oYϫ/Li`ڗfڭLV㪪L'ؤ-ez6im8%Ғ V UTxsC׬ Ǘ>seg z aVپ?JEٳz:!H 93B,cy%}΀"ڗB+ wLfxT1o{uQ祈|g:y߸C|_Owfk !/ 킰dConxև)[ M/_7v)>JC]=?}ٳebx^6A6b~ۗ)MQOQ_|TcV _K' 'LQ.<ϝԚB,-\ӿ=`/<\v \d]qak\\pAzƨ/SBuUg~=-%[?ՏxZ&lnO)I))k9o`3.u7Ծ{%[I p3ã)oiG}lu5aAaOsNMCC`Ohwj䚨S_{Ͼ2L=k7w%x\>uAϠ+ڽ1-]%}׎%9,._:q,[liϾNķϜVu=\0͌O2 !Xr}0+]uo%uv3M0M 힌~_'\s<6B:)l^n}9Ò_6'ϾkG`goO:Db&:nm֯tFOlܰ.+~Gw1{0Ȫf_N U m\?Xeb}_N=ʊ23[r,<.L4oz4c7cpZɧ{6kNz(E* V d2S:|W|hue䌓?PN=@*=cf E%}~i.#͛}IRU X=KdL>S[C!YpыmfK|ʼjyVYԴY3Z"AiŠ [S>hee>e:産/OY@JsbV3f B(_3F8 "rjIWjjBFx?-2@YY{{O==G7lҙdEɚ4i"pVWn+Sj6;,EOKo/{CXd`z-Ysٔ% w=046w y=sOQ<0 >|!ɑ 2<3VOMiQ0%W5:JӰΎޙpIa\,a4m ~n˲5ۼẉ3gϘld%ćP9<|uug% D9l7)g @\Z]MR_W/B~qҜ&v%oկ_aNш\]G~s.xk4_ m<22}tͿys_ů|_kj$X_4m dLL|WA vlI%Ur e{1CNfD󵫾+ݴyFY". D"4pKߙsԪwJp2{'aAcEtޗZr`(Ѽo|랹馗6NŐ@mɘ'UaZTeֶ\#ety ">gMj:e9[;lG̘:) Ouw ɵ,>nO[#8.VTP2m:u%@<niD6pO;$o͙>'R/tqlځ.+kZ8z{*-**r#L6Lmi7w T vnב_q^{2{1X)\@ `ZQ߳z#=ҧE}]wun3Ж_/ixUoKCCsmBl٣ * __'ca}!sp .]U}n^vYek?=~߿M& mC)TKi Q(|̂]mg6\O>|onG ULjl q <57֗!MzzD&5M/ }0 ۚzҹ'~>w_;xE.reRޭLvP(k7q,"y[cSQXo>7rAJ*jTɚW,)R56:/y`! ̮&lpvZS=A$*~-j$mŬTWU=B|]v.cYAOrdC\F ³/o{qLUcXC{l16 V\HٶZ^E_UQ:IQUaKnTFD]e'SP&cϜR!7LN [[^0ւ]4 Y(z4]O̳ !Zo 2^_3HO-O{Ϸ?庛~C! Y{8k]`QbTBl/W`} xBMe󐂻:'N${D0.egqɧ/rۍ&zՍiC@8{uxH}-8 d@ ƄG{^H#.p$6 9mb2D;7wt 6ގP@K& nlDLXi’5k(1:e*<ӓ̙3}$DքN _=_rOI3pgdR[]VS:J=0(x{w~KC,  iPTp!Cn}%O= NIM)je~AE]#7ӱdG~'2ɌG2LF/рykLlJ%s )D Xƒ~ΡuͶ&t K׬z̚5@VBMR[D' ;:dO$.\a qswg`f:&! CA≭CHv[zu3XJD9)단m -O[ӦN55oQ}86l7b0><8COb'>ыPeMغw-x>ض-[l@*K=`823 ]XfLAܴa+/~>ԓP$OeLòw`M}=UX{xɲH[.^H錾l‡|=?򞜑3m=yI"<ǿlk{xv~S/:0cW) =+vIم/Ƨ8*:J@ItzN'o͸u({%JNd j0oRFOɦQT^O {N90P1cG/@KC͜WXN>"B>l/u_ku??ytfqEMeOm%U G- ;::+#f>3Fm9oB׀HgN9`,Uvklm3+*$ՓX&)_fKsw~sj-'h$:v>͟׽tU^͋}M·g>sveT Xt1b:R,pݎga)AmՋx#;JfyHaT!*tl5aheamF-\( FufS= &J! <_Y耜KWoD &&M ,rП>܃// š7u'SF.|AU>@l>z TS$w}›:'*]!7vckk gߵCcËWoz6lV'#FKU4ApU  % CAZ/k4ZCdh|"=ڂ2,^DucP9q+-kJ Y(h2^PZNTrey7쀢8FQ9= 6gԗ_7ܞq;>ݻ@Dz|Ftl_sԗ]]EP}8ϏdW+|aǽj}1;ӼH*f ;r\g%T(, oȚNODTiz 82 KYW<ȕ݆v@2r^q.wF0\/l|=CD-?.D`g&#ۑ sQoގoRgECarz~x9r8>β !3i}G]y7? R'qgsR٢n,}w-Wˮd7~`R ]M&q-\c@ ':R/ W$+8r"E sOG#d)H|s.s4-H S1Nq} #Ӏa=7{pשT FmsqqG̵6= f',;kXgSx腿2o~Qt~R{3х.tf.p5xM\ o ;|=>ao#QG6OQ㈼T GQ n.qa_d?TyG|'%}oX SHY9b`k,g\W\~8;"VM.pTp>g B}$k0휭Ol[1]g#D9#t:A'qp2~s#m: z]p\OvRtsͩ0ʛ`;4a;Mf#cӍ4Oq{-q,8ΎtB_@DtH[{a6)L,`7%}o= `wqa `0p6_:erjԪ9֕+)ӧ:`sj"V02ݖAcVy+|hQ9u.ղYt|-8ӑ8+2ڑ\eq3dBˋ5]Yˎƿtk']l l(yC= 4{z^S#OT>p֤tE68Y7vyAxO/{j8a@Zr<+@ <DY iȕD{l-qɑF P:> bH fM9YFIvQc188n5J/gUS-K᠌8r(8\}BoepGx5V8_ N@̷d\(SL$xo:A3oGp|D\Hw.8*AmɻZ~󽎳E{޾g{ 7)- ~`Xd,_K,1_ * U AAJ fMkF8:Z.wpI6B(2srh ~a~՘-x(֢oҦeXP ±6|FB9ɹ/Qt%]9HRjM`BW$ sXz6ϲ,fmd˱@jc IuaZh/7Ư; XAaI-cf[n,&%i75<9p|8B&!jFbͦB>"1{dG[d|3z-gC;orjԁ-ݶޛ+$Ͼ7uWOEekI5#$lNVdӐA򖮎NLi*?ԣ%qI t HvXz1l-(2:Gcl MW?rV+pcfNFuD 4^Z%}/? p`T 듷qheQCGꗀ#]E>O'`)A£ds9 (H18ŀB⌐mY"/8념upP1 Z۫+-w1EwëӒ*zOoIݟcȒKΎu.J9e. `3ާ_Z͏mT*ojx8QCRiRwP=x4 uR\ ]*O*bwۜatCMeƐa"5exXR%¬v Y&4hI݂uhA T~)WɴmՇ"1޶OJ8,tfH4 )j%5xaBE(29k5E+BSOI6XO4 /fB# 邢Ǐ82bysB2O<@DUU+5[Rj`A$+Xnnm|!Ǡ}tuSKa2XӨs%0<'Ѓ< UGL_m?~qBGTou|+biy$d%GXb&&Se%!t9b L|&?JH5(]$a i %0Q ۱Dl''(CMYA2 1Ǧh<E FECH7|8ikk@PC5-ϝwlgb*>45xfBjh!S"D'd k,XaeǧQ.8i8A=LjGe އ -9QK8 :Ex1mOnޕ5/@l˾eXC&h_+>iؘb!&,U]ZVQ䛝Nf+ŔA+ 2RprK J~bk Hg0AtSmԊ^Uu 2HU'LV&:gK="NqcȦ6nm:aCf4@G17S2aOйS=ϛpA-0J /ǜu QTH1lQ 'B1|w5sNX^N~Y|Bd*'%w!k> Fō"$$ -޷桓Qz:€|TWT7&uA|~ 6<A'VӶ=30P,NRf 2RBhwD3K3,v\|O-;9zYuUd_{}yB*&l藷J" ߘ@BUg8'{mMa/>w#z.%Uw^^dm[G_M2ySN`dO¬%l2\q{PO|Q~J?YQ_]%/vSYӶaC7EWFbk=`ꤟ]~1i߱_髖-|E3wGqAcuIg <k(*w S|4ɏs10{@(@RKg͛^|^FT;笙3jaf˄m/\~KxU?spkPoETy٧?{=˫-読8<}UPL^aW^My2rʡ}dŪ͍nX00,,}}K-_bcpaRs{* #@T<|S`~xqbLTlM{2:c< zrb]3'ͨP!jnS /~VYW[W=ks9k5vĆ(<6o<҄ 2.BTE׀O¨)'P^楋cOa|dk~JԵPK^]:L<̳x) Aƺfyϣ=pYvIaES?!rW3?LVWӛ^nY7ٰeK<-_zLnbg榞Oɉw酓LJ|%v5D*̮_מ=pܩSmri^{ioPJ /#i3~H2̫$d0B }u<ЧYܧ/P꜂b~ۓM .DDbcO=WW4YGڪ-7zW vekגecLYEs$ov #݃Io0X{w˛6o6uX̙31S~+Vutt^zqzp᫯f ?0|AGT۰M?yiD}`æm ,mohB4 7aȞ~QΩhĥ7uk;L|MOps{WMMӤJrMwŲ5޴n-ƴ;࿟~mthC]߁~ډ%:P?s")~kq+,زeI'_3fL Q)8͉eqvXIIF,hAϛ7v.*{%iNCSЀYr_ϭ:ĵ_1宇^6aMgQ$} dC,?_Ǿ/̚wTvK K϶(k*k|Sꌠ?)RvPM-\U|s<`~T#pO?D*牸M5 3«W$EGUH)&$Šǽ/ } _x;G'3qw'Ww7=S0Ԇ|qYH6bLٴ\·6Oom؁%+5`v&JeB]®K^[c_ oym良۴SļE7ܱhswȋI155UӦM=7 O?;/\r΁O|`4b[ۻz7xkWG,̟{Y? O9 )], #?"h͵)_/_^Um+.;p=͌d"58䓎:7?/Ÿ~#O81f)Cvy>>#_3Z6$ YkW߼ʳ>ufJe{ tTZSp32dus v7+??t׿E_B7u&]ϼZOWoEM/oxUW]!jut7g_x QɫI]apӍ+7nD3>8vѾV Rp+8)lͺlZKY3k~?]?}u͍w=l2'#IĈ OG;\<{: TBt%'&ޜWs^ݷeR=> TMhBjJVQdW_!ض7mjFH0yBfEz;Q^ϜT?4yXRxl*#0sy3+|6Ex;۷t"V6s?cCt(#gF|˄#TR)7ұ"ڼ%Y9fO<橧NeYֻ8ˎ+8t3V.MQ 2I_KYSxpķ3(]HoN>bm;J> %zcBHa3#+n x߹fLV k𯇟2rWL'q5Nsf5A<(+< x])]ϯ_iX^EoV}Mxr^ڶJSi-Sr3VO;T@-"t{3HMIX.[tF_vHc*CdL0ƆS ↂ4Y&tX'$d5tӎ= oݼC>CgH{lPHe><ؗQlf6UIkVY>,†jR>n@z{w(ԥ}'ѰRt6pS%k{fLiD#Wu \}lz`p(&ڢ"pgG|v$\bLo2GI$R1jBPy5/Q(BD\S'4uꡈCC'{Z<{dF_: (`Dz eZ[I?}~K{񾠒H]lᇟY~T{[|mO7r7`YeZ*+f4 BHx%7K/ѓ/lFB`ٜZvc_~koe_`iH1xPVزW!w* <@.#YՁϽrn:#YFhmuwfGLRxQKy˪X[{rYdohbMR 3Y*mP.wGncNdy+E^Y֏})yɇJYK/~>v26uww GQ5O\ (ֶ-fr>/ Lj1r(e.[)Tz*BW}\XCo_GrM+ѫCv*«vKQٹysZǞy1G(>of"%#DЮ0}Gs@K[ T<)e|YGneѐwF f! 4 {AU6O9!0`[P2֜W\=K8<-9 MNqؔO\r>qg?sΘwA, Mm 3gFx7oo7?Ehgfurlz߼[sۆ8k!#L\A]6Qs227}_ $oAo tY7ߓSD:FWU- 3& e@1+mE/t"",^1D*&]>zw-XRJ [ub\?%SP2/ hXYj:)ΕGFp\Me` *q({e-g,z>)Pq][ެ"h~E>hjL` % %GV[>'? O?sO;wiS=3=GEDrd=(/?e,AX~{ ,ZU7yg^r􁇟yɧz|G~ SM1Nm\sq֍ ~`gڀFHشU=eNTT܄1t{g"H460ڍDB6 pZ'7hѣei;0ߴqͮ͝âV!y0"n`1V[&l* !zM(_ý^_9eP4eBM9(@d-^s0" {ΎX2l4jMЋ!^4'2 $L"W*LYBR<|vQ{W촓kX^Wl%yvp@[Z4SlZ'?%T4?͞VxwPX *O+~ g~|[_KtE?ƥw0Q.O^7nnD}r̿׿b䓢3gqeT*+۰] ,$Ob)A/ρVN*"UD84WWVh v\gg4Y"0w oP/lx6njU8]/|?/ӿ{?gN=`vl ٵ p]TP•ð#(NlKSBAHش#B6  :lıL*Gˆ!5#!(hHnlhEO =޾aiXO rc|%61ѲUk@H7&R⑊F;+EQꑇ_wR&LX7o&OC…+pyHBH@ x pǮ~^Cjr}]EB.3%3f =,=.pH%yDS I;z) ]LDf:u!eAϋi͕k*,ۺ5ݝ}I'#4" ]bڌ@Yr ۾Ua]U4R^[4*$HEX+sgOA ݓ!ר^/͟aje2NL}&ҒʎGnO弾lfM3>" Psί0&+_rC]ǷuڱdX= StkC% TOsWrWSA޽hpE k͝VrKW,yTM۷f̜ɡe*DƎ^D1TnӬ9>]{go"c18e.KWD1Ξ!Y̌"&DZx\)#/ P fLai`Y4".A =hQ:4¹g%`%JP^]Գ~}ף̡{8 R6F<샽sO)a;! uTxayޞǩ AClTDm8C`|.gqWk G@O}@d8\zڅW_XE^@Z?pzgK/Rg)ijܫBv0.'544MVQQwX5Msm<A u\ GFp;d5Z>0L8l@jWXzެ92!,/LUǤ'. J@V^l }HF0V@ԛ0Y)hA-G-{;+^"[V0& {4߰<ymQL.4 HM]x`&e6ϙ# ž 4g4~8瘒< 3hQN8 G]NG^Nlffݎ޾ ({|Gon3ϭ7l&H0f6gٸ ֆf򃟮l T6niFJG>јP(7P Ќvq[?gGÁƘťH&6,ǠS( }HTȘL yE؈|cJ(A\*8sSRǾݽҒ_V>`JUEL}1e ]vgE%sNEzt T["~ ~-rQWj&Va.hHKtAEjǎnMUi~~j@[Kb4|]?}{KfO3#kzwlIB.uh0sl 񥪨Ӻf;\Asxn~r٤ >D6fD1nfa_^]}V+.P]Y㇆*Z^lz^dR0f8~SOۣ$Ύy63%T7f"ǞHeںB.Eg8w.Y07{_vϹEb#|N(IW 5/_K/[  7K{v9WmFA)㜙u8WO%j Rsh_=vIj5 6Rع5Yu5ՁLL5 ?aE\=aݢp}]5c;V2uBuMeFE{[h*:ȔfqU$Fy҃{I6z16/i<1!DIjr}3@*T+^G]#.XWH5#|GARUTpu:ξ7c0S,}S&#dcm"6cjjS ,mJd$ 6[C^GPn  f4\<)N#&T #r="C^: QUkh <h"H;tK-]sfc&Pa$wEiX G\QP`v][L9;0PXY} b0#F9K ?}cz{v2c'd=ۑi-[vggvW.lBap(|&Iٳ~[,Vp`6c(ו#4cmgĤ"ҭLrL"y-,԰@" 4UQ#C/%RF*΅qGK6LC|K>^N8'Nsx!Q~슑U&jdS#_a4M_ئ'.![t푡6n++b>矴PXP$o~çP"8 WTNP~~ݸlTp?v{ߍFczzꌩSΟ78W5? p.p<2Qx> m`(bEB'}܄6 =#D0(IH=rKQY8 `~hިBɠp3đ:lsgg<)}_Z:a`{bC "d!oosf8>#!/_"+3#+X~%³M~Q01A-\*= Q|{PžoqdpOh\8ٚV (7dVf 7AG^ny$K/X gO>C}r{zr(*WTA/MeS,]? wxHTSxc#D{F$~}`! A\9~жZ?ju.06y|aO1FyNpVV?XMXl*6:'dNّ0$~" RZDŽ!8/5<䗐979㟌4'CɗoaP^CeV0(C %4 4m?e;8}8<6yB$p΄R`52oQwAE2ebTu_#EՠNC\TJ uI!3Fo^NHЂo)uo!mJ0貕6NN{pxэR m F>%1 cVe13-lV3'*f-(8{SfB|#JА'ɦI(lVU^= ZЗ(5.o[فC! ( Z05s}^^NbO= :62@'_Q'_$F2nQp ^״m:9[rْu|L @QF$SRE: :r,‚ba!}I<$bj&7 KSPI@qifcT9Er+<.Zfȍ2h% l*d8PA# r)T\)X[/4[=McRx<A1+|kr=?:x:bGOGyM)g+eX-R(%#\T9"{gˇ: 3rK1fHUm5(*[:/O1i<Ь, dyaM%.1+bhP-DQ ZgъM  [ Qhհ<PaY/ڲIdK\!D_n[0 քGF_5@lAGݕ6Y,jC2+Y](4H E4plۏ? :ܬn0!=~ddMG|HTOge?)ϋW(z8:N΀'\?sflwHs?u& @P ~GA+C"5~J CFF 610xpe8]yʊPBE(+g\j4B$( ~:20Z0"G%w _/iDKh vlVc4yv6PM/`>/7  FTupxr[GId쒣q:ɣؚB%Xe&G8Œ3mV7DB^G?m7qқA[X "a h=h1UN:0q3p 0],%Dkp$kUةfi!gËF`T&%F=x F@wxDd|zz_ӓ?C8<yUSwb]C)|zp\==CLJY7 tϷU<򗏶_'9}̪4Tc 3޸m;mt᫵ sfNdт|l"]7޻7L_bQ^օH)}vӚ657 ,ͬ?ՃK^?޲]-^OH-ǔLZ~(~+pU֭;@(VTͪՒY]<ҿfO>qM}폶mHN4iu\3\&>8ְc 렚[_{-#VV'm?֪ױUU L}@eˑ?y .LNپsߚ?ȈTɁRiLEA߯x/uhk8ƩE7X96yrզUn罏tkOF$GwuO*tήW⊕N)OCaffb7^_9s3·vt| S*`ty׃7lmw p/hھ}W~VVIqW{e/jn7}i_{{ خoWWGw[k{~~YvN:4%$O+^}2innnk.j^xnn~ۺ89TwvBgʴY>tC| Kmm'vM,{jL133*MЄĮGb2&Z:8IgYU o(8ⷜZ*!kk:~DEj`"aw j^~g`py7_%/k݃@Y{gۥ_l4Om?_ŋRR[:NHƴ\x%y\8e h+9Z!>WI'X,Y[պ~`qO/Yt>ODٖxEukmm@`gB~…(+?Cojn*˫z{&z{vV]Q6L\.də3B V;cOwh6re3g=-&ì`zϯ>:IhἪ͟6`^)ݰ8fLclKͲZ8Vc0$*!KHPU>E̮8P]əGgPc%f""g 3(ʧ"/5斐(BU'$n3+QM_^6o2wuT9澖uۏ zŚ wrsSgO&KL!^!- ,_X}G-ho}cɴ n%K/TeߑԬ̚Z4p5ĐSh0gY^GRjX~y&皮\2]DX0rjǎ+>sfM<ޯ^O^MS^鵪XYQoFV@ϋ#-fk]2qE^0׵.ӅM2!~[fxiJ~v_}oqdB,b ͕O>uf@_}YC/sTQqZC98Bj,xeYx skw}YhihgOK-"''!sy _<h§*2$t(ހhGm[qP#dLK^v:w"' y%\p:!_1*a%`S[S5nEPi J#/ cN{l KjZN~^:a#4K@YI*| =$I/Œ'S5q!:TU^0JDj5?p])bD<N9:h&riI]%42W{3̼=Q#> scweЪ5{Bt\zנiCzrLP"rYI Vt q+u8`( n<4 jg4B(RvBI'U(WVd`^ȅ?jN|ڨp}fڝH*wyn߭V|:m[DiXiª~]nP(-'n|plalĐ?;BO+̸޾CG; Ւ5ugۛ>Aj8U--bss.3)n,,J6sI;rJx=on}n&*4'-ݗ-*ϡ:,Ye 6w0hK~wXnM+lߵjMqn93@]X22,6 MuWEF_@\ ϖ;O=y($Ύh/%y}kɬ "PhFgBTZN/_|L~G<[R[. &B TGV]Vb3X[: Kn2HCkh^pumX{|޽{`piAʐp(4R^@l۱ըcKܛ휊JZNS%8!ỏ=8_$2ɱHUS*kr,ؑ`MkG}~ZiLʚPPww7?x3/~WDN*ͱش=xYg׭y'#RAVch>Դ=xoUvPgfVDƦמSU:.⋺ ݯ{|/b#,`i;~ZZkw^oXѢR 4Q{L(U>79x3VբͰ%gy*DZ+շt`ۧ[>^+}v+oDD*W^/d&w:Aͨj*+/L{- x) 1r U \yiIר||{P(yd荾s~ `z}`Lp]}] OozkoZqxUl^u@36=;*P͛vt_xn b@j~V%{pصLd `Zl{cMoEͬW6yJM N4fgL)ٴ+Ψ?GI Fq*h0Jʳ J┙us5j"Xv:̜{$ʏjW]h3 Pm>ٺ3TW]yQu]4b3~wݎw 4xI'UeU'Nxm>_b2^taY2dW{=.kQb(þ~g.Zr) 6ɴcN>֘f;a$āi8n{h̲eO椘S.;1ܙs(*Pł]=AhsIURԛi֑Sk'r=GZ{ N n9Esm\sA7b4^{o -:ιeWǴkNK-:^~{ӡc-)V fw9JgS3jR)uSX7:Z1_6 =[7b؂΁-|kZrӡ~EtRf&6I=fhop6< X uXAy'T\pYuU5Ksr9(b-?عk#`bYi?q 7,]QJ*vwu90P>{z7/[x>)~ߠR׭v-i3"DCz9to\;át.$LrOiNjZ)fZzsbn 1 Wt'@93]7@7m= bHQqضH pLk7l֑p`4(Z #3TZ,L?U⢴<٧{~}3&B-jng3@I/+Ʀ %=`ͻ[zOo| r(-(K7`Y%lQkm6 =Dt٧~O<.&?d_{U`u:8+ЛJSƱw|mc6(U,FN:]Ҳ 1:T %O[O/2oy-.LȖb <ײl2n{O|﷿s=z|ulE#奂@DN_wiYVU]]Ń!7nCV]:jJ f4`d1K$#7 +@{{H EFH^41U`[}(қZZ[]h* ,2lܲI A~JAG'zCQETd鶔TeRtmY0~J;P/fIicMQFS7{Nzv> >W$6奐=Y-?\>m4GcFVHGPI""#Jұ%y8q`gsƍ!GFn90RiȡWV fxñt D H|t;rp)㪋.C2<?$0j@woo0pIay4@?F!r#d:/]ih8{}?(k!Biac _*ZE¡`Ke .t3RB YiäC6?a_.TΛ:AUHϹБw7ȡϿ߳KY 17bј<͛6 ?A%{鹜JG8k$غ\m=-Da{_wOS߹nvجT+3N;wDȦ={aeOS[\Q[ ^t u\ IaKV9{Yi}MuMKN~rSŢ*WN20YF 3YNxi#gϿu&ObaCC:U!T樹hjmq Lzl ~""l?ｷOl`$ZY2I=Kn _3TpOb~*A4C7_1Qʚ H`ؠT>'n1Bwg%K{󭏽A›]:X&%ec @o﷾Wo{o~%Eof&bђS+IĿ}˶G򊫗?߷i]l2 2Rs3 zI^~ͷ~Wy|h`}%"N)@z7y7~'>z#^.3K1p(vFWSdΪluc.nxG"N~+Ev))ʄ'\(W\d`)cǎnZ~+`I^o1fnllD gPZ,f;t4•姢 AY!qٻW-j|-H]gWڥdY)yZb(,|d떭ݝ)y /˱P;K_ (^{`5EW]y pSszz}]zywzmB ~Σ:v{z,z6rdrE+ʬB-ñ:=>jYSnꒋ/%KSՂ& yg6 'o[]}b-4Ðkf@_[o Ψ *)/zx--;'+]TThcNN.V ,90'v.\^ec6pK̬1hd3Gc,LBZ0.JM=Ą5`PTiAD#=$%:g")&cIft"@/qk,(~QeA]alO@5lK6y/@'07.iD .q 4Fz~N -Vf4"F`{ kM|{T!|7"PCCD~G#5kAl)15ТGzKz U`ac< -`S4z k4H$O<&V/&'gn{gwpb Tw5$$: p* YJ"M 1qF,@P]v"PNNjU*El1K 1q4hts#dFyUd pWR c7 0 AD 1AzL9 M99NWT'ļ/ǐna9UEZƀ |Ei0"hD p!^;#iZECX#XuK%" (F+f-#/5hyH̥Z$1JCo"lǹtCd mC"3gn{?{v<ǡ^PK0-^ \`w0SRP 9F}(2lqFЇXt*Jg$i<`|b)6,=0/0W`.Ҩ* 7XN D+ n.pA KߗyV(BXLŽR&0Π>"Go!E[aXF@Z]` N>##CG2(sY[ ׁwCA`co;ѦQEP-4M_yF C5}>@rR2q,x4VF-DlbqqhCEu֌@Ҟ=k U;EDGq;Nj^~jRjD2Y!ӗ}7 P' OEF 0=)c]N (fr|۠haJ qH(ɧ1y ָB⪴2"KJr !vK>&>ui./~9ܬ)q3l-* f+ IHO@rF$7'%#3&HD&G 9g$q 'G 9~8;QH>I=`H$ΎGl`r#p@gl~r#0G %#3&HD&G 9g$q 'G 9~Эu-JIENDB`}DyK _Toc273725668}DyK _Toc273725668}DyK _Toc273725669}DyK _Toc273725669}DyK _Toc273725670}DyK _Toc273725670}DyK _Toc273725671}DyK _Toc273725671}DyK _Toc273725672}DyK _Toc273725672}DyK _Toc273725673}DyK _Toc273725673}DyK _Toc273725674}DyK _Toc273725674}DyK _Toc273725675}DyK _Toc273725675}DyK _Toc273725676}DyK _Toc273725676}DyK _Toc273725677}DyK _Toc273725677}DyK _Toc273725678}DyK _Toc273725678}DyK _Toc273725679}DyK _Toc273725679}DyK _Toc273725680}DyK _Toc273725680}DyK _Toc273725681}DyK _Toc273725681}DyK _Toc273725682}DyK _Toc273725682}DyK _Toc273725683}DyK _Toc273725683}DyK _Toc273725684}DyK _Toc273725684}DyK _Toc273725685}DyK _Toc273725685}DyK _Toc273725686}DyK _Toc273725686}DyK _Toc273725687}DyK _Toc273725687}DyK _Toc273725688}DyK _Toc273725688}DyK _Toc273725689}DyK _Toc273725689}DyK _Toc273725690}DyK _Toc273725690}DyK _Toc273725691}DyK _Toc273725691}DyK _Toc273725692}DyK _Toc273725692}DyK _Toc273725693}DyK _Toc273725693}DyK _Toc273725694}DyK _Toc273725694}DyK _Toc273725695}DyK _Toc273725695}DyK _Toc273725696}DyK _Toc273725696}DyK _Toc273725697}DyK _Toc273725697}DyK _Toc273725698}DyK _Toc273725698}DyK _Toc273725699}DyK _Toc273725700}DyK _Toc273725700}DyK _Ref270625779$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4ayt$$If!vh55a#v#va:V l.0 ",55a/ 4ayt$$If!vh55a#v#va:V l.0 ",55a/ 4ayt$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4ayt$$If!vh55a#v#va:V l.0 ",55a/ 4ayt$$If!vh55a#v#va:V l.0 ",55a/ 4ayt$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|$$If!vh55a#v#va:V l.0 ",55a/ 4aytv|}DyK _Ref270625884}DyK _Ref270625884$$If!vh5 555#v #v#v#v:V l40&65}55i 5/ 4ayt;-$$If!vh5 555#v #v#v#v:V l40&6++,,5}55i 5/ / / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / / 4ayt;$$If!vh5 555#v #v#v#v:V l40&6++,5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;!$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / / / 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;-$$If!vh5 555#v #v#v#v:V l40&6++,,5}55i 5/ / / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;!$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / / / 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;-$$If!vh5 555#v #v#v#v:V l40&6++,,5}55i 5/ / / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++,,5}55i 5/ / / /  4ayt;!$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / / / 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;$$If!vh5 555#v #v#v#v:V l40&6+,,5}55i 5/ / / / 4ayt;$$If!vh5 555#v #v#v#v:V l40&6+,5}55i 5/ / / 4ayt;$$If!vh5 555#v #v#v#v:V l40&6+,5}55i 5/ / / 4ayt;$$If!vh5 555#v #v#v#v:V l40&6+,5}55i 5/ / / / 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;-$$If!vh5 555#v #v#v#v:V l40&6++,,5}55i 5/ / / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;!$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / / / 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;-$$If!vh5 555#v #v#v#v:V l40&6++,,5}55i 5/ / / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;!$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / / / 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;$$If!vh5 555#v #v#v#v:V l0&6,,5}55i 5/ 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;-$$If!vh5 555#v #v#v#v:V l40&6++,,5}55i 5/ / / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;!$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / / / 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;-$$If!vh5 555#v #v#v#v:V l40&6++,,5}55i 5/ / / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;!$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / / / 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;-$$If!vh5 555#v #v#v#v:V l40&6++,,5}55i 5/ / / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;!$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / / / 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;$$If!vh5 555#v #v#v#v:V l0&6,,5}55i 5/ 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;-$$If!vh5 555#v #v#v#v:V l40&6++,,5}55i 5/ / / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++,5}55i 5/ / / /  4ayt;'$$If!vh5 555#v #v#v#v:V l40&6++,5}55i 5/ / / / / 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;-$$If!vh5 555#v #v#v#v:V l40&6++,,5}55i 5/ / / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l40&6++5}55i 5/ / / /  4ayt;$$If!vh5 555#v #v#v#v:V l4C0&6++5}55i 5/ / / / 4ayt))$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;$$If!vh5 555#v #v#v#v:V l0&6,,5}55i 5/ 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;$$If!vh5 555#v #v#v#v:V l0&6,,5}55i 5/ 4ayt;$$If!vh5)#v):V l  ļ0&65/ 4ap ļyt;$$If!vh5 555#v #v#v#v:V l0&6,,5}55i 5/ 4ayt;}DyK _Ref272505518}DyK _Ref272505518)$$If1!vh5 5 5'5#v #v #v'#v:V l  t(0;5 5 5'5a1p(yt $$If1!v h5 5 5555555 #v #v #v#v :V lU  tZ0;5 5 5555 a1pZyt kd5$$IflU  V"j(-~39>    tZ0;$$$$44 la1pZyt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd $$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd !$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd$$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd'$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd *$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd'-$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l( t0;5 5 5555 a1yt kd.0$$Ifl(  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd53$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kd<6$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kdC9$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kdJ<$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kdQ?$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If1!v h5 5 5555555 #v #v #v#v :V l t0;5 5 5555 a1yt kdXB$$Ifl  V"j(-~39>   t0;$$$$44 la1yt $$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf}DyK _Ref270692263$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh55#v#v:V l t0655ytlf$$If!vh5 595i#v #v9#vi:V l406+,555 / / / / 4yt!$$If!vh5 595i#v #v9#vi:V l406+,555 / / / 4yt!$$If!vh5 595i#v #v9#vi:V l406+555 / / / / 4yt!$$Ifl!vh5e5#ve#v:V lK0L'65e5alytq}DyK _Ref270797089$$Ifl!vh5e5#ve#v:V li0L'65e5alytq$$Ifl!vh5e5#ve#v:V lK0L'65e5alytq$$Ifl!vh5e5#ve#v:V l<0L'65e5alytq$$Ifl!vh5e5#ve#v:V lK0L'65e5alytq$$Ifl!vh5e5#ve#v:V lK0L'65e5alytq$$Ifl!vh5e5#ve#v:V lK0L'65e5alytq$$Ifl!vh5e5#ve#v:V lK0L'65e5alytq$$Ifl!vh5 55n#v #v#vn:V l40T6+,5e55r / / / / 4alyt $$Ifl!vh5 55n#v #v#vn:V l40T6+5e55r / / / 4alyt $$Ifl!vh5 55n#v #v#vn:V l40T6+5e55r / / / 4alyt $$Ifl!vh5 55n#v #v#vn:V l40T6+5e55r / / / 4alyt $$Ifl!vh5 55n#v #v#vn:V l40T6+5e55r / / / / 4alyt }DyK _Ref272411353$$Ifl!vh575!#v7#v!:V l0Q'6575!alytxM=}DyK _Ref270797089$$Ifl!vh575!#v7#v!:V l0Q'6575!alytxM=$$Ifl!vh575!#v7#v!:V l0Q'6575!alytxM=$$Ifl!vh575!#v7#v!:V l0Q'6575!alytxM=$$Ifl!vh575!#v7#v!:V l0Q'6575!alytxM=$$Ifl!vh575!#v7#v!:V l0Q'6575!alytxM=$$Ifl!vh575!#v7#v!:V l0Q'6575!alytxM=$$Ifl!vh575!#v7#v!:V l0Q'6575!alytxM=}DyK _Ref272411457$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|}DyK _Ref270797089$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$If!vh5x 55m#vx #v#vm:V l06,55+58 / 4yt] }DyK _Ref270781641$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|}DyK _Ref270797089$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh5 55n#v #v#vn:V l40T6+,5e55r / / / / 4alyt $$Ifl!vh5 55n#v #v#vn:V l40T6+5e55r / / / 4alyt $$Ifl!vh5 55n#v #v#vn:V l40T6+5e55r / / / 4alyt $$Ifl!vh5 55n#v #v#vn:V l40T6+5e55r / / / / 4alyt }DyK _Ref270784153$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|}DyK _Ref270797089$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh55 #v#v :V l0Q'655 alyt|w|$$Ifl!vh5Y 595i#vY #v9#vi:V l40T6+,55 5 / 4alyt $$Ifl!vh5Y 595i#vY #v9#vi:V l40T6+,55 5 / 4alyt $$Ifl!vh551 #v#v1 :V l0T655/ 4alyt }DyK _Ref270785290$$Ifl!vh55 #v#v :V l0Q'655 alytf}DyK _Ref270797089$$Ifl!vh55 #v#v :V l0Q'655 alytf$$Ifl!vh55 #v#v :V l0Q'655 alytf$$Ifl!vh55 #v#v :V l0Q'655 alytf$$Ifl!vh55 #v#v :V l0Q'655 alytf$$Ifl!vh55 #v#v :V l0Q'655 alytf$$Ifl!vh55 #v#v :V l0Q'655 alytf$$Ifl!vh55 #v#v :V l0Q'655 alytf$$Ifl!vh5 55n#v #v#vn:V lY0T6,5e55r 4alyt }DyK _Ref272515063$$Ifl!vh55 #v#v :V l0Q'655 alyt2X}DyK _Ref270797089$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh551 #v#v1 :V l0T655/ 4alyt $$Ifl!vh551 #v#v1 :V l0T655/ 4alyt $$Ifl!vh551 #v#v1 :V l0T655/ 4alyt }DyK _Ref270716439$$Ifl!vh55 #v#v :V l0Q'655 alyt2X}DyK _Ref270797089$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh5Y 595i#vY #v9#vi:V l40T6+,55 5 / 4alyt $$Ifl!vh5Y 595i#vY #v9#vi:V l40T6+55 5 / / / / / 4alyt $$Ifl!vh5Y 595i#vY #v9#vi:V l40T6+55 5 / / / / / 4alyt $$Ifl!vh5Y 595i#vY #v9#vi:V l40T6+55 5 / / / / / 4alyt }DyK _Ref270785464$$Ifl!vh55 #v#v :V l0Q'655 alyt2X}DyK _Ref270797089$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55{5#v#v{#v:V l06,5i575 / 4alyt }DyK _Ref270786189$$Ifl!vh55 #v#v :V l0Q'655 alyt2X}DyK _Ref270797089$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X$$Ifl!vh55 #v#v :V l0Q'655 alyt2X}DyK _Ref153264328$$Ifl!vh5/ 5"#v/ #v":V l0Q'65/ 5"alyt|$$Ifl!vh5/ 5"#v/ #v":V l0Q'65/ 5"alyt|$$Ifl!vh5/ 5"#v/ #v":V l0Q'65/ 5"alyt|$$Ifl!vh5/ 5"#v/ #v":V l0Q'65/ 5"alyt|$$Ifl!vh5/ 5"#v/ #v":V l0Q'65/ 5"alyt|$$Ifl!vh5/ 5"#v/ #v":V l0Q'65/ 5"alyt|$$Ifl!vh5/ 5"#v/ #v":V l0Q'65/ 5"alyt|$$Ifl!vh5/ 5"#v/ #v":V l0Q'65/ 5"alyt|$$Ifl!vh5/ 5"#v/ #v":V l0Q'65/ 5"alyt|$$Ifl!vh5/ 5"#v/ #v":V l0Q'65/ 5"alyt|$$Ifl!vh5/ 5"#v/ #v":V l0Q'65/ 5"alyt|}DyK _Ref270797089}DyK _Ref153261406$$Ifl!vh55q5q#v#vq:V l0&55qalyt1:z$$Ifl!vh55q5q#v#vq:V l0&55qalyt1:z$$Ifl!vh55q5q#v#vq:V l0&55qalyt1:z$$Ifl!vh55q5q#v#vq:V l0&55qalyt1:z$$Ifl!vh55q5q#v#vq:V l0&55qalyt1:z$$Ifl!vh55q5q#v#vq:V l0&55qalyt1:z$$Ifl!vh55q5q#v#vq:V l0&55qalyt1:z}DyK _Ref153261406$$If!vh55555#v#v:V 4s'+55/ 4 aytX$$If!vh55555#v#v:V 4'+55/ 4 aytX$$If!vh55555#v#v:V '55/ 4 aytX$$If!vh55555#v#v:V '55/ 4 aytX$$If!vh55555#v#v:V c'55/ 4 aytX$$If!vh55555#v#v:V '55/ 4 aytX$$If!vh55555#v#v:V ''55/ 4 aytX}DyK _Ref270797089}DyK _Ref270800379$$If!vh55#v#v:V l t0655yt~Vy$$If!vh55#v#v:V l t0655yt~Vy$$If!vh55#v#v:V l t0655yt~Vy$$If!vh55#v#v:V l t0655yt~Vy$$If!vh55#v#v:V l t0655yt~Vy$$If!vh55#v#v:V l t0655yt~Vy$$If!vh55#v#v:V l t0655/ yth)L$$If!vh5O 5v5#vO #vv#v:V l06,55(5 / 4yt$$$If!vh515#v1#v:V l t06515ayt:$$If!vh515#v1#v:V l t06515ayt:$$If!vh515#v1#v:V l t06515ayt:$$If!vh515#v1#v:V l t06515ayt:$$If!vh515#v1#v:V l t06515ayt:$$If!vh515#v1#v:V l t06515ayt:$$If!vh515#v1#v:V l t06515ayt|}DyK _Ref270797089$$If!vh55M5"#v#vM#v":V l4 t 6  6+,555 9/ O/ Oyty/$$If!vh55M5"#v#vM#v":V l4 t 6  6+555 / O/ Oyty/$$If!vh55o5X#v#vo#vX:V l4 t 6 6+,5z559/ O/ Oyt $$If!vh55o5X#v#vo#vX:V l4 t 6 6+5z55/ O/ Oyt $$If!vh5w55#vw#v#v:V l4 t 6 l6+,5559/ O/ Oyt $$If!vh5w55#vw#v#v:V l4 t 6 l6+555/ O/ Oyt qpppp00h00H@H@pJNormalCJ_HaJmHnHsH tH ud@d@pJ Heading 1$$@&'5B*CJOJPJQJ\^JaJph6_d@d@pJ Heading 2$$@&'5B*CJOJPJQJ\^JaJphO\@\@pJ Heading 3$$@&5B*OJPJQJ\^JphOb@b@pJ Heading 4$$@&%56B*OJPJQJ\]^JphOV@V@pJ Heading 5$$@&B*OJPJQJ^Jph$?`\@\@pJ Heading 6$$@&6B*OJPJQJ]^Jph$?`\@\@pJ Heading 7$$@&6B*OJPJQJ]^Jph@@@^@^@pJ Heading 8$$@&!B*CJOJPJQJ^JaJph@@@d @d@pJ Heading 9 $$@&'6B*CJOJPJQJ]^JaJph@@@DA@D Default Paragraph FontRi@R 0 Table Normal4 l4a (k( No List \O\ @pJ Char Char20+5B*CJOJPJQJ\^JaJph6_tH \O\ @pJ Char Char19+5B*CJOJPJQJ\^JaJphOtH \\ @pJ Char Char18+5B*CJOJPJQJ\^JaJphOtH b!b @pJ Char Char17156B*CJOJPJQJ\]^JaJphOtH VO1V @pJ Char Char16%B*CJOJPJQJ^JaJph$?`tH \A\ @pJ Char Char15+6B*CJOJPJQJ]^JaJph$?`tH \Q\ @pJ Char Char14+6B*CJOJPJQJ]^JaJph@@@tH NaN @pJ Char Char13B*OJPJQJ^Jph@@@tH TqT  @pJ Char Char12#6B*OJPJQJ]^Jph@@@tH VOV ,Default 7$8$H$!B*CJ_HaJmH phsH tH FOF koStyle 11$7$8$H$_HmH sH tH r"@r@pJCaption,Table and Figure name5B*CJ\aJphOb>@b@pJTitle,POm$)@B*CJ4KHOJPJQJ^JaJ4ph6]^O^ @pJ Char Char11-@B*CJ4KHOJPJQJ^JaJ4ph6]tH 6O6@pJQuote6B*]phHOH @pJ Quote Char6B*CJ]aJphtH 6U@6 ko0 Hyperlink >*B*ph8@8!koHeader 9r sH DOD ko0 Char Char10CJaJmH sH tH F@F-pTOC 2"  ^ OJQJsH B@B-pTOC 1 #  5OJQJsH B@B-pTOC 3$  S^S OJQJsH 4 @R4&Footer % B#:Oa: %0 Char Char9 CJaJtH H@rH( Balloon Text'CJOJQJ^JaJFOF ' Char Char8CJOJQJ^JaJtH POP * No Spacing) CJOJQJ_HaJmH sH tH VOV )No Spacing Char CJOJQJ_HaJmH sH tH >@>,+ Footnote Text+CJaJ2O2 ++ Char Char7tH @&@@ +Footnote ReferenceH*B'@B }HComment ReferenceCJaJ<@<0}H Comment Text/CJaJ2O2 /}H Char Char6tH @j@@2}HComment Subject15\4O!4 1}H Char Char55\jC@2j4}HBody Text Indent3d^CJOJPJQJ^J_H aJJOAJ 3}H Char Char4CJOJPJQJ^J_H tH fORfF List Paragraph5d^m$CJOJPJQJ^JaJJObJ {Heading26xB* CJOJQJaJphI}F^@rFqv0 Normal (Web)7dd[$\$tH *W@* `Strong5\*O*  highlightDZ@D;A Plain Text:OJPJQJ^JaJJOJ :A Char Char3CJOJPJQJ^JaJtH $O$ uk_wordBOB a"highlightedsearchtermjj * Table Grid7:V>0>ROR _ TableText ?$((CJOJQJaJtH u8O8 _ TableHeading@5NON B_ TableNameAxx^`5CJ@O!@ A_TableName Char 5OJQJRO2R D_ TableNotes C$$0h^`0CJBOAB C_TableNotes Char CJOJQJTB@RT F5 Body TextE%56B*CJOJ QJ aJhphuPOaP E5 Char Char2"56B*CJOJ QJ hphtH HOrH 5 Bullet G & FOJQJaJtH uXL@X I5 DateH$q]q^a$5CJ$OJQJaJtH u>O> H5 Char Char15CJ$OJQJ~O~ 5 Heading 1a,J$$h&d@& P^#B*CJ(OJQJ\aJphtH ujO!j 5 Heading 2aK$@& ^#B*CJOJQJ\aJphtH ujO1j 5 Heading 3aL$@& ^#B*CJOJQJ\aJphtH u>)@> 5 Page Number5CJOJQJrOr 5 PublicationTitleN$qd ]qa$56CJ,OJQJaJtH uTOT 5 Quote Bullet O & FOJQJaJtH u\O\ 5 ReferencesP$0^`0OJQJaJtH uZOZ 5 Sub-titleQ$q]qa$5CJ OJQJaJtH ut#@t5 0Table of Figures)R 9# x]^`OJQJaJtH F@F 5 pTOC 4S^OJQJaJtH uF@F 5 TOC 5Tp^pOJQJaJtH uF@F 5 TOC 6UL^LOJQJaJtH uF@F 5 TOC 7V(^(OJQJaJtH uF@F 5 TOC 8W^OJQJaJtH uF@F 5 TOC 9X^OJQJaJtH uXOX 5 Table Text Y$((CJOJQJaJmH sH u:O: 5 Table HeadingZ5jOj 5 figure heading[$5xx^5`5CJOJQJaJuJOJ 5 box heading\+^`+mH sH FV@F 5 FollowedHyperlink >*B* phJOJ 5 HTML Body^OJQJ_HhmH sH tH dOd `5 Table Indent 1!_ 1$^` CJaJuJOJ _5 Table Indent 1 Char CJaJtH ROR b5 Table Indent 2a W^`W>O!> a5 Table Indent 2 Char:O1: 5 mainsubheader15\BOBB 5 Bullet+12 d & F aJu<OR< 5 Bullet+6 e & F tH ubObb 5 AHTA address linesfd.6B* CJPJ aJphu.Oq. 5 regulartextBOB 5 bodytexthdd[$\$tH u^Y@^ j5 Document Mapi-D M CJOJQJ^JaJuNON i5 Char Char!OJQJ^JfH q tH POP 5 Indentk 77^7` aJtH uLLKf0RevisionlCJ_HaJmHnHsH tH uLOL Free FormmB*PJ _HmHphsHtH 0a@0 e0 HTML Cite6]\O\ psOphthal table texto]OJQJ^Ju^O^ osOphthal table text CharCJOJQJ^JaJtH v}/*&|"g< }Xq 0EH< (<?} defghijklnopqrstuvwxyz    &8IWeu':;<b~  pFZ(K b  n V ! X i2,-HNOdqr},-HNOa}~ +12Dgh :-EglKLj 5~]?@^ C h "e"f""""""""$#/#0#1#7#######$ $ $ $$j$k$l$m$s$$$$$$N%O%P%Q%W%\&]&^&_&e&&&&&&'''''''(((((()))) ))))))V*W*X*Y*Z*v*}******!+"+#+$+*+~+++++++-----/)00o11111133333w566X7z7777788Y9d9e9f9g9m9]:^:_:`:f:V;W;X;Y;_;<<<<<> >!>">#>.>4>>>>>>>K?L?M?N?T???????????9@:@;@<@B@@@@@@@@@@@AAAAA.A5AQA]A^A_A`AAA6BBBCBDBEBKBBBBBBDDDD$DBECEDEEEFEOEUE FFFFF"FFFFFFGGGGG2H3H4H5H;HHHHHHIIIII@JAJBJCJIJJJJJJJJJJJJK KKKKKKKLMMMM=N>N?N@NANNNjOvOwOxOyOOO P,P-P.P4P}P~PPPPPPPPPPQ QQQQQQQQQQQQQRRRRBRCRDRERFRRRSSSSSTT7T8T9TETFTGTHTQTXT>UJUKUUUVV/X0XXZf[[:\\?]] ^_^`^n^^CcIvy ||4}5}w}~8~^~~~~~AfefÊ ݍď>ƐǐȐF1^K,j(VA noҤӤIئ)pq MNW_u|}~ծGPQSTUVWYZvͯ%&')+,.01SfghjkmnopȰʰ˰Ͱڰ۰ݰ߰ (:;<>?ABCD *,./02356Zoqstuwy{|²òŲƲDzȲʲ˲Ҳ';=>?@ACDE#$%&'(6RvwGH @AGHb}PQtѿҿڿ&'<WXmz{ "DE\ijy7-O|mXY&'&(o`a &'4:;O\]q7KLcij{?KL >E:;<CDSfgt >?H^_`()tEFGM=>?E567={%&3<abp"gh$%0(cdlsz{QR  !)0[4 g~    - @ A N \ -     xy-Cjp!=>M`an|.Z0HIWf       !!%!!!!! " " """[#$%{%l&m&s&&&'''(((7(J(K(X(()))))))***6*9*:*B*++&+5+6+?+U+V+j+k+m+y+++++6,,,b-c-r----....////////000001 11 141516111o2p2v2333444j6k66l7m7,8-8<8O8P8]88999:::O:P:\:_:`:h:o;p;~;;;;;;< < <J<]<c<<<<<===!=I=J=K=Q====.@@ICJCDDDDDDoEpEEEEFFF,FFH]I^IiIIIIII(J)J6J}JJJJJJJKKKKKLLMMNNNpNqNrNNNOOHOIOJOOQQuQ R RRRRRRR\STT$TLTMTZT}T~TTTTTTTTTTTTTTTTTTTUUUUWWYY}[[[[[[\\F\\\\]]]]]*^^^^_____```aaaaaa_b{bbbyccccdddeeeef4frf|ffpggggg'h1hh%iWiXiiij jcjk2k3k\kkkkLllmm8mm[nennYooooooo/{ÂĂȂ :ރ߃ :?Pg >[~ۆ܆߆ TUVj&͎oCәʚ͛BCǡɡˡ͡ϡСѡۡk٢E9RScnzMݥno}6fgaIJz{)*jkHųƳ޳ ./KQRdjkv|}_ŷٸyzDuvOPd89LLEF<=RFTU )*hi)+ "jl02VX|}ABRSLMX  [\hi'u_     0123456789:=0000000000000000000000000000 0 0 0 0 0 000000000 00000000 0000000 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000000000000000 0 00#0"0"0"0#0"0"0"0#0"0"0"0"0"0"0#0"0$0"0$0"0$0$0$0$0"0"0"0"0#0#0#0000000H00202 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 02 020260202020202020202020202020260202020202020202020260202060 0 H0 0"0" 0" 0" 0" 0"0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0"0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0"0" 0"0" 0" 0" 0"0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0"0" 0"0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0"0" 0"0"0"0"0"0"0"0"0" 0" 0"0" 0" 0" 0"0"0"0" 0" 0"0"0"0" 0" 0"0" 0" 0" 0"0"0"0"0"0"0"0"0"0"0"0" 0" 0"0" 0"0" 0" 0"0" 0"0" 0" 0"0" 0"0" 0" 0"0" 0"0"0"0"0"0"0"0"0"0" 0" 0"0" 0"0" 0" 0"0" 0"0" 0" 0"0" 0"0" 0" 0"0" 0"0" 0" 0"0" 0"0" 0" 0" 0" 0" 0" `0" @0"@0"`0"0" 0" 0" @0" @0" @0" @0" @0"@0" @0"0" 0" 0" 0"0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0"0" 0"0" 0" 0" 0"0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0"0" 0" 0"0" 0"0" 0" 0" 0"0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0"0" 0"0" 0" 0" 0" 0"0" 0"0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0"0" 0" 0"0" 0"0" 0" 0" 0"0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0"0" 0"0" 0" 0"0"0" 0" 0"0" 0"0" 0" 0" 0" 0" 0"0"0":0":0":0":0" 0" 0" 0" 0" 0" 0" 0" 0" 0"0"60"0"0"0"0"0"0"0"0"0"0" 0" 0" 0" 0" 0"0"0" 0" 0" 0" 0" 0 "0"0"0"0"0"70"70"0"0"60"0"0"0"0600000006000000600 0 0F 0 01 0 0 0 0, 0 0(0606060000600006000000030300060H00 0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0 0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0  0  0  0  0  0  0  0  0  0 0 0 60 60 60 60 60 60 (0 306 306 3063060606060606060606306306606(0 0b0b30bH0b0t30t 30t 0t 30t 30t 0t 30t 30t 0t 30t 30t 0t 30t 30t 0t 30t 30t 0t 30t 30t 0t 30t 30t 0t 30t 30t 0t 30t 30t 0t 30t 30t 0t 30t30t30t30t30t0t0t0t0t0t0t0t0t0t0t0t0t30t0t0t0t60t60t0t0t0tH0b030 30 0 30 30 0 30 30 0 30 30 0 30 30 0 30 30 0 30 30 0 30 30 0 30 30 0 30 30 0 30 30 0 30 30 0 00000000(00L 0L0L0L0L 0L 0L 0L 0L 0L 0L 0L 0L 0L 0L 0L H0LH0L0<H0L0@0 @0 0 ?0 ?0?0 0 ?0 ?0 0 ?0 ?0 0 ?0 ?0 0 ?0 ?0 0 ?0 ?0 0 ?0 ?0 0 00000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0H0LH0L0@0 @0 0?0 ?0?0?0?0?0?0?0?0 0?0 ?0 0?0 + ?0+ ?0 0?0 ?0 0 ?0 ?0?0?0?0?0?0?0?0 0 ?0 ?0?0 0 ?0 ?0 0 00 000 000H0L0RH0L0@0 @0 0 ?0 ?0?0?0?0?0 0 ?0 ?0 0 ?0 ?0 0 ?0 ?0 0 ?0 ?0?0?0?0?0?0 0 ?0 ?0?0?0 0 ?0 ?0 0 000 0 0 0 0 0H0L0H0L0 @0  @0  0  ?0  ?0 ?0 ?0 ?0  0  ?0  ?0  0  ?0  ?0  0  ?0  ?0  0  ?0  ?0 ?0 ?0 ?0 ?0  0  ?0  ?0 ?0 ?0  0  ?0  ?0  0  0 0 0 0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 0  0 H0LH0L0H0L0@0 @0 0?0 ?0?0?0?0 0?0  ?0 ?0 0?0  ?0 ?0 0?0 ?0 0 ?0 ?0?0?0?0?0?0 0 ?0 ?0?0?0 0 ?0 ?0 0 0000 0 0 0 0 0 0 0 0 00 0000000 0 0 H0L0&H0L0'@0' @0' 0' ?0' ?0'?0' 0' ?0' ?0' 0' ?0' ?0' 0' ?0' ?0' 0' ?0' ?0' 0' ?0' ?0' 0' ?0' ?0' 0' 0'0'0'0' 0' 0' 0' 0' 0'H0L06,H0L0,@0, @0, 0, ?0, ?0,?0, 0, ?0, ?0, 0, ?0, ?0, 0, ?0, ?0, 0, ?0, ?0, 0, ?0, ?0, 0, ?0, ?0, 0, 0,0,0,0,0, 0, 0, 0, 0, 0, 0, 0, 0, 0,0,0, 0,H0L06H0L0m7@0m7 @0m7 0m7 ?0m7 ?0m7?0m7 0m7 ?0m7 ?0m7 0m7 ?0m7 ?0m7 0m7 ?0m7 ?0m7 0m7 ?0m7 ?0m7 0m7 ?0m7 ?0m7 0m7 ?0m7 ?0m7 0m7 0m70m70m70m70m7 0m7 0m7 0m7 0m7 0m7 0m7 0m7 0m7 0m7 0m7 0m7 0m7 0m7 0m7 0m7 0m70m70m70m70m7 0m70m7 0m750m7 0m70m7H0LH0LH0L0pE@0pE @0pE 0pE?0pE ?0pE?0pE?0pE?0pE 0pE?0pE  ?0pE ?0pE 0pE?0pE  ?0pE ?0pE 0pE?0pE  ?0pE ?0pE 0pE?0pE ?0pE ?0pE?0pE?0pE ?0pE ?0pE 0pE?0pE ?0pE?0pE?0pE 0pE ?0pE ?0pE 0pE 0pE0pE0pE0pE0pE0pE 0pE 0pE 0pE 0pE0pE0pE0pE 0pEH0L0uQH0L0 R@0 R @0 R 0 R ?0 R ?0 R?0 R 0 R ?0 R ?0 R 0 R ?0 R ?0 R 0 R ?0 R ?0 R 0 R ?0 R ?0 R 0 R ?0 R ?0 R 0 R ?0 R ?0 R 0 R 0 R0 R0 R0 R0 R0 R(00T0T0T 0T0T0T0T0TH0T0}[@0}[ @0}[ 0}[ 50}[?0}[ ?0}[?0}[?0}[ ?0}[ ?0}[ ?0}[ 0}[ 50}[?0}[ ?0}[?0}[?0}[! ?0}[! ?0}[! ?0}[ 0}[" 50}[?0}[ ?0}[?0}[?0}[# ?0}[# ?0}[# ?0}[ 0}[" 50}[?0}[ ?0}[?0}[?0}[$ ?0}[$ ?0}[$ ?0}[ 0}[" 50}[ ?0}[?0}[?0}[% ?0}[% ?0}[% ?0}[ 0}[" 50}[ ?0}[?0}[?0}[& ?0}[& ?0}[& ?0}[ 0}[" 50}[ ?0}[?0}[?0}[' ?0}[' ?0}[' ?0}[ 0}[" 50}[ ?0}[?0}[?0}[( ?0}[( ?0}[( ?0}[ 0}[" 50}[ ?0}[?0}[?0}[) ?0}[) ?0}[) ?0}[ 0}[" 50}[ ?0}[?0}[?0}[* ?0}[* ?0}[* ?0}[ 000(000H00 0 0 0 0 00 00 0 0 0 0 0 0 00 0 0 0 00000 00 0 0 0000 0 0 0 0 0 0 0(0000000000000(00H00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0006060000000000000600H0030 30 0 30 30 0 30 30 0 30 30 0 30 30 0 30 30 0 30 30 0 600000 0 0 0 0000606000006003030303030303030303030303030303030303030303030300000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 00 0 0 0 0 0000000000000000000000000000000000000000000000000000000000000000000@+0@+0@+0@+0@+0@+0@+0@+0@+0@+0@+0@+00 0E@000@000@000@000@ 0 @)0 @ 0 @0 @ 0 ` 0 @ 0 @0 @%000 b%@ 0 @)0 @ 0 @0 @ 0 ` 0 @ 0 @0 @%000 D*@ 0 @)0 @ 0 @0 @ 0 ` 0 @ 0 @0 @%000R000000k:;,-NOqr,-NO}~12gh""/#0### $ $k$l$$$O%P%]&^&&&''''(())))W*X*Y*Z***"+#+++++--11337777e9f9^:_:W;X;<< >!>">#>>>L?M?????:@;@@@@@AAAA]A^A_A`ACBDBBBDDCEDEEEFEFFFFGG3H4HHHIIAJBJJJJJJJKKMM>N?N@NANvOwOxOyO,P-P~PPPPPPQQQQRRCRDRERFRSSSSETFTGTHTJUKU|}YZ01op CD 56{|ʲ˲DE&'WXz{DEij&':;\]KLij:;fg >?^_EF=>56%&$%cd ! @ A   xy`aHI    !! " "&&J(K()))))***9*:*++5+6+U+V+++--..//////00011 1o2p23344O8P899::O:P:_:`:o;p;;;;;<<==I=J===FF]I^III(J)JJJKKMMNNHOIORRTTLTMT}T~TTTTTTTTT[[]]__aacceeggWiXi2k3kmmooÂĂރ߃ۆ܆TUϡСRSnofgųƳ./QRjk|}uvTU)*i89:=0L MK0 MK00 M0K00M0K00 DM0K0 0 |M0K0 0 PM0K00M0K00,M0K00dM0K00 M0K00< M0K00t M0K008M0K00$9M0K00\9M0K0 0!9M0K0"0#M0K0$0% M0K0&0'< M0K0(0)t M0K0*0+ԜM0K0,0- M0K0.0/DM0K0001|M0K0203M0K0405읥M0K0607dQM0K0809dQM0K0:0;eQM0K0<0=HeQM0K0>0?eQM0K0@0AeQM0K0B0CeQM0K0D0ExQM0K0F0GQM0K0H0IQM0K0J0K QM0K0L0MXQM0K0N0OQM0K0P0QȊQM0K0R0SQM0K0T0U8QM0K0V0W(M0K0X0Y`M0K0Z0[M0K0\0]M0K0^0_M0K0`0a@M0K0b0cxM0K0d0eM0K0f0gM0K0h0i M0K0j0kXM0K0l0mxM0K0n0oM0K0p0q胇M0K0r0s M0K0t0uXM0K0v0wM0K0x0yȄM0K0z0{M0K0|0}8M0K0~0pM0K00M0K00M0K00M0K00PM0K00$M0K00%M0K00@%M0K00x%M0K00%M0K00%M0K00 &M0K00X&M0K00&M0K00&M0K00'M0K008'M0K00p'M0K00'M0K00'M0K00(M0K00P(M0K00M0K00HM0K00M0K00M0K00M0K00(M0K00`M0K00M0K00EM0K00EM0K 00@"0M00x0 ۾ 00پ 6000$0 ۾ ;00 ;Q ۾0X ۾ 6KK0"0 ۾ F0 08xOyO0pD"01 ۾ F0-P00Dh0|h0h0h0$h0\h0h0h0h0<h0th00h000h000h000Th000h000h000h0004 h001l h001 h001 h001!h001 L!h00 1 !h00 1 !h001!h001<#h001t#h001#h001#h001$h001T$h001$h001$h00 1!$h00"1#4%h00$1%l%h00&1'%h00(1)%h00*1+&h00,1-L&h00.1/&h00011&h00213&h00415,'h00617d'h00819'h00:1;'h00<1= (h00>1?D(h00@1A|(h00B1C(h00D1E(h00F1G$)h00H1I\)h00J1K)h00L1M)h00N1O*h00P1Q<*h00R1St*h00T1U,h00V1W8,h00X1Yp,h00Z1[,h00\1],h00^1_-h00`1aP-h00b1c-h00d1e-h00f1g-h00h1i0.h00j1kh.h00l1m.h00n1o.h00p1q/h00r1sH/h00t1u/h00v1w/h00x1y/h00z1{(0h00|1}`0h00~10h0010h0011h001@1h001x1h0011h0011h001 2h001X2h0012h0012h0013h00183h001p3h0013h0013h0014h001P4h0014h0014h0014h0016h0017h001H7h0017h0017h0017h001(8h001`8h0018h0018h0019h001@9h001x9h0019h0019h001 :h001X:h001:h001:h001;h0018;h001p;h001;h001;h001h001H>h001>h001>h001>h001(?h001`?h001?h001?h001@h001@@h002x@h002@h002@h002 Ah002 XAh00 2 Ah00 2 Ah002Bh0028Bh002Dh002Dh002Dh002(Eh002`Eh002Eh002Eh00 2!Fh00"2#@Fh00$2%xFh00&2'Fh00(2)Fh00*2+ Gh00,2-XGh00.2/Gh00021Gh00223FX02202200220223Hh004258Hh00627pHh00829Hh00:2;Hh00<2=Ih00>2?PIh0000lT 0 0E00x 0000ŭ0x 555555______w  1H &)*.Z2;#FIMSX[]cl~-U&D(Ap_R70yX|u'K"]M# 5{j8 !%( *z+./3448;6?,@B DFWKMNQTWY[[\7ccdgjnswx}8ƌ*NP ) ÚX?Ҝ.ן,,q˯eOt׷׼ps<    $'(+2;BLV^irz  "'(/467=AFGIKNRUWYacehjmqtuvxz{~z p i,Nq,N}1g !**7++k,,O-]..//011W2Y22"3335o9;X??eA^BWCD F"FFLGGG:HHHII]I_ICJJLCMEMNNO3PPQARRRRSU>V@VvWxW,X~XXXYYZCZEZ[[E\G\J]`ǘAN|ڸD A&WzDi-:\Ki:f >^E=5$c     x $$%%H&(() *-/11)292353U33c56777889o:;<-@ABOB_BoCCCDEIEELN]QQ(RRSUVHW Z\L\}\\\\\]cefhjl|npcrLtv:ޏ WO2:Se}h^/=k ݴ 15<  !"#%&)*,-./013456789:<=>?@ACDEFGHIJKMNOPQRSTUWXYZ[\]_`abcdefghjklmnopqstuvwxy{|}~    !#$%&)*+,-.0123589:;<>?@BCDEHJLMOPQSTVXZ[\]^_`bdfgiklnoprswy|}; ;<\ 1Okmnp%ACDFf8TWXZz"%&(Hd)EHIKk|   ) @ \ _ ` b    1 L h k l n 4 P S T V v    ! A j  6 R U V X x 2Gcfgi 1?@`~&.8NP !" ""*","e`c@ceEhghhkkbl o=oonrrksvFv)QYS{)+z%W}tp +-  lR z        T|wW''''''b))),,,,,,...77_7h7s777g999;EcElEwEEE(IPIYIQQRR&R)RS TTI[q[z[[[[p-p6pp qquq2uQuux xTx{,{6{L{O{t{i%;>r $<ENdg.XP;e< X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%XX%̕  QQQQQQ  XXX XX           QQQ Q Q XXXX)+;RUe|!!!EzU HXXt    ,b$l=`;WD*@ 0(  B S  ?H0(  <F _Toc273725668 _Ref270625779 _Toc273725669 _Toc273725670 _Toc273725671 _Toc273725672 _Toc273725673 _Ref270625884 _Toc273725674 _Toc273725675 _Toc273725676 _Toc273725677 _Toc273725678 _Toc273725679 _Toc273725680 _Toc273725681 _Toc273725682 _Toc273725683 _Toc96844970 _Toc96941730 _Ref272505518 OLE_LINK1 OLE_LINK2 _Toc273725684 _Toc273725685 _Toc273725686 _Toc273725687 _Toc273725688 _Ref270692263 _Toc273725689 _Toc260228940 _Ref270710617 _Hlt272411435 _Ref272411353 _Ref270710490 _Ref272411457 _Ref270781641 _Ref270784153 _Ref270714397 _Ref270785290 _Ref272515063 _Ref270716439 _Ref270785464 _Ref270786189 _Toc273725690 _Ref153264328 _Toc260228938 _Toc273725691 _Ref153260826 _Toc260228946 _Ref270797089 _Toc153262446 _Toc260228784 _Toc273725692 _Ref153261406 _Ref118281856 _Toc133229742 _Toc260228947 _Toc273725693 _Toc273725694 _Ref270800379 _Hlt272411331 _Toc273725695 _Toc273725696 _Toc273725697 _Toc273725698 _Hlt272518837 _Toc273725699 _Toc270804633 _Toc2737257002L@ C "a^ÊȐoӤ)) yy(6Hb(L '',m7qE RT}[}[o/{/{0{VVVHzv==  @!"#$%&'()*+,-./0218934675:;<=@>?@AB@CDEQ8h\A f -"l^ۍ?~' ,zz4Qa|n~. '',7E*RU[[oP{P{t{h?H hP(=NXTsXTsXsXsXsXԡsXsXsªXTsêXsĪXtj[ŪXi[ƪX4j[ǪXsȪXi[ɪXti[ʪX4i[˪Xh[̪Xh[ͪXth[ΪX4h[ϪXg[ЪX%ѪX%ҪXD%ӪX%ԪX$ժXq[֪Xp[תXp[تX\p[٪Xp[ڪXs[۪XL>ܪX?ݪX/ުX;ߪXtX$;X XX;Xd;XL?Xt+|XX/|XD.|X,|X9XX$X4X{XxX$uXuXsXXlX<X<zX[X SX<XdXXXLXXT#X|.XLX X>Lyy}}[[gy11((.;ϙݙݙ,::nxii--:||ZZc=     ! "#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLM77DD HTTyy}}fnnēē::-:BBؙ5EEtrr6@@bjj=  ! "#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLM:M*urn:schemas-microsoft-com:office:smarttagsStreet=H*urn:schemas-microsoft-com:office:smarttags PlaceName=J*urn:schemas-microsoft-com:office:smarttags PlaceTypeB?*urn:schemas-microsoft-com:office:smarttagscountry-region;N*urn:schemas-microsoft-com:office:smarttagsaddress9K*urn:schemas-microsoft-com:office:smarttagsplace8L*urn:schemas-microsoft-com:office:smarttagsCity NMLKJKHJKHJHJKH?K?KHKJ?K??K?K?KHKHJ??K??KJHJKH?K?K?KJKHLKJKHLK?KLKHKJHKJHKJHKJ##$$T&Y&O,X,U.^.52>2>4G418;8D8R8W8d88888999999x::::::q;;;;;;<<<<< =)?1?5?:?%A-A`AhAkAzA|AABBBBpCxCCCDDDDEEFFsGG_IlIJJJJKK]LgLBMLMMMNN O*OPP)Q4QRR\RfRqRRRRRMUOUPUYUUUUYZYYYYYhZqZZZ[#[$[.[:[F[K[U[[[\\\\&]0]]]]]S^]^Z`d`vwxx)y1y"z)zzz{{#~,~q~{~<Eےܚim#$.kq/:;EZefp}'0>CP_myWeq{O]is.<>@Sau}  WYCKN]_cEMlt2:ly###$$$&&))))*'*++///(/P/T///223333K4U4::!:+:2:7:8:M:::::::::<<w@~@@@@@AA'B.BII)J5JJJrKtKKKW W.W4WYY=Z?Z@ZDZHZNZZZW\a\j\s\y\\\\\\\\\\\\]]*]-]M]P]d]g]]]]]]]]];^E^N^W^]^k^t^^^^^^^^^^^^__!_$_D_G_[_^_________`````` aaaa-a/aIaLalaoaaaaaaaaaaabbb!bBbKbbbbbbbbbbbbbcc8c;cOcRctcwcccccccd dd+d6d>dMdUdldvd|dddddddeee&e)e:e]  8 ;  I = uJ[>v|P^)t,xvPBP J5M]j40hqK3crj  +OD\]MjZo PU < X ` !!H![w!a" $,$G$\&=c&'*'n' x'6)U)q)})f*"*<*gL*Y*+9+J?+H+x+,o,o,u,c-L-`-/ //|0@1;1(;1~K18 2X233H44B4W4Pb4b456:6#h6#7Dl7x78"8 9/:;:Q:_:Ie:YN;bT;U<%=G=xM=M= !>8>;>1C>@G@"@$@lA+B2B|CC|#C%CtC~CyDPD_D,EAFUFpFcGGHtH}H6I`VI\wIJJ\JlJ@pJqK0K4KbKw Lh)L#MtMpNzNO P@P QWQZQuQvQ\R:SLT-eTHU"UXV]VO_VomVqWeW2XD%XN=XPXYxKY=ZV[Z>[R[i1\4\Z\!b\k\R$],]5]:@]_B^A_I_[` _`md`na{aA bj%bgbK,c'dhdLVflfyfe_h&ij&j^jfk#l{7lDl~mno!o=o Ioko4q;0reLs5t7t:#u,uguqvww5aw-"x5x<:x~Vylyry1:zJ{0|p||w|v}+0~JM~(t~ ,9i}&?G_r*2s#LO`y/2< *ENShc}8zej$7uw kVV5+=aZ2O`2y(*"$zVe`{Ayq(vx-@^vbCzW'Mwt2OMt)ye6*"5pAX]e?ULKDo%57FvvYj~5 9<-$UoxH;wH[[Sdzf s2OsDIsS\ZIV]s_wx:wy=(b.BTkm7~,) Hi?DczBqW(YGT.flpsz7 CCv-77DxLOa V(0dZ[@Y!@=n1//BRAnMy\Kfnz~4$$=4ZjqbIM$Wew#EfhJwg))c+Yf[z<[k`%JZa-_a[7fhp{ (0O;_.n|9NVTs Q\!&qVdGdb+J],W;`m!\i:7h%L/h5mR0 3lD;Wsi3],+v%L|[JR /ii (4|4RNr,3Dk]Y7dnos} v] :;,-HNOdqr},-HNOa}~ +12Dgh e"f""""""""$#/#0#1#7####### $ $ $$j$k$l$m$s$$$$$$N%O%P%Q%W%\&]&^&_&e&&&&&&'''''''((((()))) ))))))V*W*X*Y*Z*v*}******!+"+#+$+*+~+++++++-----1111133333z7777788Y9e9f9g9m9]:^:_:`:f:V;W;X;Y;_;<<<<<> >!>">#>.>4>>>>>>K?L?M?N?T???????????9@:@;@<@B@@@@@@@@@@@AAAAA.A5AQA]A^A_A`AAA6BCBDBEBKBBBBBBDDDD$DBECEDEEEFEOEUE FFFF"FFFFFFGGGGG2H3H4H5H;HHHHHHIIIII@JAJBJCJIJJJJJJJJJJJK KKKKKKLMMMM=N>N?N@NANNNjOvOwOxOyOOO P,P-P.P4P}P~PPPPPPPPPQ QQQQQQQQQQQQRRRRBRCRDRERFRRRSSSSSTT9TETFTGTHTQTXT>UJUKUMNW_u|}~ծGPQSTUVWYZvͯ%&')+,.01SfghjkmnopȰʰ˰ڰ۰ݰ߰ (:;<>?ABCD *,./02356Zoqstuwy{|²òŲƲDzȲʲ˲Ҳ';=>?@ACDEѿҿڿ&'<WXmz{ "DE\ijy &'4:;O\]q7KLcij{>E:;CDSfgt >?H^_)tEFGM=>?E567=%&3$%0(cdl  !) g~  - @ A N    xyCjp!=>M`anHIW      !!%!!!!! " "l&m&s&&&'(((7(J(K(X()))))))***6*9*:*B*++&+5+6+?+U+V+k+m+y++++b-c-r----...////////000001 11 16111o2p2v233344,8-8<8O8P8]8999:::O:P:\:_:`:h:o;p;~;;;;;; <J<]<c<<<<<===!=I=J=K=Q===EEEFFF]I^IiIIII(J)J6JJJJKKKMMNNNNNOOHOIORRRRRRTT$TLTMTZT}T~TTTTTTTTTTTTT[[[[[\]]]___aaaccceefgggWiXii2k3k\kmm8moo/{ÂĂȂ:ރ߃: ۆ܆߆ TUǡɡˡ͡ϡСѡۡk٢E9RScnzMݥno}6fgųƳ޳ ./KQRdjkv|}FTU)*hh     0123456=33333333333333333333333333333333qM3333EN.InstantFormat EN.Layout EN.Librariesw<ENInstantFormat><Enabled>1</Enabled><ScanUnformatted>1</ScanUnformatted><ScanChanges>1</ScanChanges></ENInstantFormat>U<ENLayout><Style>Annotated</Style><LeftDelim>{</LeftDelim><RightDelim>}</RightDelim><FontName>Times New Roman</FontName><FontSize>12</FontSize><ReflistTitle></ReflistTitle><StartingRefnum>1</StartingRefnum><FirstLineIndent>0</FirstLineIndent><HangingIndent>720</HangingIndent><LineSpacing>0</LineSpacing><SpaceAfter>0</SpaceAfter></ENLayout>Y<ENLibraries><Libraries><item>Ophthalmology protocol.enl</item></Libraries></ENLibraries>@ǥ@< @   $@ h @Unknown Public Health Gz Times New Roman5Symbol3& z ArialA& Arial Narrow7K@Cambria7&{ @Calibri?5 z Courier New5& zaTahoma9Garamond=" HelvArial3z TimesC0000҉0 Pro W3;Wingdings"1h&_Toc27372567858_Toc27372567752_Toc2737256765,_Toc2737256755&_Toc2737256745 _Toc2737256735_Toc2737256725_Toc2737256715_Toc2737256705_Toc2737256695_Toc273725668egdhttp://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1EA5http://www.aihw.gov.au/hospitals/datacubes/index.cfmNTSave  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqstuvwxy{|}~Root Entry FP #Data 1TableE4YWordDocument-SummaryInformation(rDocumentSummaryInformation8ztCompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q